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Abstract 
 
Equine strangles is a purulent lymphadenitis of the head and neck and is caused by 
Streptococcus equi ssp equi remaining a worldwide, endemic infection that represents around 
30 % of all annually recorded incidents of equine disease. Despite much effort, current 
vaccination strategies have proved largely ineffective towards S. equi, ssp equi, with the 
current focus based on ‘reverse vaccinology’, using genome sequence data of S. equi ssp equi 
to identify surface exposed and secreted proteins.  
 Streptococcus equi shares much of its genome with the genetically closely related, S. 
equi ssp zooepidemicus. Despite this close genetic association, S. equi ssp zooepidemicus 
exhibits very distinct pathogenicity variations. S. equi ssp zooepidemicus can infect a wide 
variety of vertebrate hosts showing a high degree of antigenic variability and a large amount 
of strain variability whereas S. equi is largely equine specific and processes a limited number 
of strain types. Understanding the molecular basis of virulence of these contrasting organisms 
therefore remains a key requirement if a suitable vaccination. 
Identification of potential virulence factors has been greatly aided by the availability 
of the full genome sequence of S. equi ssp equi (4047) and S. equi ssp zooepidemicus (H70). 
In this study, we identified and investigated a range of putative virulence factors 
including the covalently attached surface protein SEQ2190, the secreted phospholipase 
enzymes SlaA (SEQ0849) and SlaB (SEQ2155) and finally the lipoprotein, acid phosphatase 
SeLppC (SEQ0346) and its orthologue SzLppC (SZO16870). In all cases, using molecular 
biology techniques the coding region representative for each of these proteins was cloning 
into expression constructs, expressed and purified and further investigations carried out.  
  
 
 Although efforts to obtain a 3-dimensional structure of SEQ2190 were unsuccessful, 
bioinformatic investigations have identified SEQ2190 as a unique protein in S. equi ssp equi 
with a putative structure suggesting a role in bacteria-host interaction.  
 SlaA was demonstrated to be an active sPLA2 enzyme, active against a 1, 2-dithio 
analog of diheptanoyl phosphatidylcholine but not 2-deoxy-2-thio- Arachidonoyl 
phosphatidylcholine. It was also demonstrated to have a specific requirement for the divalent 
ion, Ca
2+
 for activity, an optimum temperature higher than expected (40°C), a Km of 14.40 ± 
7.866 mM and a specific activity of 5.06x10
-2
 ± 3.01x10
-3 
µmol/min/mg. SlaA was also 
shown to react to equine post-infection convalescent serum.  
 Although some characterisation had been previously undertaken regarding whole cell 
SeLppC extracts, in this study we produced expression constructs of SeLppC and its 
orthologous pseudogene (SzLppC) found in the genome strain of S. equi ssp zooepidemicus. 
We used purified SeLppC and SzLppC to demonstrate activity against pNPP and two 
biologically significant substrates (5’AMP and 5’UMP) and recorded the Km values for each. 
We also identified SeLppC to not possess a specific activity for the divalent ion Cu
2+
, a lower 
than expected pH optimum and a higher than expected temperature range. Furthermore we 
also demonstrated that SzLppC is not a pseudogene, indicating an error within the S. equi spp 
zooepidemicus genome strain.  
 
 
 
 
  
Table of Contents 
 
1. Introduction 
1.1. The Streptococcus             1 
1.2. Streptococcus equi subspecies equi and related taxa         3 
1.3. Equine Strangles             5 
1.4. The Gram-positive cell envelope         11 
1.4.1. Transport through the cytoplasmic membrane      15 
1.4.2. Covalent attachment of proteins to the cell wall      17 
1.4.3. Non-covalent attachment of proteins to the Gram-positive cell wall    20 
1.4.4. Lipoprotein biosynthesis         21 
1.5. The molecular basis of virulence         23 
1.6. Virulence factors of Streptococcus equi sub-species and related pathogens    24 
1.6.1. Fibrinogen-binding proteins              24 
1.6.1.1. M-protein          24 
1.6.1.2. H-binding protein         27 
1.6.2. Hyaluronic acid capsule          28 
1.6.3. Lipoproteins           30 
1.6.4. Superoxide dismutase          32 
1.6.5. Super antigens          32 
1.6.6. Fibronectin-binding proteins         34 
1.6.7. Collagen-binding proteins         36 
  
1.6.8. Immunoglobulin G (IgG) endopeptidases       37 
1.7. Vaccines against S. equi          38 
1.8. Phospholipases           41 
1.8.1. Phospholipase putative roles in bacterial virulence      43 
1.8.2. The mammalian arachidonic acid cascade       46 
1.8.3. PLA2            48 
1.8.4. sPLA2 of Streptococci species        49 
1.9. Acid Phosphatase           52 
1.9.1. Bacterial non-specific acid phosphatise (NSAP)      53 
1.9.1.1. Class A and B NSAP          53 
1.9.1.2. Class C NSAP           54 
1.9.2. Putative NSAP role in virulence        55 
2. Materials and methods  
2.1. Chemicals           57 
2.2. Commercial Kits          57 
2.3. Equipment           57 
2.4. Media and Solutions          58 
2.5. Bacterial strains, storage and growth conditions      58 
2.6. E. coli bacterial strains and vectors        58 
2.7. Antibiotics              61 
2.8. Enzymes           62 
2.9. Oligonucleotides          63 
  
2.10. Spectrophotometry          67 
2.11. Preparation of chemically competent E. coli TOP10      68 
2.12. DNA methods  
2.12.1. Streptococcal genomic DNA extraction      68 
2.12.2. Restriction enzyme digestion        69 
2.12.3. Polymerase chain reaction        69 
2.12.4. Agarose gel electrophoresis of DNA samples     71 
2.12.5. Cloning of fragments into pCR Blunt      71 
2.12.6. Plasmid isolation         73 
2.12.7. Cloning of fragments into pET28a       74 
2.12.8. DNA sequencing         76 
2.13. General protein methods        
2.13.1. SDS-PAGE          76 
2.13.2. Protein extraction         79 
2.13.3. Concentration and buffer exchange of proteins     79 
2.13.4. Protein purification by IMAC chromatography     79 
2.13.5. Protein purification by FPLC chromatography     80 
2.13.6. Western Blotting          81 
2.13.7. Protein crystallisation         84 
2.14. Enzyme assay methods        
2.14.1. General kinetic analysis considerations      84 
2.14.2. sPLA2 assay methods        
  
2.14.2.1. SIGMA assay         85 
2.14.2.2. Price colourmetic assay       86 
2.14.2.3. Chromogenic substrate release assay      86 
2.14.3. Acid phosphatase assay        89 
2.14.4. Phosphate assay         91 
2.15. Calculations of Km and specific activity        
2.15.1. sPLA2            92 
2.15.2. Acid phosphatase         93 
2.16. Zymography           93 
2.17. Bioinformatic analyses         94 
3. Investigation into the covalently attached protein SEQ2190 of S. equi.  
3.1. Introduction           96 
3.2. Bioinformatic analysis of SEQ2190        98 
3.3. PCR of seq2180 and seq2190       111 
3.4. Cloning of seq2180 and seq2190 (full length and truncated forms)  119 
3.5. Protein expression        123 
3.6. Protein purification        128 
3.7. Preperation of crystals for X-ray crystallography    135 
3.8. Discussion and future work       137 
4. Investigation into the secreted protein SlaA of S. equi 
4.1. Introduction         141 
4.2. Bioinformatical analysis of SlaA and an a SlaA homologue  in S. equi 143 
  
4.3. PCR of seq0849 and seq2155       149 
4.4. Cloning of seq0849 and seq2155      152 
4.5. Protein expression of SEQ0849 and SEQ2155    154 
4.6. Protein purification of SlaA and SlaB     160 
4.7. Confirmation of His6-tagged SlaA and SlaB by western blotting  166 
4.8. Detection of antibodies to SlaA and SlaB in equine convalescent  
Serum          167 
4.9. Enzymatic assays of SlaA and SlaB activity      
4.9.1. SIGMA™ method        169 
4.9.2. Price colourmetric method       170 
4.9.3. Chromogenic substrate release assay      174 
4.9.3.1. Michaelis-Menten parameters for SlaA and SlaB   176 
4.9.3.2. Determination of temperature optimum    179 
4.9.3.3. Determination of divalent ion requirement    179 
4.9.3.4. Determination of SlaA and SlaB against arachidonyl thio-PC 184 
4.10. Discussion and future work       186 
5. Investigation into the Acid phosphatase, LppC of S. equi and S. zooepidemicus 
5.1. Introduction         194 
5.2. Bioinformatic analysis of SeLppC and SzLppC    196 
5.3. PCR across SzLppC Signal Peptide region     202 
5.4. PCR of mature SeLppC and SzLppC      204 
5.5. DNA sequencing of SzLppC       206 
  
5.6. Identification of LppC enzymes in S. equi and S. zooepidemicus  209 
5.7. Molecular cloning of SeLppC and SzLppC     211 
5.8. Protein expression of SeLppC and SzLppC     213 
5.9. Protein purification of SeLppC and SzLppC     216 
5.10. Confirmation of His6-tagged SeLppC and SzLppC    218 
5.11. Detection of SeLppC and SzLppC using anti-LppC antiserum  218 
5.12. Western immunoblotting of purified SeLppC and SzLppC using  
equine convalescent serum       219 
5.13. Zymographic detection of acid phosphatase activity    220 
5.14. Enzymatic assays of SeLppC and SzLppC activity 
5.14.1. Michelis-Menton parameters      225 
5.14.2. Determination of temperature optimum of SeLppC and SzLppC 236 
5.14.3. Determination of divalent ion requirement    236 
5.14.4. Determination of optimum pH     237 
5.15. Discussion and future work       242 
6. Conclusion          249 
7. References          252 
i. Appendices 
a. Appendix I – Media, solutions and enzyme buffers    289 
b. Appendix II – Commercial kits and equipment    297 
c. Appendix III– Crystal tray screens      301 
d. Appendix IV– Sequencing outputs      313 
  
e. Appendix V– Cloning vector maps, molecular weight markers  
and standards       321 
 
Table of Figures 
 
Figure 1.1 Current system of differentiation of pathogenically important streptococci     2 
Figure 1.2 Pony with severe swelling of the lymph nodes        8 
Figure 1.3 Pony with submandibular lymph node abscess        9 
Figure 1.4 The characteristic signs of purpura haemorrhagica      10 
Figure 1.5 The peptidoglycan structures from S. aureus and S. pyogenes    13 
Figure 1.6 The major surface protein types in Gram-positive bacteria.     14 
Figure 1.7 The adhesion of sortase dependent proteins to the Gram-positive  
bacterial cell wall          19 
Figure 1.8  Current classifications of phospholipases       42 
Figure 1.9 The AA cascade, indicating the three key enzymatic pathways of AA   47 
Figure 1.10 The demonstrated and putative effects of SlaA from S. pyogenes  
on the eukaryotic cell          51 
Figure 2.1 Schematic representation of sPLA2 activity reaction      88 
Figure 2.2 Schematic representation of acid phosphatase activity reaction    90 
Figure 3.1 Alignment of SEQ2190 and SEQ2180     100 
Figure 3.2 Alignment of SEQ2180 and the orthologue SZO18890   102 
Figure 3.3 Multiple alignments of SEQ2190, SEQ2180 and the orthologue  
  
SZO18970         106 
Figure 3.4 Predicted secondary structure of mature SEQ2190    109 
Figure 3.5 Artemis screen capture of the seq2180 and seq2190 locus and their  
respective S. zooepidemicus orthologues szo18890 and szo18970  110 
Figure 3.6 Genomic DNA extraction of S. equi 4047 and S. zooepidemicus H70 113 
Figure 3.7 PCR amplification of seq2190 and 3’ extension     114 
Figure 3.8 PCR amplification of seq2180 and 3’ extension.    115 
Figure 3.9 PCR amplification of seq2190      116 
Figure 3.10 PCR amplification of seq2180      117 
Figure 3.11 PCR amplification of truncated seq2190 encoding SEQ2190 N  118 
Figure 3.12 Restriction endonuclease digestion of p2190 plasmid   120 
Figure 3.13 Restriction endonuclease digestion of p2180 plasmid   121 
Figure 3.14 Restriction endonuclease digestion of p2190 N plasmid   122 
Figure 3.15 15% SDS PAGE gel demonstrating SEQ2190 expression trials  124 
Figure 3.16 15% SDS PAGE gel demonstrating SEQ2190 expression   125 
Figure 3.17 15% SDS PAGE gel demonstrating SEQ2180 expression   126 
Figure 3.18 15% SDS PAGE demonstrating SEQ2190 N expression   127 
Figure 3.19 15% SDS PAGE of IMAC purified fractions of SEQ2190   129 
Figure 3.20 15% SDS PAGE of IMAC purified fractions of SEQ2180   130 
Figure 3.21 15% SDS PAGE of IMAC purified fractions of SEQ2190 N  131 
Figure 3.22 15% SDS PAGE gel of FPLC purified fractions of SEQ2190  132 
Figure 3.23 15% SDS PAGE gel showing FPLC purified fractions of SEQ2180 133 
  
Figure 3.24 15% SDS PAGE gel showing FPLC purified fractions of SEQ2190 N 134 
Figure 3.25 Crystal of SEQ2190         136 
Figure 3.26 Crystal of SEQ2190        136 
Figure 3.27 Proposed predicted secondary structure model of the mature SEQ2190  
protein with three distinct structural domains.     140 
Figure 4.1 Multiple alignment of SEQ0849, SEQ2155 and the S. zooepidemicus 
orthologue (SZO18670)       146 
Figure 4.2 Pairwise alignment of SlaA and the SpSlaA protein encoded by  
temperate phage of S. pyogenes      147 
Figure 4.3 Identification of Pfam family       148 
Figure 4.4 PCR amplification of seq0849      150 
Figure 4.5 PCR amplification of seq2155      151 
Figure 4.6 Restriction endonuclease digestion of p0849 and p2155   153 
Figure 4.7 17% SDS PAGE of SlaA expression trials     156 
Figure 4.8 17% SDS PAGE of SlaA expression trials     157 
Figure 4.9 17% SDS PAGE of SlaA expression      158 
Figure 4.10 17% SDS PAGE of SlaB expression trials     159 
Figure 4.11 17% SDS PAGE of IMAC purified fractions of SlaA   161 
Figure 4.12 17% SDS PAGE of IMAC purified fractions of SlaB   162 
Figure 4.13 17% SDS PAGE of FPLC purified fractions of SlaA   163 
Figure 4.14 17% SDS PAGE of FPLC purified fractions of SlaB   164 
Figure 4.15 17% SDS PAGE of the purified SlaA and SlaB products obtained  165 
Figure 4.16 His6-tag Western blot analyses of SlaA and SlaB    167 
  
Figure 4.17 Western blot analyses of purified SlaA and SlaB against equine  
convalescent serum (pre and post infection).     168 
Figure 4.18 Enzyme assay by the method of Price (2007)    171 
Figure 4.19 Enzyme assay by the method of Price (2007)    172 
Figure 4.20 sPLA2 enzyme assay by the method of Price (2007)    173 
Figure 4.21 Standard rate of sPLA2 activity over against time    175 
Figure 4.22 Rate of SlaA activity against substrate concentration   177 
Figure 4.23 Lineweaver-Burk plot of SlaA against DHT-PC    178 
Figure 4.24 The effect of temperature on the rate of SlaA enzyme activity  
against DHT-PC        181 
Figure 4.25 The effect of divalent cation replacement on the rate of SlaA 
enzyme activity        182 
Figure 4.26 The effect of calcum ion concentration on the rate of SlaA  
enzyme activity        183 
Figure 4.27 sPLA2 specific enzyme activity of positive control phospholipase  
against different lipid substrates      185 
Figure 4.28 Amino acid sequence of SlaA highlighting the effect of amino acid 
substitution as demonstrated by Nagiec and colleagues 
 (Nagiec et al., 2004)        193 
Figure 5.1 Figure 5.1: Pairwise alignment of SeLppC and SzLppc   198 
Figure 5.2 Translated amino acid sequence of SzLppC, either side of the stop codon 
introduced by the putative frameshift      199 
Figure 5.3 Pairwise alignment mature of SeLppC and SzLppc    200 
  
Figure 5.4 PCR amplification of SzLppC signal peptide region    203 
Figure 5.5 Multiple alignment of sequenced portion of SzLppC (this study, 4 replicates) 
and the deposited nucleotide sequence of SzLppC, obtained from the S. 
zooepidemicus H70 genome       205 
Figure 5.6 15% SDS PAGE of range of S. equi and S. zooepidemicus strains  207 
Figure 5.7 LppC Western blot analysis of a range of S. equi and S. zooepidemicus 
 Strains         208 
Figure 5.8 PCR amplification of seq0346 and szo16870     210 
Figure 5.9 Restriction endonuclease digestion of pSeLppC and pSzLppC  212 
Figure 5.10 15% SDS PAGE gel demonstrating SeLppC and SzLppC expression 
trials          214 
Figure 5.11 15% SDS PAGE demonstrating SeLppC and SzLppC expression  215 
Figure 5.12 15% SDS PAGE demonstrating proteins used in further work  
in this study         217 
Figure 5.13 His6-tag western blot analyses of SeLppC and SzLppC   220 
Figure 5.14 Anti-LppC Western blot analysis of purified SeLppC and 
SzLppC products        221 
Figure 5.15 Western blot analysis of purified SeLppC and SzLppC against equine 
convalescent serum (pre and post infection)     222 
  
Figure 5.16 15% SDS PAGE Zymograph of SeLppC and SzLppC and SDS PAGE 
(Standard Coomassie stained replicate)     224 
Figure 5.17 Standard absorbance of control potato acid phosphatase against NPP 226 
Figure 5.18 Lineweaver-Burk plot of control potato acid phosphatase against pNPP 227 
Figure 5.19 Linewever-Burk plot for SeLppC against pNPP    228 
Figure 5.20 Lineweaver Burk plot for SzLppC against pNPP    229 
Figure 5.21 Lineweaver Burk plot for SeLppC against 5’UMP    230 
Figure 5.22 Lineweaver-Burk plot for SzLppC against 5’UMP    231 
Figure 5.23 Lineweaver Burk plot of SeLppC against 5’AMP    232 
Figure 5.24 Lineweaver Burk plot of SzLppC against 5’AMP    233 
Figure 5.25 Standard curve of inorganic phosphate assay     234 
Figure 5.26 The effect of temperature on the rate of SeLppC and SzLppC  
enzyme activity.        238 
Figure 5.27 The effect of divalent ions on the rate of SeLppC enzyme activity  239 
Figure 5.28 The effect of divalent ions on the rate of SzLppC enzyme activity  240 
Figure 5.29 The effect of changes in pH on the rate of SeLppC and SzLppC  
enzyme activity        241 
 
 
 
  
List of Tables 
 
Table 2.1  Bacterial strains and plasmids used in this study      59 
Table 2.2 Antibiotics used in this study         61 
Table 2.3 Enzymes and co-constituents         62 
Table 2.4 Nucleotide primers used in this study       64 
Table 2.5 Recombinant plasmids generated in this study      66 
Table 2.6 PCR reaction conditions         70 
Table 2.7 Components of PCR-Blunt ligation reaction       72 
Table 2.8 Components of pET vector ligation        75 
Table 2.9 Composition of SDS-PAGE stacking gel       77 
Table 2.10 Composition of SDS-PAGE resolving gel       78 
Table 2.11 Primary antibodies used in this study        82 
Table 2.12 Secondary antibodies used in this study       83 
Table 3.1 Significant orthologues of the mature SEQ2190 protein   107 
Table 4.1 Representative homologues of SEQ0849     145 
Table 5.1 Significant orthologues of mature SeLppC     201 
Table 5.2 Km (mM) activities of SeLppC and SzLppC     235 
Table 5.3 Recorded Km’s of SeLppC and SzLppC for three substrates and 
other closely related NSPC’s       248 
 
 
  
Acknowledgements 
 
 
First and foremost, I would like to thank Prof. Iain Sutcliff and Prof. Gary Black for all of the 
help, support, guidance and advice they have given me during this project.  
I would also like to thank Dr. Andrew Waller for his assistance and the Animal Health Trust 
for contributing to the funding of this work.  
I would also like to show my gratitude to Dr. Alistair Brown assisted in giving me the 
opportunity to fund myself while writing this thesis and the countless number of colleagues 
from lab A307/321 both past and present. Especially I would like to thank Paul Purcell who 
remains the only individual I’ve ever met to share the same sense of humour as me and Claire 
Jennings for her valuable support.  
I would also like to show my appreciation for the teachings of the Buddha whose wisdom and 
guidance has provided me with comfort during the many difficult times I experienced during 
the production of this work.   
Finally I wish to thank most of all, my grandfather Thomas (Tot) Gill. Without my 
grandfathers constant support, advice and humour I would have never made it through these 
long and difficult years.  
 
 
 
 
  
Declaration 
 
I declare that the work contained in this thesis has not been submitted for any other award 
and that it is all my own work.  
 
 
 
 
 
Name:  
 
 
 
Signature: 
 
 
 
Date: 
 
 
 
 
 
  
Abbreviations 
 
5’AMP   Adenoside-5’-monophosphate 
5’UMP   Uridine-5’-monophosphate 
ABC    ATP-binding cassette 
AA     Arachidonic acid 
AP    Acid phosphatase 
APS    Ammonium persulphate 
AT-PC    2-deoxy-2-thio- Arachidonoyl phosphatidylcholine 
ATP    Adenosine triphosphate 
BCIP    5-bromo-4-chloro-3-indolyl-phosphate 
BSA    Bovine serum albumin 
CaCl2    Calcium chloride 
CDS    Coding sequences 
CuSO4    Copper(II) sulfate 
DNA    Deoxyribonucleic acid 
dNTPs    Deoxynucleotide triphosphates 
DHT-PC   1, 2-dithio analog of diheptanoyl phosphatidylcholine 
DTNB    5, 5’-dithio-bis-(2-nitrobenzoic acid) 
  
EDTA 2-({2-[bis(carboxymethyl)amino]ethyl} 
(carboxymethyl)amino)acetic acid 
ELISA    Enzyme-linked immunosorbent assay 
FPLC    Fast Protein Liquid Chromatography 
Fn    Fibronectin 
G    Graviton 
gluU    N-acetyl-glucosamine-1-phosphate uridyltransferase 
HA    Hyaluronic acid 
HAP    Hyaluronate-associated protein 
hasA     Hyaluronate synthase 
hasB     UDP-glucose dehydrogenase 
hasC    Glucose-1-phosphate uridyltransferase 
HCl    Hydrochloric acid 
HEPES   2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
H2O    Water 
IL-8     Interleukin 8 
IMAC Protein purification by Immobilized Metal Affinity 
Chromatography 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
  
KCl Potassium chloride 
KH2PO4 Monopotassium phosphate 
kHz    kilohertz 
Lgt    Prolipoprotein diacylglyceryl transferase 
Lnt    Lipoprotein N-acyl-transferase 
Lsp    Lipoprotein signal peptidase 
mA    Milliampere 
MHC    Major histocompatibility complex  
mg    Miligram 
MgCl2    Magnesium chloride 
ml    Mililitre 
MLST    Multilocus sequence typing 
MSCRAMM’s Microbial surface components recognising adhesive matrix 
molecules. 
Nag N-acetylglucosamine 
NBT-BCIP Nitro Blue Tetrazolium/5-Bromo-4-Chloro-3-Indolyl 
Phosphate 
Nam N-acetylmuramic acid 
NaOH Sodium hydroxide 
  
nm Nanometer 
NSAP     Bacterial nonspecific acid phosphatase 
OMPLA   Outer membrane phospholipase A 
PAF     Platelet activating factor 
PBS    phosphate buffered saline 
PBST    phosphate buffered saline and Tween 80 
PCR    Polymerase Chain Reaction 
pgi    Glucose-6-phosphate isomerise 
PL     Phospholipase 
PLA     Phospholipase A 
PLA1     Phospholipase A1 
PLA2      Phospholipase A2 
PLB      Phospholipase B 
PLC      Phospholipase C 
PLD     Phospholipase D  
pNPP    Para-nitrophenylphosphate 
rpm    Revolutions per minute 
sAg    Super-antigen 
  
SBP    Substrate-binding protein  
Sec pathway   Secretory pathway 
SeLppC   LppC of Streptococcus equi sub sp equi 
S. equi    Streptococcus equi subspecies equi 
SFS    Secreted fibronectin binding protein 
SOD     superoxide dismutase 
SPase    Signal peptidase 
SpSlaA   S. pyogenes sPLA2 
sPLA2     Secreted phospholipases A2  
S. ruminatorum   Streptococcus equi subspecies ruminatorum 
SzLppC   LppC of Streptococcus equi sub sp zooemidemicus 
S. zooepidemicus   Streptococcus equi subspecies zooepidemicus  
TAT pathway   Twin arginine pathway 
TEMED   Tetramethylethylenediamine 
TNFα     Tumour necrosis factor 
Tris    2-Amino-2-hydroxymethyl-propane-1,3-diol 
µg    Microgram 
µl    Microlitre 
  
V    Volt 
ZnCl2    Zinc chloride 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
1. Introduction 
 
1.1. The genus Streptococcus 
 
Differentiation of the genus Streptococcus was initially made by Schottmuller in 1903 using 
haemolysis of blood agar. Subsequently, simple fermentation and tolerance tests were later 
developed to distinguish many of the streptococci (Facklam 2002). Lancefield later 
significantly improved the means of streptococcal differentiation with the discovery of 
specific carbohydrate ‘group’ antigens associated with specific strains of Streptococcus 
(Lancefield 1933). Sherman then expanded on the work of Schottmuller in 1937, proposing 
the use of the reactions some streptococci produced on blood agar plates (Sherman 1937). 
This led to streptococci species being placed into either an alpha-haemolytic, beta-haemolytic 
or non-haemolytic group although in practice haemolysis can be variable (Figure 1.1).  
The genus Streptococcus was eventually split into three genera, Enterococcus, 
Lactococcus and Streptococcus as defined in Bergey’s Manual of Determinative Bacteriology 
in 1986. Currently, simple differentiation of streptococcal species is based on an 
amalgamation of haemolytic phenotype on blood agar plates and Lancefield serotyping. For 
example, Streptococcus pyogenes is regarded as a β-haemolytic, Lancefield Group A 
Streptococcus (Figure 1.1).  
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Figure 1.1: Current simplified system of differentiation of pathogenically important 
streptococci.  
Note that many non-haemolytic ‘streptococci’ have since been reclassified as members of the 
genus Enterococcus. 
 
 
 
 Streptococcus 
α- Haemolytic (partial 
haemolysis)  
β- Haemolytic 
(full haemolysis) 
γ- Haemolytic 
(non- haemolytic)  
   
S. pneumoniae 
S. mutans  
S. constellatus 
S. mitis 
S. sanguinis 
S. salivarius 
S. pyogenes 
S. agalactiae 
S. equi sp zooepidemicus 
S. equi sp equi 
S. equi sp rumminatorum   
S. bovis 
S. equinus  
S. canis  
A B C   G  D 
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1.2. Streptococcus equi subspecies equi and related taxa 
 
Streptococcus equi is a β-haemolytic, Lancefield group C Streptococcus and consists of three 
subspecies of zoonotic agents including Streptococcus equi subspecies equi (herein S. equi), 
Streptococcus equi subspecies zooepidemicus (herein S. zooepidemicus) and Streptococcus 
equi subspecies ruminatorum (herein S. ruminatorum). S. equi is the causative agent of 
equine strangles, an important worldwide infection in equine species. S. equi is regarded as a 
subtype of S. zooepidemicus (Harrington et al. 2002) based on multilocus enzyme 
electropherotypes (Jorm, et al. 1994) and also due to comparisons made regarding the 16S-
23S rRNA gene intergenic spacers of S. equi and S. zooepidemicus (Chanter et al. 1997). 
Multilocus sequence typing (MLST) has also revealed this close genetic relationship of S. 
equi and S. zooepidemicus (Webb et al. 2008).  
S. equi shares much of its genome with the genetically closely related S. 
zooepidemicus, with 1671 S. equi predicted coding sequences (CDS) having S. zooepidemicus 
orthologues (Holden et al. 2009). Both genomes are similar in size with that of S. equi (strain 
4047) 2,253,793 bp in length compared to S. zooepidemicus (strain H70) which is 2,149,866 
bp in length. Interestingly, S. equi (4047) has a larger number of predicted coding sequences 
(2,137) than S. zooepidemicus (H70). From the remaining 466 non-orthologues S. equi CDS 
the majority (422) are found on mobile genetic elements, accounting for the increase in the S. 
equi genome size (Holden, et al. 2009). Additionally S. equi displays a larger number of 
partially deleted genes and pseudogenes than S. zooepidemicus indicating a degree of 
functional loss (Holden, et al. 2009). Analysis of the genome strains of S. equi, S. 
zooepidemicus and S. pyogenes also provides evidence of horizontal genetic exchange 
occurring between the three species that has influenced the pathogenicity of these bacteria 
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(Holden et al. 2009). The two genome sequenced S. equi sub-species also share many 
structural proteins with S pyogenes, sharing 80% DNA identity (Holden et al. 2009). 
Despite a large degree of genetic homology the three Group C streptococcal 
subspecies have many distinct variations regarding each organism’s pathogenicity, the 
molecular basis of which therefore remains an important area of study. Polymorphism of 
DNA restriction fragments also suggests that there is some limited genomic sequence 
variability (Takai et al. 2000). Populations of S. zooepidemicus are extremely diverse with at 
least 219 sequence types identified. Strains of S. equi in comparison are highly homogenous 
(Kelly et al. 2006).  MLST of a large collection of isolates identified S. equi strains to be 
either ST-151 or ST-179 (Webb et al. 2008). 
S. equi is antigenically conserved and is highly host adapted to equids where as the 
antigenically diverse,  S. zooepidemicus can be found in many vertebrate hosts including 
horses (Timoney et al. 2007). S. zooepidemicus also persists indefinitely as a mucosal and 
tonsillar commensal. Often a predisposing factor is required prior to S. zooepidemicus 
infection (Timoney et al. 2007). Although rare, several cases of human S. zooepidemicus 
infections have been recorded, including a large outbreak of glomerulonephritis in Nove 
Serrana, Brazil caused by unpasteurised cheese (Baiter et al. 2000). Infections of S. 
zooepidemicus in humans have also been implicated in cases of meningitis (CDC 1983) and 
sepsis (Edwards et al. 1988).   
S. ruminatorum is a relatively newly classified organism and awaiting further study 
(Fernandez et al. 2005) but has also been shown to cause infections in humans (Marchandin 
et al. 2007).  
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1.3. Equine Strangles 
 
Equine strangles is a purulent lymphadenitis of the head and neck and is caused by S. equi 
(Timoney et al. 2007) remaining a worldwide, endemic infection that represents around 30 % 
of all annually recorded incidents of equine disease (Timoney 2004). Strangles disease is 
regarded as of significant welfare and economic importance (Guss et al. 2009). 
Clinical characteristics of equine strangles include fever, cough and pyrexia. This is 
followed by profuse nasal discharge (Waller and Jolley 2007a) and enlargement/ulceration of 
the submandibular lymph nodes (Figure 1.2) (Laus et al. 2007) as well as abscessation 
(Figure 1.3). This increased lymph node swelling gives rise to the term ‘strangles’ as in 
severe cases it can result in restriction of the airways (Waller and Jolley 2007a). Initially S. 
equi enters the host via the nose or mouth, binding to cells on the tonsillar crypts and ventral 
surface of the soft pallet (Timoney 1999). Infection of the nasopharynx spreads rapidly to the 
lymph nodes (Timoney 2004) where bacterial multiplication occurs unhindered by 
polymorphonuclear leukocytes infiltration (Harrington, et al. 2002). Lymphadenitis then 
develops into abscessation.  
Bacteria can disseminate to organs distinct from the equine respiratory systems either 
hematogenously or via lymphatic channels resulting in metastasis, often referred to as 
‘bastards strangles’ (Timoney 2004). For example, metastasis of a S. equi infection to the 
brain has been reported (Evers 1968).  Purpura haemorrhagica can also be triggered due to 
infections of S. equi (Pusterla et al. 2003), which is an immune complex disease and capable 
of causing oedema (Figure 1.4). The occurrence of oedema in an infected horse is often fatal 
(Waller and Jolley 2007a).  
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The recognised site of prolonged bacterial carriage is the guttural pouch (Timoney 
2004). This organ has an elusive role but is thought to be implicated in brain-cooling 
mechanisms in the horse by ventilating and cooling internal carotid arteries (Baptiste 1998; 
Baptiste et al. 2000; Parillo, et al. 2009). Prolonged bacterial carriage within the guttural 
pouch can eventually result in the formation of chondroids, which are discrete bodies formed 
by the drying and hardening of exudates (Waller and Jolley 2007b). An indicator of 
subclinical inflammation is often the presence of chondroids within the guttural pouch. The 
high quantities of S. equi bacteria within chondroids suggests that a continual stimulation of 
the host immune system occurs in the guttural pouch (Verheyen et al. 2000).  
Common morbidity and mortality rates during an infection outbreak amongst a 
population are up to 100 % and 10 % respectively (Laus et al. 2007).  
A variety of mechanisms can allow transmission of S. equi amongst susceptible 
populations, many of which do not require direct horse-horse contact. S. equi can persist in 
standing water for several weeks but has limited survivability in soil and on pasture (Timoney 
1999). Incubation can be between four to five days or anything up to 14 days depending on 
population susceptibility (Timoney 2004). Nasal shedding of bacteria begins after a few days 
following the onset of pyrexia and can persist for several weeks. Intermittent shedding can 
occur for several years after infection onset (Timoney 2004). The presence of asymptomatic 
carriers within susceptible horse populations gives rise to an infection that is endemic in 
character (Laus et al. 2007). Carriers can carry and shed viable infectious quantities of S. equi 
for between seven and thirty nine months (Newton et al. 1997). This leads to much difficulty, 
as it cannot always be determined whether or not an out-break associated horse has the 
potential to develop the disease or indeed transmit the infection to other horses (Waller and 
Jolley 2007b).  
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An efficient method of diagnosis is crucial when dealing with any outbreak of 
strangles in a susceptible population. Previous diagnostic procedures required utilising 
traditional microbiological techniques and Polymerase Chain Reaction (PCR) screening of 
nasopharyngeal swabs of exposed horses (Timoney and Artiushin 1997). A recently 
developed diagnostic tool is an enzyme-linked immunosorbent assay (ELISA) based 
detection of serum antibodies that target a full-length protein, SeM (IDEXX™). However, 
ELISA based testing can be difficult to interpret due to overlapping detection breakpoints in 
normal and convalescent horses (Davidson et al. 2008). Regarding potential carriers, 
endoscopic examination to confirm chondroids and the sampling of the guttural pouch 
content remains the only reliable means of identification (Timoney 2004). 
S. equi is susceptible to a wide spectrum of current antibiotics in use. However, 
opinion on whether antibiotic treatment is effective in combating strangles remains a divisive 
issue (Sweeney et al. 2005). The use of antibiotics during the early acute phase of infection 
may prevent abscess formation. However, the development of protective immunity is often 
inhibited (Piche 1984), leading to susceptibility to further infections remaining (Sweeney et 
al. 2005). Additionally during treatment, relapses are common. It has been hypothesised that 
the reason for this is due to ineffective antibiotic penetration to therapeutic levels 
(Harrington, et al. 2002). However, the majority of animals do recover from the disease and 
are able to eliminate S. equi within a period of 4-6 weeks. Complications caused by a 
strangles infection include metastatic spread of infection, myositis, muscle infarctions and 
agalactia (Timoney 2004).  
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Figure 1.2: Pony with severe swelling of the lymph nodes 
(Image obtained from The British Horse Society, http://www.bhswm.org.uk) 
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Figure 1.3: Submandibular lymph node abscess 
(Image obtained from The Animal Health Trust, http://www.aht.org.uk/bact_intro.html) 
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Figure 1.4: The characteristic signs of purpura haemorrhagica 
Formation of an immune complex resulting in haemorrhage in the mucous membrane. 
(Image obtained from The Animal Health Trust, http://www.aht.org.uk/bact_intro.html) 
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1.4. The Gram-positive cell envelope 
 
Morphologically, Gram-strain positive (‘monoderm’) bacteria consist of three distinct cellular 
compartments: the cytosol, a single cytoplasmic membrane, and the surrounding cell 
envelope (Giesbrecht et al. 1976; Sutcliffe 2010). Gram-positive bacteria are differentiated 
from Gram negative bacteria by having a thicker peptidoglycan wall (also known as murein) 
and lack a defined outer membrane (Scott and Barnett 2006).  
The peptidoglycan is a large macromolecule 15-30 nm thick that encases the cell. The 
glycan of peptidoglycan is a repeating disaccharide of N-acetylmuramic acid linked to N-
acetylglucosamine by a β-1,4 glycosidic bond (Navarre and Schneewind 1999; Scott and 
Barnett 2006). The glycan strands vary in length (between 5 to 30 subunits) in relation to the 
bacterial species and the complete peptidoglycan is formed by the cross-linking of stem 
peptides and a peptide cross-bridge (Navarre and Schneewind 1999; Snowden and Perkins 
1990). In some cases the stem peptides are not linked by peptide-cross bridges but instead via 
an amide bond as demonstrated by Listeria monocytogenes. The exact composition of 
peptidoglycan is variable based on the organism (Schleifer 1973) (Figure 1.5) .  
The primary function of peptidoglycan is in providing a physical protective barrier 
against osmotic and mechanical stress (Dramsi et al. 2008; Navarre and Schneewind 1999). 
However peptidoglycan has a further primary function in that it provides a scaffold for the 
anchorage of external structures including secondary cell wall polymers such as teichoic and 
teichuronic acids and also for the attachment of surface proteins and adhesions (Dramsi et al. 
2008; Salton et al. 1994; Sugiyama et al. 2002). The basis of bacterial species and strain 
specific properties as well as bacteria-host interactions in the case of pathogenic bacteria is 
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due in many ways to the collective action of these molecular peptidoglycan ‘decorations’ 
(Marraffini, et al. 2006). Bacteria have evolved several unique mechanisms in which to 
transport and facilitate the attachment of these proteins, to be discussed in later sections. This 
includes covalent and non-covalent attachment as well as lipoproteins (figure 1.6).  
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Figure 1.5: The peptidoglycan structures from Staphylococcus aureus and S. pyogenes.  
The glycan chains are composed of a repeating disaccharide, N-acetylmuramic acid and N-
acetylglucosamine. These are linked through the lactyl moiety of N-acetylmuramic acid to 
short wall peptides. The linking of adjacent wall peptides is usually through crossbridge 
peptides (pentaglycine in S. aureus or dialanine in S. pyogenes). Figure taken from Navarre 
and Schneewind (1999). 
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Figure 1.6: The major surface protein types in Gram-positive bacteria. 
(1) Covalently bound to the cell wall. (2) noncovalently bound to the cell wall. (3) Membrane anchored lipoprotein. (4) Secreted; M, cell 
membrane; W, cell wall; E, surface exposed or secreted. Adapted from Barinov et al (2009).  
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1.4.1. Transport through the cytoplasmic membrane 
 
Bacterial cell integrity is maintained by the separation of the cell cytoplasm from the external 
environment by a phospholipid membrane. Proteins which function outside the cytoplasm but 
are synthesized in the cytoplasm therefore need a method of transport through this barrier 
without compromising cell integrity (de Keyzer et al. 2003). The initial step in protein 
localisation is the transport of the proteins through or into the cell membrane, with most 
bacterial proteins transported unfolded (Scott and Barnett 2006). The most common 
mechanism of protein transport is the secretory (Sec) pathway. Further methods of transport 
include the twin arginine pathway (TAT), although this seems to not be a major pathway in 
streptococci (Dilks et al. 2003) and some specialised proteins also utilise specialist pathways 
for their transport (Scott and Barnett 2006). 
The Sec pathway was originally identified in Escherichia coli (Bieker et al. 1990; 
Schatz and Beckwith 1990). The Sec pathway consists of an ATPase, known as SecA (Oliver 
and Beckwith 1981), and a protein-conducting channel which acts as a large integral 
membrane domain. The membrane channel is formed by the interaction of two cell 
membrane proteins, SecY (Emr et al. 1981) and SecE (Riggs et al. 1988) and their 
interactions with SecG (Nishiyama et al. 1993). SecA enables the use of Adenosine 
triphosphate (ATP) as an energy source to drive the Sec pathway and when associated with 
other Sec proteins are referred to as a translocon (Du Plessis et al. 2011). Recent studies have 
also proposed that translocons in Gram-positive bacteria are clustered in restricted regions of 
the cell membrane known as an ExPortal (Rosch and Caparon 2005) or in other domains 
(Buist et al. 2006). The Sec pathway has two substrate dependent modes of operation: the 
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insertion of transmembrane segments through a lateral opening and a transversal opening, 
allowing secretory proteins across the membrane to the periplasm (Facey and Kuhn 2010) 
The presence of an N-terminal signal sequence (signal peptide) and Type I signal 
peptidases (SPase) are a requirement for secreted proteins to use the Sec pathway. Type I 
Spase is an essential membrane bound endopeptidase, which cleaves the amino-terminal 
signal peptide from an exported pre-protein (Tuteja 2005). This can be either during or after 
translocation of the protein has occurred across the membrane (van Roosmalen et al. 2004). 
Following cleavage the mature protein is released from the membrane. Signal peptides 
consist of three regions: a region at the N-terminus with a net positively charged stretch of 
polar residues (N-region); a hydrophobic core (H-region) which consists of 10-15 amino acid 
residues; and finally a region adjacent to the H-region (C-region) which contains the 
recognition site for Spase I. The H-region is thought to adopt a α-helical conformation 
(Nielsen et al. 1997) where as the C-region is proposed to have a β-stranded conformation 
(Paetzel et al. 1998).  
Signal peptides currently have several characterised roles. Signal peptides act as 
topological determinants for membrane pre-proteins, initiating translocation of pre-protein 
hydrophilic C-terminal regions. They also ensure that the hydrophobic N-terminal regions of 
proteins remain in the cis orientation at the membrane during translocation (Andersson et al. 
1992). Signal peptides can also prevent the activation of harmful secretary enzymes in the 
cell by preventing the folding of nascent chains (Vonheijne and Abrahmsen 1989). Gram-
positive bacteria have been shown to have signal peptide sequences that are longer and more 
hydrophobic than their Gram-negative counterparts (Park et al. 1988). Type I Spases are 
approximately 200 amino acids in size in Gram-positive organisms, compared to around 300 
amino acids in Gram-negative organisms. The only known exception to this is the Type I 
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Spases from Streptomyces and Mycobacterium, which resemble those of Gram-negative 
bacteria in size (van Roosmalen et al. 2004).  
Most bacteria contain at least a single chromosomal copy of the SPase I gene, 
however many Gram-positive bacteria also encode multiple type I Spases. Bacillus subtilis 
for example has five chromosomally encoded type I SPases (Tjalsma et al. 1997). Additional 
type I Spases can have either a complete or partial redundancy, an example of which can be 
found in Staphylococcus aureus where spsA has been found to be redundant (Cregg et al. 
1996). Regarding bacteria with only one chromosomally encoded type I SPases, this enzyme 
is essential for the processing of all secretory pre-proteins (van Roosmalen et al. 2004). 
However with those bacteria that possess multiple type I SPases, it has been shown that none 
of the enzymes by themselves are essential for cell viability (Palacin et al. 2002). It is 
unknown why this is the case but it has been proposed that SPase redundancy may be an 
advantage for these organisms (van Roosmalen et al. 2004). 
 
1.4.2. Covalent attachment of the proteins to the cell wall 
 
Covalent linkage of proteins to the peptidoglycan initially emerged from investigations of 
protein A of S. aureus (Sjoquist et al. 1972). Following translocation through the membrane 
by the Sec pathway, surface proteins are attached covalently to the peptidoglycan wall and 
are anchored through their carboxyl terminus by membrane-bound thiol transpeptidases 
called sortases (Mazmanian et al. 1999). Surface proteins that are sortase attached also 
possess a cell wall anchoring domain at their C-termini, constituting a sortase recognition 
sequence, known as the cell-wall sorting signal (Mandlik et al. 2008). This amino acid 
sequence is often Leu-Pro-X-Thr-Gly (LPXTG) and is followed by a hydrophobic stretch of 
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amino acids known as a membrane-spanning domain and a positively charged tail (Fischetti 
et al. 1990). Although this motif is common some putative covalently attached proteins of 
streptococci apparently have displayed an atypical sorting motif (Egan, et al. 2010). During 
the initial process of sortase-mediated attachment, the N-terminal signal sequence is cleaved 
with the C-terminal hydrophobic domain retaining the protein in the membrane, allowing the 
LPXTG motif to be recognised. The LPXTG motif is cleaved by sortase between the 
threonine (T) and glycine (G) and catalyses the formation of an amide bond between the 
carboxyl group of the threonine and the amino group of peptidoglycan precursor peptides 
(Jovel et al. 2006; Navarre and Schneewind 1994), thus covalently linking the mature protein 
to the peptidoglycan precursor, which is ultimately incorporated into the growing 
peptidoglycan (Pallen et al. 2001) (Figure 1.7).  
Almost all Gram-positive bacteria possess sortase-like proteins, along with two 
Archaea, Methanobacterium thermoautotrophicum (Pallen et al. 2001) and Methanopyrus 
kandler (Slesarev et al. 2002), which have also been found to encode putative sortase-like 
proteins. Bioinformatical analysis has also shown that the majority of Gram-positive bacteria 
also possess additional sortases, and several sortase-like proteins can be found in some 
individual species (Navarre and Schneewind 1999). These sortases have been shown to be 
involved in a variety of processes such as pilus assembly, iron acquisition and sporulation 
(Mandlik et al. 2008). A large majority of important surface proteins including virulence-
related MSCRAMM (microbial surface components recognising adhesive matrix molecules) 
and enzymes are covalently anchored in this way to the cell wall in Gram-positive bacteria 
(Pallen et al. 2001). As such, sortase-like proteins have since become an interesting 
therapeutic agent target in many pathogenic bacteria (Matoba et al. 2002).  
 
19 
 
 
 
 
Figure 1.7: Example of the adhesion of sortase-dependent proteins to the Gram-positive 
bacterial cell wall (S. aureus). 
(A) The sortase dependent protein with characteristic LPXTG motif, the hydrophobic domain 
is shown in grey. (B) The hydrophobic domain and the positively charged carboxyl-terminus 
prevent the complete secretion of the protein. The protein is instead cleaved between 
threonine and glycine residues of the LPXTG motif by the action of sortase enzyme. (C) The 
released amino-terminal portion of the protein becomes attached to the free amino-group of 
the peptidoglycan cross-linking pentaglycine bridge, anchoring the protein to the cell wall. 
Nag: N-acetylglucosamine; Nam: N-acetylmuramic acid (Neville 2010).  
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1.4.3. Non-covalent attachment of proteins to the Gam-positive surface 
 
Although many Gram-positive surface proteins are attached covalently to stem peptides and 
thence peptidoglycan, some are attached via noncovalent ionic interactions to peptidoglycan 
or teichoic acids (Silhavy et al. 2010). For example, some proteins have been found to 
interact via C-terminal repeats with choline residues present in lipoteichoic or teichoic acids 
(Garcia et al. 1998). An example of this concerns the virulence factor, PspA in Streptococcus. 
pneumoniae (Briles et al. 1998). A further method is by glycine and tryptophan repeats, 
referred to as ‘GW modules’(Mesnage et al. 2000). GW  modules are 80-amino acid tandem 
repeats starting with a GW di-peptide present at the protein C-terminus (Cossart and 
Jonquieres 2000) and initially identified in L. monocytogenes (Cabanes et al. 2002). The 
protein InlB of L. monocytogenes, a requirement for host cell invasion, was found to lack a 
LPXTG motif and instead have a series of GW repeats in its C-terminal region (Gaillard et al. 
1991). Like PspA, InIB also contains an N-terminal Sec secretion signal and lipoteichoic 
acids are the cell wall ligand of GW modules (Jonquieres et al. 1999).  
Some cell envelope proteins can also be membrane associated and anchored by a 
hydrophobic stretch of around 20 amino acids. This is preceded by a stop-transfer signal, a 
stretch of positively charged amino acids at the C-terminus of the protein. The actin-
polymerizing protein, ActA of L. monocytogenes is an example of a membrane-anchored 
protein exposed to the medium (Kocks et al. 1992).  
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1.4.4. Lipoprotein biosynthesis 
 
As originally described for Braun’s lipoprotein of E. coli, proteins can also be localised to the 
bacterial cell envelope as lipoprotein (Braun et al. 1994). A specific signal peptide motif is 
required, known as a ‘lipobox’ for those proteins destined to become lipidated. The lipobox is 
characterised as having an L-3-[A/S/T]-2-[G/A]—1-C+1 sequence with a conserved cysteine 
as an absolute requirement (Hutchings et al. 2009; Rahman et al. 2008). Putative lipoproteins 
are typically directed initially through the Sec pathway, crossing the cytoplasmic membrane 
unfolded. Recently studies have also suggested a SecA2-dependent accessory Sec pathway 
(Gibbons et al. 2007; Lenz et al. 2003) and TAT pathways may also be used (Gralnick et al. 
2006; Thompson et al. 2010; Widdick et al. 2011). 
Biogenesis of Lipoproteins involves at least two enzymes: prolipoprotein 
diacylglyceryl transferase (Lgt) and lipoprotein signal peptidase (Lsp). Lgt initially catalyses 
the transfer of a diacylglyceryl moiety onto the conserved cysteine of the lipobox via a 
thioether linkage (Hutchings et al. 2009). Lsp then cleaves the signal peptide at the conserved 
cleavage site in the lipobox, ensuring the retention of the lipid-modified cysteine at the N-
terminus of the mature lipoprotein. This pathway is conserved in all bacteria (Hutchings et al. 
2009) whilst in Gram-negative bacteria there is a third step whereby, following Lsp mediated 
cleavage, Lipoprotein N-acyl transferase (Lnt) adds a further fatty acid in an amide linkage to 
the free amino group of the lipidated cysteine. 
Homologues of Lnt have been identified in some high G/C content Gram Positive 
bacteria (Widdick et al. 2011) and there is evidence of N-acylation in some low G/C Gram-
positive bacteria in the absence of Lnt homologues (Asanuma et al. 2011; Navarre et al. 
1996). Some Gram Positive bacteria also possess more than a single copy of lgt with two 
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putative paralogues encoded in the genomes of Bacillus cereus ATCC10987 (Rasko et al. 
2004), Clostridium perfringens (Shimizu et al. 2002) and Streptomyces coelicolor (Bentley et 
al. 2002; Thompson et al. 2010). The role of Lgt enzyme paralogues is currently unknown 
but has been suggested that a possible role could be the availability of an alternative 
lipoprotein specific pathway, akin to that of sortase paralogues. Bacterial lipoproteins have 
since been proposed to be functional equivalents of Gram-negative periplasmic proteins 
(Hutchings et al. 2009).  
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1.5. The molecular basis of virulence 
 
Bacterial surface proteins have a wide variety of functions and are critically important in 
determining the success of a bacterial strain. Typical bacterial surface functions include those 
proteins involved in bacterial adherence or protection (either against toxins, environmental 
conditions or host responses). Some also provide bacteria with an enhanced ability to acquire 
nutrients, allow bacteria to interact with each other and compete for specific environmental 
niches. Some surface proteins are also essential for bacterial growth, maintenance and cell 
division.  
General examples include MSCRAMM’s which act as ligands; anti-phagocytic 
bacterial capsules; transporters to aid in the acquisition of nutrients; and extracellular toxins 
which damage or subvert the host immune system.  
Understanding the role played by virulence factors can help elucidate the 
understanding of the pathogenesis of infection and identify potential points of treatment or 
vaccination (Mitchell and Mitchell 2010). 
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1.6. Virulence factors of Streptococcus equi subspecies and related pathogens 
 
1.6.1. Fibrinogen-binding proteins 
 
1.6.1.1. M-protein 
 
Arguably the best studied cell wall-associated proteins of streptococci are the M protein 
family of S. pyogenes (Meehan et al. 1998; Smeesters et al. 2010) and other M-like proteins 
identified in Groups C and G streptococci (Bisno et al. 1997; Simpson et al. 1992).  
The term M protein refers to fibrillar surface proteins of streptococcal species that 
have a variety of ligand activities. M proteins also have a variety of common structural 
attributes including variable N-terminal region, signal and cell wall anchoring (LPXTG) 
sequences, conserved central C repeats and C-terminal domains rich in proline. The term is 
also restricted to those proteins that induce opsonic antibodies for the strain from which the 
protein is derived. M protein has long established clear virulence functions primarily in 
inhibiting phagocytosis in the absence of opsonising antibodies (Smeesters et al. 2010). 
Strains that fail to express M protein are avirulent (Lancefield 1962). Key characteristics of 
M protein also include a hypervariable N-terminal region (Cunningham 2000) which results 
in a large degree of antigenic variation and the ability to elicit type-specific protective 
antibodies via the interaction of M protein with a wealth of host proteins (Smeesters et al. 
2010).  
S. zooepidemicus expresses two M-like proteins known as SzP (Moore and Bryans 
1969) and SzM (Kelly et al. 2006) which are antigenically variable amongst strains and are 
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acid-extractable surface antigens. SzP elicits serum opsonic and protective responses and is a 
40.1kDa, acid-resistant protein. It has also been shown to bind to human Hep-2 epithelial 
cells (Fan et al. 2008).  Two similar M proteins are expressed in S. equi, one of which is 
highly sequence related to SzP and cross-reactive to anti-SzP antibodies, known as SzPSe 
(Timoney et al. 1995); the other is unique to strains of S. equi (SeM). Despite having 
functional similarities, SzP and SeM do not share a high degree of sequence homology to 
each other or indeed to the M proteins of S. pyogenes (Timoney et al. 1997). The M proteins 
of S. pyogenes have three distinct functional domains (A, B and C); regarding SzP or SeM 
only the C domain is present. They do however possess an N-terminal leader peptide and C-
terminal cell wall sorting signal. SeM and SzPSe are also suggested to have extensive regions 
of α-helical coils as predicted by their secondary structures (Harrington et al. 2002). The M-
like protein SzM of S. zooepidemicus is thought to be a replacement or modification of the 
SeM gene rather than a direct acquisition (Kelly et al. 2006).  
Regarding SeM, sequence variation has been shown to be a key aspect S. equi 
virulence. Despite being uniform in size (~58 kDa), many isolates have been shown to 
possess a large degree of N-terminal variations (at amino acid positions 37-143) and 
occasionally signal peptide variation. For example, examination of a sample of horses with 
chronic guttural pouch empyema found up to 25% N-terminal deletion of the entire sequence 
had occurred (Chanter et al. 2000). N-terminal variance has also been noted in a variety of 
other isolates collected from 1950 onwards in North America, Japan and Europe (Anzai et al. 
2005; Ivens et al. 2011; Kelly et al. 2006). Several other studies have shown that the rate of 
SeM mutation is high and evidence has been presented that changes can occur in the SeM 
allele in an infected horse during a outbreak (Anzai et al. 2005; Kelly et al. 2006). These 
studies also indicate that there may be diversifying selective pressure of variants with N-
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terminal amino acid substitutions. Evidence also suggests that N-terminal variation affects 
only a conformational and not a linear epitope (Timoney et al. 2007). A possible explanation 
for the prevalence of N-terminal variation could be that SeM sequence changes enhance 
bacterial survival in the host. This conclusion is reinforced with emergent strains more 
commonly identified in chronically infected guttural pouches and cranial sinuses indicating 
that N-terminal variation may aid the process of immune evasion in these niches (Ijaz et al. 
2011). Currently there are 87 allelic variants listed on the SeM database (http://pubmlst.org/).  
Both SzP and SeM have been shown to bind to equine fibrinogen and 
immunoglobulin G (IgG) (Meehan et al. 2009; Timoney et al. 1997). The binding of 
fibrinogen reduces C3b deposition on the bacterial cell wall and resists neutrophil mediated 
phagocytosis (Boschwitz and Timoney 1994). This method of phagocytosis resistance is 
similar to that of the previously described M proteins of group A streptococci (Boschwitz and 
Timoney 1994). SeM antigens are also opsonised by antibodies against SeM that have no 
effect on SzP and vice-versa (Timoney et al. 1997). Studies have shown that resistance to 
phagocytosis in vitro in S. equi is predominantly due to the action of SeM with SzPSe having 
a more secondary role (Timoney et al. 1997). Investigations by Timoney and co-workers  
have also shown that the N-terminus of SeM contains epitopes reactive with mucosal IgA and 
stimulatory for lymph node T lymphocytes in immunized horses (Timoney et al. 2010). 
Variation of this region can also render the conformation of a B cell epitope un-reactive but 
surprisingly has no effect on fibrinogen binding or S. equi opsonisation. 
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1.6.1.2. H-binding protein 
 
Recently a new fibrinogen binding protein unique to S. equi  (Se18.9) was identified by 
Timmony and co-workers (Tiwari et al. 2007). This new protein was found to bind to 
complement regulatory protein factor H and found to reduce the bactericidal activity of 
equine neutrophils in serum. In the presence of Se18.9 specific antiserum, a two-fold increase 
in phagocytosis of S. equi was observed. As an anti-phagocytic protein, Se18.9 was shown to 
act a cofactor for factor I, inhibiting the C3 convertase pathway and thus reducing C3b 
deposition on the bacterial cell surface. Other proposed Se18.9 effects on 
opsonophagocytosis include direct toxic damage and neutrophil adhesion interference. 
Additionally since Se18.9 also binds to tonsillar epithelial cells and elicits strong serum and 
mucosal antibody responses it was theorised that Se18.9 may be directed by a similar 
acquired immune response selective pressure as illustrated by SeM (Ijaz et al. 2011).  
In contrast however, to SeM it has since been shown that Se18.9 exhibits very little 
variation in a population of seM allelic variants. This suggests that Se18.9 structure may 
either be important for virulence function or may alternatively be minor compared to SeM 
(Ijaz et al. 2011). Although some S. zooepidemicus strains were shown to have similar sized 
open reading frames, no specific homologue has currently been found of Se18.9 in any 
known strains of S. zooepidemicus.  
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1.6.2. Hyaluronic acid capsule 
 
In vertebrate species, hyaluronic acid (HA) is an important extracellular matrix polymer 
involved in a variety of functions such as cell trafficking and binding of water molecules. 
Investigations into pathogenic Group A and C streptococci have also found HA to be a key 
constituent of the streptococcal capsule material (Lee and Spicer 2000). Considering the 
morphology of S. equi, virulent isolates of S. equi are highly encapsulated producing mucoid 
colonies when cultured due to the presence of hyaluronic acid (Anzai et al. 1999). The 
capsule is a high molecular weight polymer of HA, a polysaccharide with alternating residues 
of N-acetylglucosamine and glucuronic acid (Timoney 2004). The capsule has several 
functions, the primary one being phagocyte resistance, preventing large numbers of 
streptococci from being associated with the surface of neutrophils. The negative charge of the 
capsule also produces a reducing environment, protecting the activity of streptolysin S and 
oxygen-labile proteases. The HA capsule of S. pyogenes has also been shown to act as a 
ligand for the receptor CD44 on human epithelial and haematopoietic cells (Harrington et al. 
2002).  
In S. equi an absence of the HA capsule has been shown to result in the aggregation of 
SeM, thereby causing a loss of the three-dimensional conformation and preventing the 
functionality of SeM (Timoney, 1999). The adherence of S. zooepidemicus to HeLa cells has 
also been shown to be significantly reduced in non-encapsulated strains (Wibawan et al. 
1999). 
Synthesis of the HA capsule is by the multifunction membrane-bound enzyme, HA 
synthase which assembles HA from two precursor sugars, UDP-glucoronic acid and UDP-N-
acetylglucosamine (Tlapak-Simmons et al. 1999).   
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The has operon gene products are responsible for the synthesis of the capsule. The 
operon consists of (the aforementioned) hyaluronate synthase (hasA) (Deangelis et al. 1993), 
UDP-glucose dehydrogenase (hasB) and UDP-glucose pyrophosphorylase (hasC) 
(Dougherty and Vanderijn 1994). Two has operons were recently identified in S. equi and S. 
zooepidemicus and are likely the result of intragenome gene duplications (Blank et al. 2008).  
In S. zooepidemicus (H70), hasC has been translocated to an opposite replichore by a 
large genome inversion (Blank et al. 2008). The constituents of the has operon in S. 
zooepidemicus; hasA, hasB and hasC, as well as N-acetyl-glucosamine-1 phosphate 
uridyltransferase [glum] and Glucose-6-phosphate isomerise [pgi] are all located in order 
(Blank, et al. 2005). However, in S. equi the genes are separated onto two operons; hasA, 
hasB, hasC and hasC, glmU and pgi (Blank et al. 2008). Both Pgi and GlmU are both 
involved in the synthesis of the UDP-N-acetyl-glucosamine precursor, with the hasB and 
hasC gene products responsible for the synthesising UDP-glucuronic acid precursor.   
The hasC-mediated inversion in S.equi (4047) has been theorised to account for an 
increased production of hyaluronate capsule compared to isolates of S. zooepidemicus 
(Holden et al. 2009).  The inclusion of additional genes in the has operons of both S. equi and 
S. zooepidemicus also indicates a selective advantage of enhanced HA production with S. 
zooepidemicus able to direct more than 10% of its carbon towards HA production, far higher 
than other streptococci (Blank et al. 2005). 
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1.6.3. Lipoproteins 
 
Currently five lipoproteins have been identified in S. equi and S. zooepidemicus; hyaluronate-
associated protein (HAP) (Chanter et al. 1999), metal binding lipoprotein (MBL) 
(Harrington, et al. 2000), SeHtsA (Nygaard et al. 2006), PrtM (Hamilton et al. 2006) and the 
acid phosphatase lipoprotein, LppC (Hamilton et al. 2000).  
HAP was first described in S. equisimilis as a hyaluronate synthase (Lansing et al. 
1993) and is a 56-kDa extracellular threonine kinase thought to relate to the regulation of HA 
capsule synthesis and HA release from the cell surface (Lansing et al. 1993). This is said to 
have been achieved through HAP autophosphorylation (Nickel et al. 1998). Two proteins 
similar to HAP were subsequently identified in S. equi and S. zooepidemicus and were 
thought to be hyaluronate (capsule)-associated proteins (Chanter et al. 1999). It has since 
been shown that they are instead likely to act as substrate-binding lipoprotein for the uptake 
of oligopeptides via ATP-binding cassette (ABC) transporters (Harrington et al. 2002).  
The ability of bacteria to scavenge a wide variety of nutrient substrates is a key aspect 
of infection. Bacterial ABC import transporters are typically ATP-driven three component 
systems involving a substrate-binding protein (SBP), a trans-membrane transport unit and a 
cytoplasmic ATP-binding component (Facey and Kuhn 2010). The majority of ABC 
transporters are importers and a characteristic component of such systems is a solute binding 
lipoprotein encoded within the same operon as the other previously stated ABC transporter 
components (Harrington et al. 2000).  
A well characterised SBP is PsaA, a member of the LraI family of metal-binding 
lipoproteins and a substrate-binding component of a manganese import system, identified in 
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S. pneumoniae (Johnston et al. 2004). PsaA has been shown to perform a role in bacterial 
protection from superoxide with mutant strains of psaA shown to cause deficiencies in 
growth, virulence, adherence and the oxidative stress response (Johnston et al. 2004).  
The LraI family of proteins also consists of MtsA of S. pyogenes and SloC of 
Streptococcus mutans.  Mutant strains with an absence of SloC  have been shown to possess a 
decreased virulence in animal model studies (Kitten et al. 2000).  S. equi contains a 
homologue of PsaA (87% similarity) and, MtsA (95% similarity), originally termed MBL 
(Harrington et al. 2000). Despite the PsaA homologue also being present in S. zooepidemicus, 
western blot analysis using anti-PsaA serum and whole cell extracts showed a weaker level of 
detection in S. zooepidemicus than that of S. equi. A plausible explanation for this occurrence 
is that gene expression of this SBL is lower in S. zooepidemicus during standard growth 
conditions; however the employment of different bacterial growth conditions did not 
intensify the reaction (Harrington et al. 2000) although this could also be due to weaker 
cross-reactivity.  
The acquisition of iron is notably essential to establish infection (Wooldridge and 
Williams 1993). In Gram-positive pathogens, this is usually achieved via heme specific ABC 
transporter systems and cell surface proteins capable of binding heme, known as 
hemoproteins. Considering S. pyogenes, a heme-specific ABC transporter is encoded by 8 
specific genes and regulated by MtsR. One such operon htsABC, with a lipoprotein 
homologue demonstrated in S. equi notated as SeHts. Studies have shown that SeHtsA binds 
heme and hemin and consequently this iron acquisition mechanism is likely to be conserved 
between S. equi and S. pyogenes. In addition to this system, a siderophore type (‘equibactin’) 
iron-uptake locus has also been identified in S. equi (Heather et al. 2008). 
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A specific lipoprotein known as maturase (PrtM) has also been characterized as a 
virulence factor. Mutants of PrtM were shown to have an impared ability to colonize the 
equine upper respiratory tract (Hamilton et al. 2006). In addition to these 5 lipoproteins, 
genomic analysis of S. equi and S. zooepidemicus suggests that at least 30 other putative 
lipoproteins are encoded in these genomes (Sutcliffe, unpublished data). The acid 
phosphatase lipoprotein, LppC will be discussed in greater detail in section 1.19 and is the 
subject of Chapter 5 of this thesis. 
 
1.6.4. Superoxide dismutase 
 
S. equi has been shown to encode a manganese-dependent superoxide dismutase (SOD) 
(Poyart et al. 1998). SOD catalyses the conversion of superoxide anions to hydrogen 
peroxide and water, converting reactive oxygen intermediates into less toxic forms. The 
generation of reactive oxygen intermediates is associated with phagocytosis and thus SOD 
may allow S. equi to combat oxidative stress. Although not investigated in S. equi it has been 
shown that inactivation of the manganese-dependent SOD gene (sodA) of S. pneumoniae led 
to a reduction in pneumococcal virulence in a mouse model (Gibson and Caparon, 1996). The 
gene sodA has been shown to be conserved amongst all S. equi isolates investigated (Poyart, 
et al. 1998) and has become a target gene of interest for real-time PCR based detection and 
differentiation of S. equi and S. zooepidemicus (Båverud et al. 2007).  
 
1.6.5. Super-antigens 
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Emerging strains of S. pyogenes with particularly high mortality and morbidity were 
identified in the 1980s to produce super-antigens (sAgs) (Ikebe et al. 2002). sAgs interfere 
with the development of a protective immune response, by disrupting antigen-specific T cell 
responses and inhibiting the production of antibodies (Llewelyn and Cohen 2002). As well as 
disrupting the mechanism of major histocompatibility complex (MHC)- restricted antigen 
presentation (Dellabona et al. 1990), the ability to augment endotoxin activity and cause local 
inflammation are other related properties of sAgs (Llewelyn and Cohen 2002). The 
stimulation of a non-specific T cell response and proinflammatory cytokine release results in 
toxic shock syndrome in individuals suffering a S. pyogenes infection (Artiushin et al. 2002; 
Sriskandan et al. 2007).  
Currently 11 sAgs have been identified in S. pyogenes with some chromosomally 
located and others located on mobile genetic elements (Smoot et al. 2002; Sriskandan et al. 
2007). Several clinical features of strangles disease are associated with proinflammatory 
cytokine release and therefore S. equi sAgs are of great interest (Artiushin et al. 2002). Four 
homologues of S. pyogenes sAgs have been identified in S. equi: seeH, seeI, seeL, and seeM 
(Holden et al. 2009). All S. equi sAgs are carried on two prophages i.e. ΦSeq3 (SeeM and 
SeeL) and ΦSeq4 (SeeH and SeeI) with SeeL and SeeM identified in S. equi strains that 
predate the isolation of sAg encoding S. pyogenes strains (Ikebe et al. 2002). The 
pyrogenicity of SeeH and SeeI were recently investigated and found to result in a raised 
temperature in animal models post injection  (Artiushin et al. 2002). SeeH and SeeI also 
appeared to be potent for equine peripheral blood mononuclear cells, at least when compared 
to Spe-A and Spe-C for human T cells (Braun et al. 1993). Recently S. equi sAg-induced 
lymphoproliferation was also shown in vitro, with SeeM indicating the highest degree of 
potency. Deletion of sAg genes was also shown to annul mitogenic activity (Paillot et al. 
34 
 
2010). It has also been speculated that differences in the level of sAgs expression amongst 
strains may account for strain specific differences in disease severity, although this has yet to 
be clarified (Paillot et al. 2010).  
It was previously thought that sAgs were absent in S. zooepidemicus as strains with 
mitogenic activity were screened for the presence of S. equi sAgs homologues and none were 
found (Holden et al. 2009). However three novel sAgs - SzeF, SzeN, and SzeP from S. 
zooepidemicus (strain BHS5) have been recently identified and were found to be significantly 
associated with isolation from equine cases of non-strangles lymph node abscessation (Paillot 
et al. 2010). 
 
1.6.6. Fibronectin-binding proteins 
 
Fibronectin (Fn) is found in plasma and in the extracellular matrix in a fibrillar form and is a 
dimeric glycoprotein (Lindmark et al. 1999). Specific cell surface receptors bind to specific 
domains of fibronectin, mediating the substrate adhesion of eukaryotic cells. Fibronectin also 
interacts with a variety of macromolecules including collagen, fibrin, heparin and DNA 
(Lindmark et al. 1999).  
Fn-binding proteins are cell surface proteins which have been shown to enhance 
bacterial potential to cause disease (Lindmark et al. 2001; Schwarz-Linek et al. 2003). The 
Fn-binding proteins SfbI/protein F1 and M1 from S. pyogenes have been shown to enable the 
spread of bacteria deeper into tissues (Jadoun et al. 1997) by mediating the adherence to and 
the invasion of epithelial cells (Lapenta et al. 1994). Fn-binding proteins have also been 
shown to mediate host cell invasion without the presence of other virulence factors in S. 
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aureus (Sinha et al. 1999)  and S. pyogenes (Ozeri et al. 1998). Fn-binding proteins may also 
be significant in the pathogenesis of streptococcal endocarditis (Jakubovics et al. 2009). 
Currently three Fn-binding cell proteins, FNZ (Lindmark, et al. 1996), FNZ2 (Hong 
2005) and secreted fibronectin binding protein (SFS) (Lindmark and Guss 1999) have been 
identified in S. zooepidemicus. FNZ and FNZ2 has been shown to encode all the features 
typically associated with cell wall associated proteins including a C-terminal domain 
containing LPXTG, a hydrophobic spanning domain and a signal peptide (Lindmark et al. 
1996).  
Homologues of FNZ and FNZ2 have also been identified in S. equi, notated as FNE 
(seq0375) (Lindmark et al. 2001) and FNEB (Lannergard et al. 2005). SFS has also been 
identified in all investigated strains of S. equi.  FNE however binds fibronectin considerably 
more weakly than FNZ due to a one-base deletion present in the fne gene, enabling the 
translation of only the 5’-terminal portion of the gene and thus an absence of terminal 
sequence motifs involved in protein cell wall anchoring. FNZ also possess two Fn-binding 
sites in the C-terminal and N-terminal region in contrast to FNE (Lannergard et al. 2005). 
SFS was found to inhibit binding between collagen and Fn (Lindmark and Guss 1999). 
However studies have shown that SFS has a limited effect on Fn binding in S. equi and it is 
not known whether or not SFS is cell bound or secreted (Lindmark and Guss 1999).  
Horses with strangles have been shown to produce a strong IgG antibody response to 
FNE, SFS and FNEB. However antibody titres to each have no correlation, indicating that 
while an antibody response is generated to each individual Fn-binding protein, there is no 
general Fn-binding antibody response, with each individual horse responding differently to 
different antigens (Lannergard et al. 2005).  
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1.6.7. Collagen-binding proteins 
 
The ability of bacteria to adhere to host collagen via collagen-binding protein has been 
characterised as a virulence factor in S. aureus (Hienz et al. 1996). A collagen-binding 
protein, similar to CNA of S. aureus (231/657 amino acids), was identified in S. equi and 
denoted as CNE (Lannergard et al. 2003). The highest degree of homology between CNE and 
CNA was also found to be in the collagen binding region.  
The cne gene encodes a 657 amino acid protein and contains an N-terminal signal 
sequence, a hydrophobic C-terminal transmembrane region and an LPXTG motif (LPDTG). 
The cne gene has also been identified in S. zooepidemicus but is not identical to that of S. 
equi. Although the significance of CNE in virulence has not been established, an evolutionary 
relationship between CNE and CNA is suggested (Lannergard et al. 2003). Following a study 
into putative extracellular proteins in S. equi using signal sequence phage display, another 
collagen-like protein was identified and notated as SclC (Karlstrom et al. 2004). The 
identified protein was found to share similarity to the N-terminus of SclB, a collagen-like 
protein of S. pyogenes (Whatmore 2001). However no specific binding activity of SclC has 
currently been shown and despite high collagen-binding activities in S. equi and S. 
zooepidemicus no collagen-binding activity was detected in material released from the cell 
surface (Karlstrom et al. 2004). This is in agreement to similar findings concerning CNE 
(Lannergard et al. 2003).  
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1.6.8. Immunoglobulin G (IgG) endopeptidases 
 
An important participant of the adaptive immune system is IgG, with the binding of IgG to an 
antigen providing an enhancement to several reactions including complement activation and 
phagocytosis (Hulting et al. 2009). In order to evade recognition by immunoglobulins, some 
bacterial pathogens possess IdeS which is a cysteine protease that cleaves IgG and therefore 
interferes with phagocytic killing. An example of this is IdeS from S. pyogenes (von Pawel-
Rammingen et al. 2002). A homologue of IdeS has since been found in S. equi and S. 
zooepidemicus, notated as IdeE and IdeZ respectively (Lannergard and Guss 2006). Cell 
culture studies show that active IdeE is expressed during the logarithmic phase only in the 
presence of horse serum (Lannergard and Guss 2006). IdeE has also been shown to block 
phagocytosis in vitro by reducing the bactericidal activity of equine neutrophils (Timoney et 
al. 2008).  
Recently a further IgG endopeptidase was found in S. equi, with a similar protein also 
present in S. zooepidemicus, notated as IdeE2 and IdeZ2 respectively (Hulting et al. 2009). 
Sequence comparisons have shown that IdeE2 and IdeZ have a closer relationship to IdeS 
than IdeE/IdeZ2 and that IdeE and IdeE2 were conserved amongst all S. equi strains 
investigated. In contrast, IdeZ and IdeZ2 were only found in a selection of S. zooepidemicus 
strains (Hulting et al. 2009). IdeE and IdeZ were also found to exhibit a broader substrate 
activity than either IdeE2 or IdeZ2. Immunization experiments have also demonstrated that 
IdeE and IdeE2 induce protection in a mouse model with IdeE2 in particular shown to 
significantly reduce both nasal growth of S. equi and improve the condition of vaccinated 
animals (Hulting et al. 2009).  
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1.7. Vaccines against S. equi 
 
Conventional vaccination strategies have proved largely ineffective towards S. equi. Little 
efficacy and an undesirable level of adverse reactions were shown when trialling vaccines 
containing inactivated whole bacteria or extracts (Lr 1990). Initially a protein-rich acid 
extract (Reif 1981) and a mutanolysin extract (Bryant et al. 1985) vaccine was introduced in 
the 1980s in North America but showed only a moderate level of efficacy with no reduction 
in bacterial shedding or a reduced transmission. Vaccinations based on bacterins and 
adjuvanted extracts were also shown to have little efficacy (Jorm 1990). A vaccine consisting 
of a non-encapsulated strain of S. equi was then later developed and used (Pinnacle IN
tm
) as a 
nasal vaccine but never licensed in Europe. A second live attenuated vaccine (Equilis StrepE) 
was also developed and granted a licence in Europe (Jacobs et al. 2000), but later removed 
from use due to safety concerns (Kemp-Symonds et al. 2007; Newton et al. 2005). Equilis 
StrepE has since been re-launched in Europe, initially in the Netherlands in May 2010. 
However a need for an improved vaccine remains prominent.  
Further vaccination strategies are based on ‘reverse vaccinology’, using genome 
sequence data of S. equi to identify surface exposed and secreted proteins. The target protein 
initially of many of the early vaccines using this strategy was the SeM protein. Often 
vaccination challenge studies using the mouse model were encouraging. However, despite the 
presence of SeM reactive antibodies, significant protection in horses was not shown (Sheoran 
et al. 2002) and high level of side effects with SeM based vaccination trials had previously 
been shown (Hoffman et al. 1991). The general consensus for an improved vaccination 
strategy, based on the shortcomings of past vaccine trials are that of multiple protective 
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epitopes. An alternative to live attenuated vaccines are therefore multi-component subunit 
based vaccines of several immunogenic S. equi surface proteins (Waller and Jolley 2007b).  
The first vaccine based on combinations of subunits contained the surface proteins 
FNZ, SFS and EAG. The use of EAG was shown to demonstrate protection as a single 
antigen but its efficacy was significantly improved by the addition of FNZ and SFS (Flock et 
al. 2004). 
Using recombinant antigens against S. equi, numerous groups have shown some 
success in mouse model systems, similar to the SeM based vaccine. Partial protection was 
achieved in ponies challenged with (‘Trivacc’) (Waller et al. 2007) consisting of EAG (Flock 
et al. 2004), SclC (Karlstrom et al. 2004) and CNE (Lannergard et al. 2003). However, 
despite promising reductions in nasal discharge, bacterial carriage and empyema the level of 
protection in individual horses was limited (Waller et al. 2007). The ‘Trivacc’ vaccine has 
since been improved and revaluated (‘Septavacc’). Two cell surface anchored proteins of 
unknown function (SEQ0256 and SEQ0402) were added to EAG, CNE and SclC as were the 
two endopeptidases (IdeE and IdeE2), which resulted in an improved level of protection with 
only one pony out of seven developing lymph node abscesses (Guss et al. 2009).  
A further recent development has concerned the cell envelope proteinase, SpyCEP 
(cepA). SpyCEP was found in S. pyogenes to represent a convincing vaccine candidate due to 
its high degree of conservation between S. pyogenes isolates (Turner et al. 2009). Data 
showed that immunity to SpyCEP prevented severe infection dissemination in eight BALB/c 
mice. The group also investigated functional homologues of SpyCEP in other streptococcal 
species with homologues of 74% similarity to SpyCEP identified in S. equi (SeCEP) and S. 
zooepidemicus (SzoCEP). Cross-protectivity of SpyCEP immunization was also investigated 
and showed that immunization against SpyCEP induces neutralizing immunity, preventing 
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dissemination of disease from the site of infection (Turner et al. 2009). However S. equi is 
more suppurative than S. pyogenes and despite a reduction of disease dissemination the 
infection was not completely inhibited. Little protection was shown with an immunization 
challenge against S. equi and SzoCEP (98% identical to SeCEP) was found to be poorly 
expressed in the strains tested. 
Common difficulties with many of the recent vaccine attempts include a short 
duration of immunity and purulent reactions at the site of injection. The emphasis on subunit 
and inactivated vaccines has also created a need for more competent adjuvants and delivery 
systems (Meeusen et al. 2007). An example of how to address this need is the use of surface 
modified polymeric nanoparticles, which displayed an improved adsorption efficacy for S. 
equi extract proteins (Florindo et al. 2010).  
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1.8. Phospholipases 
 
Phospholipids were once thought of as inert building blocks of cellular membranes, but are 
now considered important metabolic entities with phospholipids and their metabolites 
providing prominent roles in many cellular control systems. The elevation of the importance 
of phospholipids has thus given phospholipases (PL) a preeminent standing with regard to 
potential roles of phospholipases in biological systems. PL are now regarded as more than 
simple maintenance enzymes being considered as important metabolic entities (Dennis 2000) 
and have now been shown to play a role in a large variety of biological functions, including; 
host defence, signal transduction and lipid mediator production (Lambeau and Lazdunski 
1999), along with the ability to destroy or disrupt components of host cells membranes 
(Ghannoum 2000).  
The PL comprise of an expanding family of distinct enzymes which share the ability 
to hydrolyze one or more ester linkage in glycerophospholipids to release fatty acids and 
lysophospholipids (Lambeau and Lazdunski 1999). Differentiation of PL into groups PLA, 
PLB, PLC and PLD indicate the specific bond targeted in the phospholipid molecule (Figure 
1.8).  
The repertoire of potential functions and impact on host biological functions ensure 
that characterised PL enzymes are of great interest regarding the search for novel virulence 
determinants of pathogenic bacteria and two recently identified PL enzymes in S. equi are the 
subject of chapter 4.  
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Figure 1.8: Current classification of phospholipases. 
Group A cleave the fatty acid carboxylic acid ester from phospholipids. Group A are further 
divided into two sub-groups (PLA1 and PLA2) based on position specificity of fatty acid 
cleavage; either sn-1 (PLA1) or sn-2 (PLA2). R1 and R2 represent fatty acid chains in either 
the sn1 or sn2 position of the phospholipid, respectively. PLB can result in total deacylation 
of phospholipids with the potential of dual PLA1 and PLA2 activity. PLC and PLD catalyze 
the hydrolysis of one of the two phosphate ester bonds. X refers to the phospholipid head 
group.  
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1.8.1. Phospholipase putative roles in bacterial virulence 
 
Historically PL enzymes have been shown to have a well-defined function regarding the 
damage and destruction of biological tissue. A large body of literature is available regarding 
venom secreted phospholipase enzymes, which can be potent toxins exerting a wide range of 
effects including neurotoxicity, myotoxicity, cardiotoxicity and inflammation (Lambeau and 
Lazdunski 1999).  
The number of identified and classified PL enzymes from bacterial and protozoan 
pathogens has recently been increasing at a steady rate. Although many PLs have now been 
identified in bacteria, many have as yet undefined roles. Although originally thought of as 
possessing sole putative roles in membrane maintenance, mutants have shown that some PLs 
are not necessarily essential for viability (Oki et al. 1972). In view of this, several PL 
enzymes have now been identified as important virulence factors for pathogenic bacterial 
species. A common theme is the breakdown of host cell barriers and the creation of a more 
favourable bacterial niche.  
Most characterised PL virulence factors belong to the PLC class. Indeed, historically, 
initial investigations regarding phospholipases as virulence factors concerned the 
reclassification of some prominent bacterial toxins such as α toxin of Clostridium perfringens 
(Macfarlene 1941) and β toxin of S. aureus (Doery et al. 1963) as PLC. PLs as toxins are 
generally linked to the active destruction of membrane phospholipids (cytolysis), aiding the 
bacterium to degrade and penetrate the mucous layer or to avoid immune cells. Other non-
cytolytic tissue destruction has also been attributed to the presence of PLC from C. 
perfringens. Incubation with purified α-toxin also induced the expression of cytokines 
including tumour necrosis factor (TNF-α), platelet activating factor (PAF) (Stevens et al. 
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1997) and Interleukin 8 (IL-8) (Bryant and Stevens 1996) as well as the triggering of the 
arachidonic acid cascade (see section 1.8.2). In contrast some PLs have more subtle roles in 
bacterial pathogenicity. The facultative intracellular pathogen L. monocytogenes possesses 
two PLC enzymes, PlcA and PlcB. Mutation of PlcA demonstrated that Plc provides a clear 
role in bacterial escape from the macrophage phagosome (Camilli et al. 1993). Further to the 
evidence provided from investigations into PLCs, PLD secreted by Corynebacterium 
pseudotuberculosis has been shown to play a major role in caseous lymphadenitis, enhancing 
the spread of infection through tissues to the lymphatics by increasing vascular permeability 
as well as being dermonecrotic (Muckle and Gyles 1983).     
Recently more characterised examples of the lesser understood PLA2s have begun to 
emerge. For example, Yersinia enterocolitica secretes PLA2 which has been shown to 
contribute to enhanced bacterial colonisation in a mouse model (Schmiel et al. 1998). A 
reduced bacterial colonization was exhibited in the Peyer’s patches and mesenteric lymph 
nodes of mice infected with mutants of Y. enterocolitica lacking PLA2.  
Bacterial haemolytic and cytotoxic activities have also been attributed to the activity 
of PLA2. For example bacteria belonging to the genus Rickettsia have been shown to display 
haemolytic activity, requiring a mildly acidic pH and divalent cations consistent with PLA2 
activity. The role of rickettsial PLA2 was confirmed by showing effective inhibition of the 
cytotoxic effect of Rickettsia prowazekii following the addition of the PLA2 inhibitor  bromo-
phenacyl bromide (BpB) and by western blot studies with anti-phospholipase A antibody 
from king cobra venom (Walker et al. 2001).  
Several PLA2 enzymes have also been implicated as virulence factors in Helicobacter 
pylori. The role acts by hydrolysing the fatty acid from the second carbon of membrane 
phospholipids such as lysolecithin, the metabolism of lysolecithin therefore occurs slower 
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than fatty acids, allowing the bacteria to persist in host tissues longer (Langton and Cesareo 
1992). Recently a PLA2 (PlaB) was characterised as a new virulence factor in Legionella 
pneumophila. This cell-associated PLA was found to express contact-dependent haemolytic 
activity and mutant strains were identified to have an impaired replication in the lungs and 
dissemination to the spleen in a guinea pig infection model (Schunder et al. 2010).  
A further well characterised family of prokaryotic PL is the OMPLA (outer 
membrane phospholipase A) family found in many Gram-negative bacteria. Originally 
identified in E.coli (Scandell and Kornberg 1971), several similar OMPLA have been 
identified in H. pylori and several enterobacteriaceae. Regarding H. pylori, a specific 
characteristic of this human pathogen is its ability to reversibly alter its membrane lipid 
composition from <2% lysophospholipid (a product of phospholipase A2 reactions)  in one 
variant to >50% in another (Tannaes et al. 2000). This increase of lysophospholipids in H. 
pylori is due to action of OMPLA on the ordinary phospholipids, rather than the 
lipopolysaccharide anchor. This then increases the bacteria’s tolerance to pH and improves 
host cell attachment. This increase in lysophospholipid allows the release of further H. pylori 
virulence factors such as VacA and urease, overall altering the host environment to favour 
bacterial growth, colonization and survival (Istivan and Coloe 2006). 
When the fatty acid, arachidonic acid (AA) is released from phospholipids, PLA also 
provide key precursors for the generation of eicosanoids by several eicosanoid-generating 
enzymes (See section 1.8.2). AA metabolism has also been shown to regulate E. coli 
penetration of the Blood-Brain barrier (Zhu et al. 2010). Although the exact mechanisms 
remain unknown, gene deletion of the PLA2 of E. coli K1 and pharmacological inhibition 
resulted in reduced bacterial penetration into the brain, but not into non-brain organs (Das et 
al. 2001)  
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1.8.2. The mammalian arachidonic acid (AA) cascade 
 
AA (cis-, cis-, cis-, cis-5, 8, 11, 14-eicosatetraenoic acid) is a 20-carbon polyunsaturated fatty 
acid (C20:4) and axial eicosanoid precursor derived from dietary sources (linoleic acid) in 
mammals once AA is biosynthesised, it is esterified into the phospholipids of the other cell 
membranes (Hyde and Missailidis 2009).  
AA and its metabolites are therefore essential fatty acids in the majority of mammals. 
AA released by PLA2 is the key constituent of the AA cascade (Fig 1.9). The AA metabolites 
produced during the AA cascade are termed eicosanoids and produced by the catalytic 
activities the constituents of three pathways: cyclooxygenase (COX), lipoxygenase (LOX) 
and cytochrome P450 epoxygenase (CYP450) (Hyde and Missailidis 2009).  Eicosanoids 
include lipid signal mediators which play a key role in cellular signalling cascades. The 
majority of AA metabolites can act as both pro- and anti- inflammatory mediators by 
modulating gene expression, cytokine signalling and other regulatory factors (Cabral, 2005).  
Drugs with the action of inactivating human PLA2 and thus inhibiting the AA cascade 
are currently of much pharmacological interest regarding potential suitability as anti-
inflammatory targets (Sugiyama et al. 2002). 
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Figure 1.9: The AA cascade, indicating the three key enzymatic pathways of AA. 
Taken from (Hyde and Missailidis 2009) 
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1.8.3. PLA2 
 
As described in section 1.8.1, the PLA2 group of PL enzymes are of particular interest as 
potential virulence factors. This group of enzymes can be either high molecular weight 
cytosolic (CPLA2) or low molecular weight secreted (sPLA2) and represent a super family 
which also contains calcium independent PLA2 (iPLA2), the latter being widely distributed in 
eukaryotic cells and tissues (Madsen, et al. 2011).   
sPLA2 have also been further classified into currently 11 distinct groups (I-XI) and a 
variety of sub-groups, based upon their amino acid sequences. At present, each group has at 
least one member with a majority containing two or more members (Meyer, et al. 2005). All 
the above groups of sPLAs share a common catalytic mechanism of activity. The active site 
is similar to that of the Ser/His/Asp catalytic triad found in proteases (Poi, et al. 2003) 
andcalcium ions are a requirement for sPLA2 and provide coordination between the substrate 
and the main carbonyl oxygen (aspartate).  
A water molecule acts as the nucleophile in the attack on the sn-2 position of the 
carbonyl carbon in the phospholipid, acting in the same role as the serine in proteases 
(Madsen, et al. 2011). A tetrahedral intermediate is thus formed and the sn-2 oxygen becomes 
protonated, releasing the products (a fatty acid and a lysophospholipid).   
All sPLA2 enzymes characterised so far are water-soluble and are required to bind to 
organized lipid interfaces for catalytic turnover. Naturally occurring phospholipids have poor 
solubility in water as monomers. Therefore it is necessary for hydrolysis to occur at the lipid-
water interface (Ghomashchi, et al. 1998). All phospholipases are subjected to an increase in 
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activity when the lipid concentration is above the critical micelle concentration (interfacial 
activation) (Sekar, et al. 1997). 
Different subtypes of sPLA2 exhibit lipid substrate specificity, for example both sub 
groups V and X are able to catalyze the hydrolysis of both anionic and zwitterionic 
phospholipids in contrast with subgroup II, which is only active towards anionic 
phospholipids. CPLA2 differs in catalytic mechanism, as the presence of Ca
2+
 is not required 
at the active site. These enzymes are translocated from the cytosol to intracellular membranes 
in response to an increased intracellular Ca
2+
 presence (Schievella, et al. 1995).   
 
1.8.4. sPLA2 of streptococci species 
 
A prophage-encoded extracellular PLA2, designated SlaA of S. pyogenes has been recently 
identified (Nagiec, et al. 2004). SlaA expression in S. pyogenes (strain MGAS315) has been 
shown to be induced when exposed to human pharyngeal epithelial cells indicating a role in 
virulence (Banks, et al. 2003). It has been recently identified that the acquisition by a S. 
pyogenes strain of an SlaA encoding bacteriophage has been responsible for the vast majority 
of human infections by serotype M3 strains in many countries (Sitkiewicz, et al. 2006). SlaA 
contains a region of conserved C-terminal amino acid residues; homologous to several sPLA2 
enzymes including toxins produced by venomous snakes such as textilotoxin produced by the 
Australian common brown snake, Pseudonaja textilis. SlaA has since been shown to have 
enzymatic activity against phospholipids with several head groups, releasing the acyl chains 
in the sn-2 position including the ability to release AA (Nagiec, et al. 2004). Evidence 
regarding SlaA as a virulence factor of S. pyogenes has been established using isogenic 
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mutant strains with genetically inactivated slaA (Sitkiewicz, et al. 2006). Purified 
recombinant SlaA was found to not express cytotoxic activity to cultured epithelial cells 
when added exogenously but the mutant lacking SlaA was found to be significantly less toxic 
to epithelial cells.  
It has been suggested that SlaA enters host epithelial cells through an active transport 
mechanism utilising an as yet unknown host-cell receptor (Sitkiewicz, et al. 2007). Entry 
does not require the pore forming toxin Slo. Mouse models have also been utilised in 
clarifying SlaA as a virulence factor in S. pyogenes as comparison between the isogenic 
mutant strain and the wild type showed that the presence of SlaA increased tissue destruction 
and systemic spread in vivo. Larger lesions and a more rapid mortality were also observed in 
mice after subcutaneous injection (Sitkiewicz, et al. 2006).  A cynomolgus macaque model of 
pharyngitis has also been employed to investigate the role of SlaA in upper respiratory tract 
colonisation. SlaA was thus revealed to be a key colonisation factor as the SlaA mutant strain 
was shown to have severely compromised colonisation ability (Sitkiewicz, et al. 2006). It is 
as yet unknown whether SlaA contributes to human invasive diseases such as necrotizing 
fasciitis or if an inflammatory cascade is triggered by SlaA in vivo. A summary of putative 
virulence SlaA effects on eukaryotic cells is shown in figure 1.10 
The S. equi homologues of SlaA are the subject of Chapter 4 
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Figure 1.10: The demonstrated and putative effects of SlaA from S. pyogenes on the eukaryotic cell.  
Figure originally adapted from (Sitkiewicz, et al. 2007). 
 
 
 
 
 
Alteration  
of gene 
Expression? 
 
 
 
Increased bacterial 
attachment 
Membrane 
association 
of PLA
2
 
   
   
   
Receptor mediated 
signal transduction 
 
 
 
Release of AA from 
damaged membranes, 
production of 
eicosanoids and 
induction of an 
inflammatory response? 
 
 
 
 
 
 
 
 
Bacterial Secretion of 
PLA
2 
 
 
Endosomal transport into the host cell? 
  
 
Vacuole degradation? 
Signal Transduction? 
 
 PLA2  Vacuole  Endosome 
 
 PLA2 bound 
to a receptor 
 Nucleus 
52 
 
1.9. Acid phosphatase 
 
The ability to dephosphorylate organic compounds is a key requirement for bacteria, with 
most bacteria encoding several enzymes (known as phosphohydrolyases or phosphatases) 
which are able to hydrolyse phosphoesters or phosophoanhydride bonds (Rossolini et al. 
1998). In many cases, these enzymes can either be membrane bound or secreted outside the 
plasma membrane in soluble form. Phosphatases were initially classified based on 
biophysical properties such as pH optimum and substrate profile but have now been grouped 
following the availability of molecular sequence data and the identification of conserved 
sequence motifs  (Rossolini et al. 1998).  
Despite being of considerable scientific interest, little information regarding the 
nature of bacterial phosphatases exists with most information derived from a small set of 
bacterial models (E. coli or Salmonella enterica ser. typhimurium). Furthermore the 
phosphatase pattern of activity is indicated to be highly variable with a large degree of 
variation shown even in closely related species (Thaller et al 1995).  
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1.9.1. Bacterial non-specific acid phosphatase (NSAP) 
 
A group of phosphatases of particular interest are the bacterial non-specific acid phosphatase 
(NSAP). The term ‘NSAP’ initially indicated bacterial enzymes that  show optimal activities 
at acidic to neutral pH conditions and are active towards a variety of different structurally 
unrelated substrates (Rossolini, et al. 1998).  
NSAP activity was first identified in periplasm of E. coli (Dvorak 1967). However 
characterisation of a bacterial NSAP was not available until the studies of PhoN (non-specific 
acid phosphatase I) and AphA (non-specific phosphatase II), produced by S. enterica ser. 
Typhimurium (Kier 1977; Uerkvitz 1998). Subsequent studies indicated similar proteins to 
AphA and PhoN in a widespread variety of microbial taxa (Rossolini et al. 1998).  
In contrast some secreted phosphatases have specialization towards specific substrates 
such as AppA from E. coli to 2’:3’-cyclic phosphodiesterase (Golovan et al. 2000). Several 
NSAPs from different molecular families can be found encoded by the same organism, which 
suggests that different classes are responsible for different physiological roles. NSAPs have 
now been characterised into three molecular families (A, B and C) (Reilly and Calcutt 2004; 
Rossolini et al. 1998; Thaller et al. 1998). 
 
1.9.1.1. Class A and B NSAP 
 
Molecular class A and B were proposed following investigations into PhoC (Thaller et al 
1994) and NapA (Thaller et al 1995) of Morganella morganii respectively. Class A NSAPs 
share conserved sequence motifs with other eukaryotic phosphatases, with the presence of 
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conserved residues (G-S-Y-P-S-G-H-[TA]) (Rossolini et al. 1998) suggesting an active site. 
They are also secreted monomeric or oligometic proteins and consist of a 25-27 kDa 
polypeptide components. In comparison Class B NSAPs are 100-kDa secreted 
homotetrameric metallo-proteins with a 25-kDa component. While similar in polypeptide 
size, class A and B NSAPs are unrelated in terms of sequence homology.  
Differentiation of class A and B NSAPs can be achieved via zymographic 
investigations. Class A acid phosphatases can be detected by zymography i.e renaturing SDS-
PAGE using various substrates, usually 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) 
(Thaller, 1995). BCIP however has not yet been shown to be hydrolysed by any molecular 
class B NSAP. Resistance to inhibition by EDTA can also be used to differentiate class A to 
class B (Rossolini et al. 1998).  
 
1.9.1.2. Class C NSAP 
 
Of particular interest is the class C NSAP which, are characterized by the presence of four 
invariant aspartic acid residues within a signature motif (Thaller et al. 1998). These are 
structurally and evolutionary similar to the Class B NSAPs but typically contain an amino-
terminal signal sequence type found in putative membrane-bound lipoproteins, hence are not 
secreted across the cytoplasmic membrane as soluble periplasmic proteins (Rossolini et al. 
1998).  
The first identified class C NSAP was OlpA of the clinically significant 
Chryseobacterium (formerly Flavobacterium) meningosepticum, which was detected by 
zymography screening of a group of non-enterobacterial species (Thaller et al. 1998). 
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Following detection and identification of OlpA, two other Class C NSAPs were identified 
through BLAST searches: e(P4) of Haemophilus influenzae and LppC of Streptococcus 
equisimilis (Gase et al. 1997; Green et al 1991). Since this initial identification, e(P4) of H. 
influenza was purified and the first Class C NSAP to be characterised in any detail (Reilly 
and Smith 1999). This has since been followed by several other NSAPs including LppC 
(Malke 1998) which was also found to be expressed in S. pyogenes (Gase et al. 1997). 
Recently acid phosphatase activity has also been detected in whole cell assays of S. equi 
strain 9682 and S. zooepidemicus strain 7023 with both organisms showing western blot 
cross-reaction with anti-LppC  polyclonal antibody, although neither organisms displayed 
NSAP activity zymographically (Hamilton et al. 2000).  
 
1.9.2. Putative NSAP role in virulence 
 
A well established function of NSAP regards the acquisition of nutrients in the form of 
inorganic phosphate (Pi) and organic by-products that are able to be transported across the 
membrane (Rossolini et al. 1998). However some NSAPs have evolved specialized functions 
relating to microbial virulence. A common implication of acid phosphatases as a virulence 
factor lies in aiding bacteria to survive inside phagocytes (Baca et al. 1993; Felts et al. 2005; 
Reilly et al. 1996; Saha et al. 1985).  
Coxiella burnetti is a well described pathogen known to proliferate within host acidic 
phagolysosomes (Akporiaye 1983). Despite possessing superoxide dismutase and catalase 
which are likely to protect it from the action of host phagocytes (Akporiaye 1983b), it has 
been shown that C. burnetti possesses acid phosphatase activity which is also likely 
responsible for inhibiting human neutrophils (Baca 1993).  
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Of particular interest and controversy are the respiratory-burst inhibiting acid 
phosphatases of Legionella micdadei (Das et al 1986) and Francisella tularensis (Saha et al 
1985). A strain of F. tularensis (ATCC 6223, B38) in particular has been shown to exhibit 
very large amounts of a tartrate-resistant NSAP activity, AcpA (Reilly, et al 1996). AcpA 
was also shown to be unique in that it was easily released in soluble form from the bacterium. 
AcpA mutants have also been shown be more susceptible to intracellular killing than wild-
type strains in the THP-1 human macrophage-like cell lines. An increased survival was also 
shown in mice infected with AcpA mutants compared to the wild-type (Mohapatra 2007). 
However conflicting evidence has been presented to suggest that acid phosphatases do not 
contribute to the pathogenesis of Type A F. tularensis (Child et al 2010).  
The P4 NSAP has also demonstrated potential as a vaccine target in H. influenza as it 
is widely conserved amongst H. influenza strains (Green et al. 1991). Reduced intranasal 
colonization has also been demonstrated in a mouse model with a recombinant form of 
lipidated P4 protein (Hotomi et al. 2005).  
The S. equi LppC acid phosphatase is the subject of Chapter 5.  
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2. Materials and methods 
 
2.1. Chemicals 
 
Solution recipes are included in Appendix I or are presented in the text. Standard laboratory 
chemicals and reagents were obtained from either Sigma-Aldrich
®
 (UK) or Fisher Scientific 
(UK) unless stated otherwise. Unless otherwise stated all solutions and buffers were made 
using 18.2 MΩ/cm H2O purified using a Milli-Q plus 185 water purification system, and 
stored at room temperature.  
 
2.2. Commercial kits 
 
A number of commercial kits were used during this research and a list can be found in 
Appendix II. Manufacturer’s instructions were followed without modification unless 
otherwise stated. 
 
2.3. Equipment 
 
A list of equipment used in this study can be found in Appendix II. 
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2.4. Media and solutions 
 
Media recipes are included in Appendix I or are presented in the text. All media were 
prepared using 18.2 MΩ/cm H2O. Liquid media was stored at room temperature and solid 
media at 4ºC.  
 
2.5. Bacterial strains, storage and growth conditions 
 
Streptococcus equi 4047 and Streptococcus zooepidemicus H70 were from the collection of 
Prof. Iain Sutcliffe and were originally kindly provided by Dr Neil Chanter (The Animal 
Trust [Newmarket, Suffolk]). 
Glycerol bacterial stocks (0.5 ml overnight culture and 0.5 ml 50% (v/v) glycerol) 
were aliquoted into Nalgene tubes (Sigma-Aldrich
®
, UK) and stored at -80°C. For agar plate 
storage, S. equi and S. zooepidemicus streak plates were grown using Todd Hewitt agar 
(Oxoid, UK) overnight at 37°C in a candle jar and stored at 4°C. S. equi and S. zooepidemicus 
broth cultures were grown without agitation at 37°C. To confirm the nature and purity of 
cultures gram-staining and Lancefield group C testing (Prolab Diagnostic) was undertaken.  
 
2.6. E. coli bacterial strains and vectors 
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All bacterial strains were maintained at -80°C in 50% (v/v) glycerol, and were used as 
detailed in Table 2.1. 
 
Table 2.1: Bacterial strains and plasmids used in this study 
 
E. coli strain/Vector Characteristics Application Reference/Supplier 
One Shot™ TOP10 
F
-
 mcrA Δ (mmr- 
hsdRMS-mcrBC) 
Φ80lacZΔM15 
ΔlacX74 deoR recA1 
araD139 Δ(ara-
leu)7697 galU galK 
rspL endAI nupG 
Cloning host Invitrogen™ 
BL21 (DE3) 
F- ompT hsdSB (rB
-
mB
-
) gal dcm 
Expression host 
Novagen - (Wood 
1966) 
B834 (DE3) 
F- ompT hsdSB (rB
-
mB
-
) gal dcm met 
(DE3) 
Expression host Novagen 
C41 (DE3) 
F- ompT hsdSB (rB
-
mB
-
) gal dcm lacY1 
Expression host 
Lucigen - (Miroux 
and Walker 1996) 
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C43 (DE3) 
F- ompT hsdSB (rB
-
mB
-
) gal dcm lacY1 
Expression host 
Lucigen - (Miroux 
and Walker 1996) 
Tuner™ 
F- ompT hsdSB (rB
-
mB
-
) gal dcm lacY1 
Expression host Novagen 
BL21 (DE3)pLysS 
F- ompT hsdSB (rB
-
mB
-
) gal dcm met 
(DE3) pLysS (Cam
R
) 
Expression host Novagen 
pCR
®
 -Blunt 
Kan
r
, Zn
r
, T7 lacZα- 
ccdB 
Cloning vector Invitrogen™ 
pET28a Kanr, T7 lac, lacI
q
 Expression vector Novagen 
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2.7. Antibiotics 
 
All antibiotics were purchased from Sigma-Aldrich
®
 (UK) and stock solutions were filter 
sterilised (Table 2.2).  
 
Table 2.2: Antibiotics used in this study 
 
Antibiotic Stock Concentration and Solvent Storage 
Chloramphenicol 
(Melford) 
30 mg/ml in 100% Ethanol -20 ˚C 
Kanamycin (Melford) 10 mg/ml in 18.2 MΩ/cm H2O 
4 ˚C for less than 7 
days or -20 ˚C for 
long term storage 
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2.8. Enzymes 
 
All enzymes and reaction co-constituents were maintained at -20 °C, in 50 % (v/v) glycerol 
unless otherwise stated. A list of general enzymes used in this study is shown in Table 2.3.  
 
 
Table 2.3: Enzymes and co-constituents 
Enzyme (Stock concentration) Co-constituents Supplier 
KOD DNA polymerase Amplification buffer (1 x): Patented Novagen 
RNase (10 mg/ml) 
Added to Qiagen Resuspension buffer: 10 
mM Tris-HCl pH 7.5, 1 mM EDTA, to a 
final concentration of 100 µg/ml RNase 
Qiagen 
T4 DNA ligase 
Ligation buffer (1 x): 50 mM Tris-HCL 
pH 7.5, 10 mM MgCl2 
New 
England 
Biolabs 
Restriction enzymes: 
NdeI 
EcoRI 
XhoI 
A list of buffer constituents used for each 
restriction enzyme is given in Appendix I 
New 
England 
Biolabs 
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Acid Phosphatase, from Potato 18.2 MΩ/cm H2O – Stored at -20 ˚C 
Sigma-
Aldrich
®
 
 
PLA2, from Bee 
10 mM Tris-HCL, pH 7.5, containing 
0.9% KCl and 0.2% BSA – Stored at -
20˚C 
Caymen 
Chemical 
 
2.9. Oligonucleotides 
 
Oligonucleotides were synthesised by TAGN, International Centre for Life, Newcastle, UK. 
Lyophilised oligonucleotides were resuspended in an appropriate volume of sterile 18.2 
MΩ/cm H2O to produce a stock concentration of 100 pmol/µl.  
Oligonucleotides were stored at -80°C and working stock concentrations were 10 
pmol/µl in 18.2 MΩ/cm H2O, stored at -20°C. Oligonucleotides used in this study are listed 
in Table 2.4. The plasmids generated in this study are listed in Table 2.5.  
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Table 2.4: Nucelotide primers used in this study 
Name 
Nucleotides (5’-3’) 
GC 
content 
(%) 
Tm (°C) Restriction enzyme 
Const_2180_R
*
 
ATC CAT TAA GAA TCA AAT GAA AAG 
25.0 52.5 N/a 
Const_2190_R
*
 
AGG ACA GCC TGT TTA GCT TGA 
47.6 57.9 N/a 
Full_2180/90_X_R 
CTC GAG TTA AGT TGC TGG TAA TTG TTT TTT AGG 
36.4 64.5 XhoI 
Full_2180_N_F 
CAT ATG GAT ATG AGT GCG GAC GTA AA 
42.3 61.6 NdeI 
Full2180/2190_E_R 
GAA TTC TTA AGT TGC TGG TAA TTG TTT TTT AGG 
30.3 62.0 EcoRI 
Full2190_N_F 
CAT ATG GAT ATG AAA AGC GAT 
38.5 60.1 NdeI 
Part_2190_E_R 
GAA TTC TTA CTC AGC CAT TAA TTG TTT TTC 
30.0 59.9 EcoRI 
Seq0849f 
CAT ATG GAA GGG ATA AAT GAT AAA A 
40.0 48.0 NdeI 
Seq0849f 
CTC GAG AAT AAA TAA TAT TCC CCA AA 
52.0 54.0 XhoI 
Seq2155f 
CAT ATG GCA GAT ACT GCA CCT GCA AGT 
56.2 62.4 NdeI 
Seq2155r 
CTC GAG ATT TCC CAA AAG TCC AGG TAA 
56.0 57.0 Xhol 
4047LppCf 
TGCCATAGGAATTCACGACAAATGGAGAGAAAAAA 
37.1 66.0 NdeI 
65 
 
4047LppCr 
TGCCATAGCTCGAGTTAATAAGCCTCTAAAGCCTT 
42.9 68.3 XhoI 
H70LppCf 
TGCCATAGGAATTCGCGACAAATGGAGAGAAA 
43.8 66.9 NdeI 
H70LppCr 
TGCCATAGCTCGAGTTAATAAGCCTCTAAAGCT 
42.4 67.0 XhoI 
H70LppCSeqF 
CCTTGTCTTGACTAGGAG 
52.4 59.8 N/a 
H70LppCSeqR 
TGAGAGGTGGATAAATAACCG 
42.9 55.9 N/a 
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Table 2.5 : Recombinant plasmids generated in this study. 
Plasmid name Constituent 
pb2190 pCR’Blunt / S. equi, seq2190 
pb2190 N pCR’Blunt /S. equi, seq2190 (truncated gene) 
Pb2180 pCR’Blunt / S. equi, seq2180 
Pb0849 pCR’Blunt / S. equi, seq0849 
Pb2155 pCR’Blunt / S. equi, seq2155 
PbSeLppC pCR’Blunt / S. equi, seq0346 
PbSzLppC pCRBlunt / S. zooepidemicus, szo16870 
p2190 pET28a / S. equi, seq2190 
p2190 N pET28a /S. equi, seq2190 (truncated gene) 
P2180 pET28a / S. equi, seq2180 
P0849 pET28a / S. equi, seq0849 
P2155 pET28a/ S. equi, seq2155 
PSeLppC pET28a / S. equi, seq0346 
PSzLppC pET28a / S. zooepidemicus, szo16870 
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2.10. Spectrophotometry 
 
DNA concentration was quantified accurately using an ultraviolet (UV) spectrophotometer 
(Helios Alpha UV-vis spectrophotometer from Thermo Scientific).  
DNA was quantitatively determined by preparing a dilution sample into 50 µl and 
transferring the dilution to a quartz cuvette. The UV spectrophotometer was previously 
zeroed with 18.2 MΩ/cm H2O between the wavelengths of 200 and 300 nm. The optimal 
wavelength for the absorbance of DNA was assumed to be 260 nm and protein at 280 nm.  
Double stranded DNA at 50 µg/ml has an A260 reading 1.0, allowing the concentration and 
purity was determined using the below formula. 
[dsDNA] µg/µl – (A260) x 50 x dilution/ 1000. 
DNA purity ratio = (A260)/ (A280)      
 
A purity ratio of 1.5-1.8 was accepted as minimal protein concentration. 
Protein Concentration was quantified accurately by preparing a dilution of 50 µl and 
transferring the dilution to a quartz cuvette. The UV spectrophotometer was previously 
zeroed with buffer appropriate to the specific protein at 280 nm.  The concentration was 
determined using the estimated absorbance coefficient of each protein, determined 
bioinformatically using ExPASy ProtPram tool (http://expasy.org/tools/protparam.html). 
 The formula below was then used when pathlength was 1 cm. 
Concentration (mg/ml) = Absorbance at 280 nm / absorbance coefficient. 
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2.11. Preparation of chemically competent E. coli Top10 
 
50ml of LB media was inoculated with a loop full of E. coli TOP10 cells from a glycerol 
stock and grown at 37°C and 200 rpm until an optical density (O.D) of 0.35-0.4 was observed 
at 600 nm. 25 ml of this culture was then transferred to a sterile tube and kept on ice for 10 
minutes. The culture was then centrifuged at 4000 rpm for 10 minutes at 4
◦
C, the supernatant 
was removed and the pellet retained. The pellet was re-suspended in 7.5 ml of ice cold 
MgCl2-CaCl2 solution and centrifuged at 4000 rpm for a further 10 minutes at 4
◦
C. The pellet 
was retained and further re-suspended in 0.5 ml of ice cold 0.1M CaCl2. The re-suspended 
pellet was then retained on ice for 2 hours to allow for chemical competence to be induced.  
 
2.12. DNA methods 
 
2.12.1. Streptococcal genomic DNA extraction  
 
One loop full of S. equi and S. zooepidemicus glycerol stock was placed in a 0.5 ml culture of 
Todd-Hewitt media and grown overnight in a candle jar with no agitation at 37
◦
C. The culture 
was then centrifuged at 5000 x G (7500 rpm for 10 minutes), the resulting pellet retained and 
supernatant discarded. To obtain the genomic DNA a DNeasy kit (Qiagen) was used 
following the protocol supplied by the manufacturer. The volume of DNA obtained was 100 
µl. 
69 
 
2.12.2. Restriction enzyme digestion 
 
DNA was digested using restriction enzymes with their appropriate buffers following the 
manufacturer instructions (New England Biolabs). Each µg of DNA was cut with 5 units of 
enzyme at 37˚C for > 2 hours. Double digests were performed with buffers compatible with 
both enzymes. Where necessary, Bovine Serum Albumin (BSA) was added at a ratio of BSA 
to buffer of 1:1. Each digest was ensured to have a glycerol concentration not exceeding 10 
% (w/v). 
 
2.12.2.1. PCR 
 
All PCR reactions used KOD DNA polymerase. The PCR reaction master mixture’s for KOD 
DNA polymerase each contained 10 pmols of each primer, 200 µM of deoxynucleotide 
triphosphates (dNTPs), MgCl2 in a range of 1.5-3 mM concentrations, 1 µl of template DNA, 
1 unit of KOD polymerase and 10x KOD reaction buffer. The reaction master mix was made 
up to a total volume of 50 µl with 18.2Ω/cm H2O. Reaction mixtures were prepared in sterile 
microcentrifuge tubes on ice. Samples were loaded into a temperature gradient thermocycler 
(Analytik-jena). The general reaction employed for standard PCR was set up as detailed in 
Table 2.6. 
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Table 2.6: Reaction conditions for standard PCR. 
 
Temperature (ºC) Duration (min: sec) Cycles 
94.0 02:00 First Denaturation 
94.0 00:15 
 
25 
Annealing 
temperature†  
00:30 
70.0 00:30* 
70.0 10:00 Final Extension 
10.00 Hold  
 
* Length of extension was determined by expected DNA product size, an 
extension time of 30 seconds was employed per 500 bp. 
† Appropriate annealing temperature for each primer set is detailed in  
Table 2.4 and adjusted where nessesary for best results. 
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2.12.3. Agarose gel electrophoresis of DNA samples 
 
DNA samples were separated by agarose gel electrophoresis. 10 µl samples were mixed with 
2 µl of 10x loading buffer (0.1% bromophenol blue, 0.1% xylene cyanol, 60% glycerol, 60 
mM EDTA), prior to being loaded onto the agarose gel. The samples were electrophoresed at 
100 mA for 20-30 minutes on a 1 % agarose gel in 1x TAE buffer (40 mM Tris-acetate, 
10mM EDTA) with one lane containing a 10 kb DNA size standard. The tank buffer was also 
composed of 1x TAE buffer. Following electrophoresis, the DNA products were stained for 
5-10 minutes in 0.5 µg/ml ethidium bromide and visualised using UV light using a gel 
documentation system (Bio-Rad, UK).  
 
2.12.4. Cloning of DNA fragments into pCR Blunt 
 
Blunt-ended PCR products were produced by amplification with a proofreading DNA 
polymerase (KOD polymerase) and were ligated into pCR Blunt Vector using T4 DNA ligase. 
The reaction mixture was prepared according to the manufacturer’s instruction (Table 2.6).  
Recombinant plasmids were transformed into chemically competent E. coli TOP10 
cells and were selected for on Luria-Bertani (LB) plates containing kanamycin. 
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Table 2.7: components of PCR
®
-Blunt ligation reaction. 
 
Component Volume 
PCR
®
 -Blunt vector (linearised; 25 ng) 1 µl 
10 x Ligation buffer (with ATP) 1 µl 
Blunt PCR product 1-5 µl 
18.2 MΩ/cm H2O To total 10 µl 
T4 DNA Ligase (4U/µl) 1 µl 
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2.12.5. Plasmid isolation 
 
Plasmid DNA was extracted from the E. coli transformant cultures and detection of the insert 
was performed by undertaking appropriate restriction enzyme digestions. Following 
identification of the correct sized product, plasmid stocks were purified from the cultures of 
E. coli transformants using a QIAprep spin mini-prep kit (Qiagen, UK) following the 
protocol supplied by the manufacturer.  
For large scale plasmid extractions an alternative STET preparation protocol was 
employed. A 1.5 ml culture of each E. coli strain containing a plasmid was centrifuged at 
16,000 rpm for one minute, the supernatant was removed and resuspended in 150 µl of 
STETS buffer (Appendix I). A total of 100 µg of lysozyme was added to each sample and 
incubated at room temperature for 15 minutes. The sample was then boiled, centrifuged at 
16,000 rpm for 15 minutes and the pellet subsequently removed. The supernatant sample was 
mixed with 150 µl of chilled isopropanol and stored at -20 °C for around one hour. Following 
incubation at -20 ºC the sample was immediately centrifuged at 16,000 rpm for 5 minutes and 
a total of 500 µl of ice-cold ethanol (100%) was added. The sample was centrifuged at 16,000 
rpm for 3 minutes and the supernatant removed. To obtain the DNA from each sample, the 
remaining pellet was resuspended in 18.2Ωcm H2O containing 100 µg of RNAse. 
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2.12.6. Cloning of fragments into pET28a 
 
A total amount of 1500 ng of pET28a vector was cut with appropriate restriction enzymes 
and concentrated via ethanol precipitation, re-suspended in 10 µl of 18.2Ω/cm H2O. Strains 
carrying plasmids of pCR Blunt vector with the desired DNA product cloned were inoculated 
into 5 ml of LB with appropriate antibiotic. Plasmid DNA was obtained using a Qiagen mini- 
prep kit (see above). pCR Blunt vectors with the desired DNA insert were then sequentially 
digested with appropriate restriction enzymes (Table 2.4).  
Digested DNA fragments were separated by electrophoresis and extracted using the 
Gel Extraction kit (Quigen). Cut purified plasmid DNA and cut purified pET 28a vector was 
then ligated using T4 DNA Ligase. The reaction mix employed is detailed in Table 2.8. 
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Table 2.8: components of pET vector ligation. 
 
Component Volume 
pET vector cut with appropriate restriction enzyme (100 ng/µl) 1 µl 
10 x Ligation buffer 1 µl 
Fragment cut from pCR
®
 -Blunt vector and gel purified (100 ng/µl) 1 µl 
18.2 MΩ/cm H2O 6 µl 
T4 DNA Ligase (3 U/µl) 1 µl 
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2.12.7. DNA Sequencing  
 
DNA samples were prepared at a concentration of 30-100 ng/µl in 30 µl aliquots.  
Sequencing was undertaken by GATC Biotech, London.  
 
2.13. General protein methods 
 
2.13.1. SDS-PAGE 
 
Polyacrylamide gel electrophoresis was carried out using the method of Laemmli (1970). 
SDS prepared cell extracts or protein purification fractions (10 µl - 20 µl) were boiled for 4 
minutes and separated by electrophoresis (using a polyacrylamide gel with a voltage of 
200V) until the dye fronts left the gel (approx. 60 min). This was undertaken using a Bio-Rad 
mini-Protean II system (Bio-Rad, UK). Lanes containing molecular weight standards were 
included to give an approximate indication of the size of specific proteins. SDS-PAGE gels 
consisted of a stacking gel (5%) and resolving gel (12 - 17% depending on target protein 
size), prepared as indicated in Table 2.9 and table 2.10 respectively.  
Following electrophoresis, SDS-PAGE gels were stained in coomassie blue dye (see 
appendix I) for around 20 minutes and placed in de-stain (see appendix I) for around 6 hours 
or overnight. Visualisation was achieved using a 2D scanner (Bio Rad, UK).   
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Table 2.9: Composition of SDS-PAGE stacking gel 
 
Component 
12% Resolving gel 
(Volume) 
15% Resolving 
gel (Volume) 
17% Resolving 
gel (Volume) 
40% (w/v) solution (37.5:1 
acrylamide: bisacrylamide) 
(Fisher Scientific) 
3.0 ml 3.75 ml 4.25 ml 
Solution B* 2.5 ml 2.5 ml 2.5 ml 
18.2 MΩ/cm H2O 4.5 ml 3.75 ml 3.25 ml 
10% (w/v) Ammonium 
persulphate (APS)(Fisher 
Scientific) 
50.0 µl 50.0 µl 50.0 µl 
Tetramethylethylenediamine 
(TEMED) (Fisher Scientific) 
10.0 µl 10 µl 10 µl 
* see appendix I  
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Table 2.10: Composition of SDS-PAGE stacking gel 
 
Component 
12% Stacking gel 
(Volume) 
40% (w/v) solution (37.5:1 acrylamide: bisacrylamide) (Fisher) 0.5 ml 
Solution C* 1.0 ml 
18.2 MΩ/cm H2O 0.5 ml 
10% (w/v) APS (Fisher) 30.0 µl 
TEMED (Fisher) 10.0 ul 
* see appendix I  
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2.13.2. Protein extraction 
 
Protein as a cell-free extract was obtained from cultures expressing the target protein by 
centrifugation of culture at 4000 x g. The supernatant was then removed and re-suspended in 
Start buffer (See appendix I). The re-suspension was then sonicated at ~15 kHz, 14 mA for 2 
minutes in 10 second bursts followed by centrifugation at 24,000 x g for 20 minutes at 4°C. 
This final supernatant was then removed and either purified or analysed by SDS-PAGE.  
 
2.13.3. Concentration and buffer exchange of proteins 
 
Proteins were concentrated by performing centrifugation at 4000 x g at 4 ºC using Vivaspin 
concentration units with an appropriate volume and molecular weight cut-off (Viva Science, 
USA). Proteins were also buffer exchanged by dilution within concentrator units.  
 
2.13.4. Protein purification by Immobilized Metal Affinity Chromatography (IMAC)  
 
Purification of recombinant protein containing a His6-tag was undertaken under native 
conditions. High yield purification of protein was achieved using an automated FPLC
®
 
system gradient elution technique. The column was prepared by adding ~ 50 ml Sepharose
TM
 
chelating fast flow resin to a C series column (GE Healthcare, UK) and connected to a 
FPLC
®
 column. 1M NiSO4 solution was initially passed through the resin until a uniform 
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colour was achieved. The column was then washed with ~200 ml of Start Buffer (See 
appendix I) and equilibrated. Appropriate volumes of cell free extract (10-20 ml) was then 
loaded onto the column at a rate of 4 ml/min and washed through with 100 ml of appropriate 
buffer at a flow rate of 5 ml/min generated by the FPLC
® 
system. Finally, the protein was 
eluted at a flow rate of 5 ml/min using a linear gradient of extending from 10 mM to 500 mM 
imidazole with start buffer as diluents (Elution buffer) for 50 minutes.  
Monitoring at A280 using an inline UV spectrometer allowed the presence of target 
proteins to be confirmed, and samples were collected in 5 ml volumes on a fraction collector 
carousel. The purity of protein was confirmed by analysing 20 µl of each 5 ml fraction 
containing target protein by SDS-PAGE.   
 
2.13.5. Protein purification by Fast Protein Liquid Chromatography (FPLC) 
 
Concentrated protein samples were loaded onto a gel filtration column by injection and eluted 
over 120 min with gel filtration buffer (See appendix I) running at 1 ml/min. The gel 
filtration column was of dimensions 1.6 cm (i.d.) x 60 cm (L), with a bed volume of 120 ml 
and prepared by equilibration at 0.5 ml/min with 120 ml of gel filtration buffer. The point of 
target protein elution was identified using an inline UV spectrophotometer at A280 and 
samples were collected on a fraction collector in 5 ml volumes. The purity of protein was 
confirmed by analysing 20 µl of each 5 ml fraction containing target protein by SDS-PAGE.   
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2.13.6. Western blotting 
 
SDS-PAGE gels for Western blotting were incubated in transfer buffer (25 mM Tris, 192 
mM glycine, 10% analytical grade methanol) for 15 minutes, as were the nitrocellulose 
membranes and blotting paper. Protein transfer onto the nitrocellulose membrane was 
performed using a Transblot semi-dry system (BioRad, UK). The current applied was 0.6 
milliamps per nitrocellulose membrane transfer for 90 minutes. Efficient protein transfer was 
confirmed by reversible staining with Ponceau S dye (Sigma-Aldrich®, UK). This also 
allowed the positions of the protein standards to be marked on the nitrocellulose. Blots were 
blocked overnight with 5% (w/v) skimmed milk in phosphate buffered saline (PBS) and 
0.05% (w/v) Tween 80 (PBST) and then incubated for 90 minutes at room temperature with 
recommended dilutions of the required antibody (Table 2.11). Blots were extensively washed 
with several changes of PBST and incubated with an appropriate dilution of antisera (Table 
2.12). After extensive washing with several changes PBST, blots were developed with Nitro 
Blue Tetrazolium/5-Bromo-4-Chloro-3-Indolyl Phosphate (NBT-BCIP) (Zymed 
Laboratories, USA), the alkaline phosphatase substrate. 
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Table 2.11: Primary antibodies used in this study 
 
Antibody Appropriate dilution Protein detected Supplied by 
Anti-His6-Tag 1/3000 
Specific His6-
Tagged protein 
Sigma-Aldrich® 
Anti-LppC 1/1000 
LppC acid 
phosphatase 
Dr Horst Malke (Jena 
University, Germany) 
Equine 
Convalescent 
serum (Pre 
infection) 
1/1000 
Non-
Immunoreactive 
S. equi proteins 
(Control) 
Animal Health Trust, 
Newmarket, UK 
Equine 
Convalescent 
serum (Post 
infection) 
1/1000 
Immunoreactive 
S. equi proteins 
Animal Health Trust, 
Newmarket, UK 
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Table 2.12: Secondary antibodies used in this study 
 
Secondary antibody 
Appropriate 
dilution 
Relevant primary 
antibody 
Supplied by 
Alkaline phosphate-
conjugated goat anti-
rabbit IgG 
1/30,000 Anti-LppC Sigma-Aldrich® 
Alkaline phosphate 
conjugated horse IgG 
1/10,000 Anti-His6-Tag Sigma-Aldrich® 
Alkaline phosphate 
conjugated mouse IgG 
1/10,000 
Equine 
Convalescent 
serum (pre and post 
infection) 
Sigma-Aldrich® 
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2.13.7. Protein crystallisation 
 
Cover slips were initially prepared using liquid Aquasil. Prior to use, cover slips were wiped 
with a clean cloth. Crystal tray wells were filled with the appropriate buffer solutions from 
various screens and the coverslips containing drops of protein at a working concentration of 
15 mg/ml in three different ratios of 1:1, 1:2 and 2:1 respectively and were inverted onto the 
surface of the wells which were previously greased. Once the tray of 24 wells was set up, 
they were incubated at 21.0°C in a crystallisation incubator and monitored for the presence of 
crystals every week by microscopy. The various screens used and their buffer compositions 
are included in Appendix III.  
 
2.14. Enzyme assay methods 
 
2.14.1. General kinetic analysis considerations 
 
All kinetic assays were performed using the same set of calibrated pipettes (Gilson
®
) and all 
enzyme assays were performed in triplicate with mean values presented on the graphs with 
error bars to represent the range for each data set where nessesary. Each assay dataset was 
also produced using the same aliquot of purified enzyme.  
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2.14.2. sPLA2 assay methods 
 
2.14.2.1. SIGMA assay 
 
Initially putative secreted phospholipase activity was investigated using a method supplied by  
Sigma-Aldrich
®
 
(http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/General_Information/phospholipase
_a2_colorimetric.Par.0001.File.dat/phospholipase_a2_colorimetric.pdf). 
70 µl of phospholipase assay buffer (500 mM Tris HCL. 10 mM CaCl2, pH 8.5) was 
added to 70 µl of 2% (w/v) L-a-phosphatidylcholine (Sigma-Aldrich
®
) and 1.5% (w/v) 
Deoxycholate solution. This mixture was then equilibrated to 37ºC and 0.5 µl of purified 
enzyme added. Following addition, the sample was mixed by inversion and incubated at 37ºC 
for a further 5 minutes and 20 µl removed. To the removed 20 µl sample; 150 µl of ether, 20 
µl of 2 M hydroxylamine solution and 20 µl of 14 % (w/v) sodium hydroxide solution were 
added. This was then incubated at 25ºC for 20 minutes and finally, 30 µl of 3 N hydrochloric 
acid solution and 30 µl of 10% (w/v) ferric chloride solution was added. The reaction mixture 
was mixed and absorbance recorded at A570nm.   
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2.14.2.2. Price colourmetric assay 
 
A further biochemical assay for putative phospholipase activity was investigated using a 
colorimetric assay developed by Price (2007). The degradation of a common phospholipase 
A2 substrate (phosphatidylcholine) allows for maximal detection of many PLA2 at 
physiological pH using an indicator dye. Samples were diluted in a cold saline solution (2 
mM HEPES at pH 7.5. 20 µl of each sample was loaded into wells of a round bottom 96 well 
microplate. 180 µl of an assay mixture was loaded to each assayed sample after pre-warming 
in a water bath at 37ºC. The assay mixture contained 5 mM Triton X-100, 5 mM 
phosphatidylcholine, 2 mM HEPES, 10 mM calcium chloride, and 0.124% bromothymol 
blue dye in 18.2 MΩ/cm H2O at pH 7.5. 
Phosphatidylcholine had been dissolved at 160 mg/mL in molecular grade methanol 
and stored at -70
o
C prior to use. Stock phosphatidlycholine samples were re-suspended at 
45
o
C immediately before use. The final assay mixture concentration of methanol was 5%. 
After the reaction was initiated, the multiwell assay plate was immediately analyzed 
at 595 nM with an EL 808 Ultra microplate reader (Biotek Instrument Inc). The plate was 
read at 1 minute intervals at 37°C and rates of change were blank adjusted.  
 
2.14.2.3. Chromogenic substrate release assay 
 
Putative phospholipase activity was investigated using sPLA2 Assay Kit (Caymen Chemical 
Company, USA). The assay uses 1, 2-dithio analog of diheptanoyl phosphatidylcholine 
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(DHT-PC) as a standard substrate and detects free thiols using upon hydrolysis of the thio-
ester bond at the sn-2 position by PLA2 using the chromogen DTNB (5, 5’-dithio-bis-(2-
nitrobenzoic acid)) (Figure 2.1). Assay was performed as instructed by the manufacturer. 
Prior to assay all protein samples were concentrated in sPLA2 assay buffer (25 mM Tris-
HCL, pH 7.5, containing 10 mM CaCl2, 100 mM KCl and 0.3 mM Triton X-100). DTNB 
was reconstituted in 1.0 ml of 18.2Ωcm H2O per supplied vial to yield 10 mM DTNB in 0.4 
M tris-HCl, pH 8.0. The reagent was then stored on ice in the dark and used within eight 
hours. An alternative substrate, 2-deoxy-2-thio- Arachidonoyl phosphatidylcholine (AT-PC) 
(see appendix I), was also tested utilizing the same method as above.  
All substrates were reconstituted with supplied assay buffer and stored at -20 ºC. For 
investigations regarding Ca
2+
 ion requirements, the assay buffer was modified accordingly. 
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Figure 2.1: Schematic representation of sPLA2 activity reaction.  
Figure obtained from sPLA2 assay kit booklet, Caymen Chemical Company. 
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2.14.3. Acid phosphatase assay 
 
Putative acid phosphatase activity was investigated using a method developed by Reilly et al 
(2009). The assay utilises para-nitrophenyl phosphate (pNPP) as a chromogenic substrate. 
The acid phosphatase dephosphorylates pNPP and under alkaline conditions the phenolic 
OH-group is deprotonated resulting in p-nitrophenolate (Figure 2.2). A standard 190 µl assay 
mixture (0.2 M Sodium acetate, pH 5.0, 0.1 mM CuSO4, 10.0 mM p-nitrophenylphosphate 
(pNPP)) was added to 10 µl of sample. The reaction was incubated at 37˚C for 10 minutes 
and stopped by the addition of 100 µl of 0.5 mM NaOH, pH 10.0. The concentration of p-
nitrophenol produced was measured using an EL 808 Ultra microplate reader (Biotek 
Instrument Inc, UK) microtiter plate reader at 410 nm. Prior to assay all protein samples were 
concentrated in buffer containing 0.2 M sodium acetate, pH 5.0. For investigations regarding 
divalent ion requirement, the standard assay mixture was modified accordingly.  
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Figure 2.2: Schematic representation of acid phosphatase activity reaction. 
Figure obtained from Caymen Scientific. 
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2.14.4. Phosphate assay 
 
In order to investigate further investigate acid phosphatase activity using the non-
chromogenic substrates Uridine 5’ monophosphate (5’UMP) and adenosine 5’ 
monophosphate (5’ AMP) the phosphate assay developed by Chen (1956) was used to 
determine the released phosphate.  
Assay was performed as above (Section 2.14.3) and assay mixture removed. The total 
assay volume (300 µl) of sample was added to 300 µl of colour reagent (3 M Sulphuric acid, 
2.5% w/v ammonium molybdate, 114 mM Ascorbic Acid). Sample and colour reagent was 
incubated at 37°C for 2 hours and absorbance value was calculated via spectrophotometer at 
A820. A set of standards was produced using dilutions of 33 mM KH2PO4. 
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2.15. Calculations of Km and specific activity 
 
2.15.1. sPLA2 (Chapter 4) 
 
Considering the calculations of sPLA2, rate was determined by plotting the absorbance values 
as a function of time to obtain the slope (rate) of the linear portion of the curve. Two points 
were chosen on the linear portion of the curve and the change in absorbance calculated by the 
following equation: 
   ∆A414 = A414 (Time 2) – A414 (Time 1) 
      Time 2(min.) – Time 1 (min.) 
 
The rate of ∆A414/min for the non-enzymatic controls (blank) was determined and 
subtracted from this value. The following formula was then used to calculate sPLA2 rate.  
sPLA2 Activity =   ∆A414/min    0.225 ml 
    DTNB adjusted extinction      x 0.01  ml  x Sample 
coefficient (10.66 mM
-1
)          Dilution 
 
     = mM of substrate converted per minute 
The values of Km obtained in this study were calculated by fitting the data directly to 
the Michaelis-Menten equation using Graphpad (Graphpad software, Inc). Data was 
displayed as Lineweaver Burk plots (Lineweaver, 1934) and all Km values were presented in 
mM. 
Regarding specific activity, the obtained values were converted into µmol of 
substrateconverted per min and further converted into µmol/min/mg in relation to the amount 
of enzyme added in each reaction.  
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2.15.2. Acid phosphatase (Chapter 5) 
 
Considering the calculations of acid phosphatase activity, the value for Km was obtained as 
above (section 2.15.3) with the exception of a pNPP adjusted coefficient of 9.248 mM
-1 
and 
adjusted volumes specific to the assay.  
For AP assays using non-chromogenic substrates a line of best fit was instead obtained using 
dilutions of 33 mM KH2PO4 and individual activity values were determined from the 
standard curve.  
 
2.16. Zymography 
 
Acid phosphatase enzymes can be assayed in gel (‘zymography’) following electrophoresis 
(Thaller et al 1995). Putative acid phosphatase enzymes were electrophoresed through 12% 
polyacrylamide gels. Following SDS-PAGE, separated protein was renaturated for 4 hours by 
incubation in several changes of renaturation buffer (100 mM Tris-HCL pH 7.0, containing 2 
mM MgSO4, 0.05 mM ZnCl2 and 2% (v/v) Triton X-100). After renaturation the gels were 
further incubated for 1 hour in several changes of equilibration buffer (100 mM sodium 
acetate, pH 5.0).  
Activity of acid phosphatases was detected following overnight incubation, at 37
◦
C, in 
fresh equilibration buffer containing phosphatase substrate, 0.25 mM BCIP, with the addition 
of 0.25 mM NBT as described by Hamilton et al. (2000). The in gel appearance of blue bands 
indicated the presence of phosphatase activity.  
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2.17. Bioinformatic analysis 
 
Nucleotide sequences determined in this research were translated into amino acid sequences 
using the ExPAsy translate tool (http://expasy.org/tools/dna.html). All 6 frames are read 
highlighting start and stop codons. DNA and protein sequences were compared to those in the 
public domain (notably genbank) using the Basic Local Alignment Search tool (BLAST; 
Altschul et al 1990) (http://blast.ncbi.nlm.nih.gov/).  
The Sanger Centre S. equi finished genome BLAST server 
(http://www.sanger.ac.uk/cgi-bin/blast/submitblast/s_equi) was used to search for S. equi 
sequences. The Sanger Centre S. zooepidemicus finished genome BLAST server 
(http://www.sanger.ac.uk/cgi-bin/blast/submitblast/s_zooepidemicus) was used to search for 
S. zooepidemicus sequences. Homologous proteins were aligned and overall percentage 
identity and similarity calculated using the ClustalW (Larkin et al 2007) alignment tool 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). The membrane spanning domains of proteins 
were predicted using the topology program TMPRED (Hofmann and Stoffel 1993) 
(http://www.ch.embnet.org/software/TMPRED_form.html) and the putative signal peptide 
regions were identified using SignalP (Nielsen et al 1997) 
(http://www.cbs.dtu.dk/services/SignalP/signal P/). Putative lipoprotein signal peptide 
regions were identified using PRED-LIPO (Bagos et al 2008) 
(http://biophysics.biol.uoa.gr/PRED-LIPO/). 
Restriction enzyme mapping was performed using Webcutter 2.0 (Maarek et al 1997) 
(http://bio.lundberg.gu.se/cutter2/). The program was used to identify restriction enzyme sites 
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within target sequences so that restriction enzyme sites, which were not present within the 
sequences to be amplified, could be incorporated into the primers designed. 
Putative protein structure prediction was undertaken using phyre
2 
(Kelley 2009) 
(http://www.sbg.bio.ic.ac.uk/~phyre/) 
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3. Investigation into the cell wall anchored protein SEQ2190 of S. equi.  
 
3.1. Introduction 
 
As previously described (section 1.5), proteins identified as cell surface associated via sortase 
mediated attachment to the cell wall have been previously shown to function as virulence 
factors with prominent interactions between bacteria and host cells.  
As stated in section 1.2, S. equi and S. zooepidemicus share a very large proportion of 
conserved proteins but exhibit very different pathogenicity. Expressed proteins unique to 
each species are therefore of considerable interest in terms of investigating the molecular 
basis of host specificity with regard to virulence. The putative cell wall anchored protein 
SEQ2190 protein represents one such unique expressed protein and further bioinformatic 
analysis (section 3.2) has revealed the N-terminal region of SEQ2190 (1-252 nucleotides of 
full length protein) to be only present in known strains of S. equi and not present in any 
known strain of S. zooepidemicus. Since bacterial evolution typically favours small genomes 
to reduce the metabolic cost, it is indicated that the retention and conservation of seq2190 N-
terminal in S. equi must provide a significant bacterial survival advantage and hence 
represent a putative pathogenicity characteristic unique to S. equi.  
Importantly, SEQ2190 has been previously shown to be immunogenic early in the 
onset of a S. equi infection and is conserved amongst a wide variety of S. equi isolates 
(Waller, Mitchell & Robinson – unpublished). Furthermore an 235 amino acid 
immunoreactive protein fragment has also been identified (Se68.9) (Timoney et al. 2007) 
which is identical to a portion of the SEQ2190 protein (amino acids 376-610).  
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Aims of the present study 
The aims of the present study were: 
a) To produce cloning constructs expressing the SEQ2190 and its paralogue 
SEQ2180 to allow further investigation of protein structure and function. 
b) To obtain x-ray crystallography structures to allow for structural comparisons to 
reveal possible structural orthologues.  
c) To produce gene ‘knock-out’ mutants of SEQ2190 and related homologues.  
The overall aim is to assess the potential of SEQ2190 as a virulence factor of S. equi and a 
future target for novel therapeutic or preventative strategies.    
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3.2. Bioinformatic analysis of SEQ2190 
 
The amino acid sequence of the putative surface associated protein SEQ2190 was obtained 
from UniProt in a FASTA format. The sequence encoding SEQ2190 was analysed for 
identification of a signal peptide cleavage site by using the SignalP Hidden Markov Models 
and Neural Networks outputs, with a cleavage site predicted between position 45 and 46. 
SEQ2190 was annotated as a putative surface attached protein due to the presence of an 
LPXTG sortase recognisition motif within the C-terminal of the mature protein (position 589-
593) with alanine present as the X within the motif. A BLAST search of the translated S. equi 
genome database for homologues to SEQ2190 revealed an amino acid sequence with 80% 
identity, SEQ2180 (Figure 3.1). The full amino acid sequence of SEQ2180 is shorter than 
SEQ2190 (626 amino acids in length compared to 673) suggesting a truncation of the amino 
acid sequence or an insertion in SEQ2190. SEQ2180 also differs from SEQ2190 in that the 
signal peptide cleavage site was instead predicted between position 37 and 38. Notably, 
sequence differences between the two mature proteins are restricted to the N-terminal region 
of the two proteins (from amino acid position 3 to position 197 of the mature SEQ2190 
protein, Figure 3.1). 
A tBLASTn search was undertaken for both SEQ2190 and SEQ2180 against the S. 
equi sub sp. zooepidemicus H70 genome project (http://www.sanger.ac.uk/cgi-
bin/blast/submitblast/s_zooepidemicus). Notably, an orthologue of SEQ2180 was found in S. 
zooepidemicus H70. The orthologue, annotated as SZO18890, was found to have 95.0% 
identity to the full  SEQ2180 amino acid sequence (Figure 3.2). In contrast SZO18890 shared 
only 80% homology with SEQ2190.     
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A further, shorter (372 amino acids in length) homologue, SZO18870, was also 
identified and annotated as a pseudogene due to the absence of the signal peptide region or a 
transcription innitation sequence. The translated pseudogene SZO18870 was shown to have 
83.0% and 82.0% identity to the corresponding regions of SEQ2190 and SEQ2180 
respectively (Figure 3.3).  Database searches for other orthologues to the amino acid 
sequence of the mature SEQ2190 protein using BLASTP and tBLASTn revealed low but 
significant homologies to the Fc Gamma receptor protein (M family protein) and M-protein 
of S. pyogenes (Table 3.1). Significantly no homologues to the unique N-terminal regions of 
SEQ2190 or SEQ2180 were identified. The amino acid sequence of the mature SEQ2190 
protein was also analysed for a predicted secondary structure. This was undertaken using 
Phyre, providing a consensus predicted secondary structure based on the predicted results 
from Psipred, Jnet and Sspro (Figure 3.4). The amino acid sequence of the mature SEQ2180 
protein was also analysed for a predicted secondary structure and as expected demonstrated 
an almost identical predicted structure (data not shown).  
The overall organisation of the SEQ2180 and SEQ2190 locus between the genomes of 
S. equi and S. zooepidemicus is shown below (Figure 3.5). Cumulatively these analyses 
confirm that SEQ2190 is a protein unique to S. equi whereas SEQ2180 has a S. 
zooepidemicus orthologue.  
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SEQ2190         DMKSDAKKVLATLQKGNHKQELKKVLRTIGD-DSLLLLWLLVSGDSNLDESNKSFDYLSI 59 
SEQ2180         DMSADVKKIEQVLQ--SDSGKLKTVLGQISDPNTLFALFAIISADVNIDPESFSF----I 54 
                **.:*.**:  .**  ... :**.**  *.* ::*: *: ::*.* *:* .. **    * 
 
SEQ2190         WNTGSRVGKVISPTEYFKQESKNTENRQAVYSEFKQRVEERSKKAKEATEALNQKAQLEA 119 
SEQ2180         LN-----GPITPLLSYFNNPNKN-DNRKAVVNEIKKRVS-----ALEQAQKLETKAKIEK 103 
                 *     * : .  .**:: .** :**:** .*:*:**.     * * :: *: **::*  
 
SEQ2190         TVKNINEELEKTREGFKVVSENSNKLEKQLMAEKIKTRTAEETAKQAKTDKERAEAEAKK 179 
SEQ2180         QIAES--ELEKTRNAFKVTIENLHKLEGLLDTEKQKTRKVEEDYQQAKTDKEKAEAD--- 158 
                 : :   ******:.***. ** :***  * :** ***..**  :*******:***:    
 
SEQ2190         AKEEAKTAEGKVKQAETEKRNAEAKARTAEEEAKQATADKEKAETEAKKAKEEAKTAKEA 239 
SEQ2180         ------------------KRNAETKARTAEEEAKQATADKEKAETEAKKAKEEAKTAKEA 200 
                                  *****:************************************ 
 
SEQ2190         AHQEQEKAKQLEQANQQANQRANLAEKSKKDLETQKEKLEQEIKEATEAKNKAEQKLKDL 299 
SEQ2180         AHQEQEKAKQLEQANQQANQRANLAEKSKKDLETQKEKLEQEIKEATEAKNKAEQKLKDL 260 
                ************************************************************ 
 
SEQ2190         QDSASQGSELSKQLLKEKEELTTKLQELQKQAEEKTTEIEKLKQELEANKQNSGQLGQQE 359 
SEQ2180         QDSASQGSELSKQLLKEKEELTTKLQELQKQAEEKTTEIEKLKQELEANKQNSGQLGQQE 320 
                ************************************************************ 
 
SEQ2190         QKLQEQLNKVQKELKQKEMELKQAQEQLKQEQKPHEGGGDSDASKARITELEKQVQTLTK 419 
SEQ2180         QKLQEQLNKVQKELKQKEMELKQAQEQLKQEQKPHEGGGDSDASKARITELEKQVQTLTK 380 
                ************************************************************ 
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SEQ2190         EKADLSSTLESTKAQLSETQARLSEAQKQLTAAQEKLTTLEAEKTALQHQVETISKQLSE 479 
SEQ2180         EKADLSSTLESTKAQLSETQARLSEAQKQLTAAQEKLTTLEAEKTALQHQVETISKQLSE 440 
                ************************************************************ 
 
SEQ2190         TRDLSEKEKAALQEQINKLKAEIEQKTKEIEALKQGMQSHQGQEKPKDPKTPETPKDPKT 539 
SEQ2180         TRDLSEKEKAALQEQINKLKAEIEQKTKEIEALKQGMQSHQGQEKPKDPKTPETPKDPKT 500 
                ************************************************************ 
 
SEQ2190         PEKNDQPQAPEKRSVPWTALTPAKPIDTTKAPKSSAPSPQTGAATPKKQLPATGDTATPS 599 
SEQ2180         PEKNDQPQAPEKRSVPWTALTPAKPIDTTKAPKSSAPSPQTGAATPKKQLPATGDTATPS 560 
                ************************************************************ 
 
SEQ2190         FFTAAAMAVLASVGVLNLSPRRKKNQNNR 628 
SEQ2180         FFTAAAMAVLASACALTLSPRRKKNQNNR 589 
                ************. .*.************ 
         
 
Figure 3.1: Alignment of mature SEQ2190 and SEQ2180. 
Alignment was performed using ClustalW2.* indicates identical amino acids, : indicates similar amino acids. The LPXTG cell wall anchoring 
motif in each sequence is underlined. 
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SEQ2180        MKRQSNIRRLCHQALAATLITGSLIGTGLLGNKVVYGDMSADVKKIEQVLQSDSGKLKTV 60 
SZO18890       MKRQSNIRRLCHQALAATLITGSLIGTGLLGNKVVYGDMSADVKKIEQVLQSDSGKLKTV 60 
               ************************************************************ 
 
SEQ2180        LGQISDPNTLFALFAIISADVNIDPESFSFILNGPITPLLSYFNNPNKNDNRKAVVNEIK 120 
SZO18890       LGQISDPNTLFALFAIISADVNIDPESFSFILNGPITPLLSYFNNPNKNDNRKAVVNEIK 120 
               ************************************************************ 
 
SEQ2180        KRVSALEQAQKLETKAKIEKQIAESELEKTRNAFKVTIENLHKLEGLLDTEKQKTRKVEE 180 
SZO18890       KRVSALDQAQKLETKAKIEKQIAESELEKTRNAFKVTIENLHKLEGLLDTEKQKTRKVEE 180 
               ******:***************************************************** 
 
SEQ2180        DYQQAKTDKEKAEADKRNAETKARTAEEEAKQATADKEKAETEAKKAKEEAKTAKEAAHQ 240 
SZO18890       DYQQAKTDKEKAEADKRNAETKARTAEEEAKQATADKEKAETEAKKAKEEAKTAKEAAHQ 240 
               ************************************************************ 
 
SEQ2180        EQEKAKQLEQANQQANQRANLAEKSKKDLETQKEKLEQEIKEATEAKNKAEQKLKDLQDS 300 
SZO18890       EQEKAKQLEQANQQANQRANLAEKAKTALETQKQKLEQEIKEATEAKNKAEQKLKDLQDS 300 
               ************************:*. *****:************************** 
 
SEQ2180        ASQGSELSKQLLKEKEELTTKLQELQKQAEEKTTEIEKLKQELEANKQNSGQLGQQEQKL 360 
SZO18890       ASQGSELSKQLLKEKEELTTKLQDLQKQAEEKTTEIEKLKQELEANKQNSGQLGQQEQKL 360 
               ***********************:************************************ 
 
SEQ2180        QEQLNKVQKELKQKEMELKQAQEQLKQEQKPHEGGGDSDASKARITELEKQVQTLTKEKA 420 
SZO18890       KEQLNKVQEELKQKEMELEKAKEQLKQEQKPHEG---DDTSKAKIAELEQQVQTLTKEKE 417 
               :*******:*********::*:************   .*:***:*:***:*********  
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SEQ2180        DLSSTLESTKAQLSETQARLSEAQKQLTAAQEKLTTLEAEKTALQHQVETISKQLSETRD 480 
SZO18890       NLSSTLESTNAQLSETQAKLSEAQKQLTAAQEKLTTLEAEKVALQHQVETISKQLSEARD 477 
               :********:********:**********************.***************:** 
 
SEQ2180        LSEKEKAALQEQINKLKAEIEQKTKEIEALKQGMQSHQGQEKPKDPKTPET------PKD 534 
SZO18890       LSEKEKAALQEQINKLKAEIEQKTKEIEALKQGMQSHQGQEKPKDPKTPETPKAPKVPKD 537 
               ***************************************************      *** 
 
SEQ2180        PKTPEKNDQPQAPEKRSVPWTALTPAKPIDTTKAPKSSAPSPQTGAATPKKQLPATGDTA 594 
SZO18890       PKTPEKNDQPQAPEKRSVPWTALTPAKPIDTTKAPKSSAPSPQTGAATPKKQLPATGDTA 597 
               ************************************************************ 
 
SEQ2180        TPSFFTAAAMAVLASACALTLSPRRKKNQNNR 626 
SZO18890       TPSFFTAAAMAVLASVGVLSLSPRRQKNQNNR 629 
               ***************. .*:*****:****** 
 
Figure 3.2: Alignment of SEQ2180 and the orthologue SZO18890. 
Alignment was performed using ClustalW2. * indicates identical amino acids,: indicates similar amino acids. The point of predicted signal 
peptide cleavage is indicated in bold and the LPXTG cell wall anchoring motif in each sequence is underlined.  
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SEQ2190         MITKKQRKLKRHTTIRRLCHQALAATLITGSLMGTGLLGNKVVYGDMKSDAKKVLATLQK 60 
SEQ2180         --------MKRQSNIRRLCHQALAATLITGSLIGTGLLGNKVVYGDMSADVKKIEQVLQ- 51 
SZO18970        ------------------------------------------------------------ 
                                                                             
 
SEQ2190         GNHKQELKKVLRTIGD-DSLLLLWLLVSGDSNLDESNKSFDYLSIWNTGSRVGKVISPTE 119 
SEQ2180         -SDSGKLKTVLGQISDPNTLFALFAIISADVNIDPESFSF----ILN-----GPITPLLS 101 
SZO18970        ------------------------------------------------------------ 
                                                                             
 
SEQ2190         YFKQESKNTENRQAVYSEFKQRVEERSKKAKEATEALNQKAQLEATVKNINEELEKTREG 179 
SEQ2180         YFNNPNKN-DNRKAVVNEIKKRVS-----ALEQAQKLETKAKIEKQIAES--ELEKTRNA 153 
SZO18970        ------------------------------------------------------------ 
                                                                             
 
SEQ2190         FKVVSENSNKLEKQLMAEKIKTRTAEETAKQAKTDKERAEAEAKKAKEEAKTAEGKVKQA 239 
SEQ2180         FKVTIENLHKLEGLLDTEKQKTRKVEEDYQQAKTDKEKAEAD------------------ 195 
SZO18970        ------------------------------------------------------------ 
                                                                             
 
SEQ2190         ETEKRNAEAKARTAEEEAKQATADKEKAETEAKKAKEEAKTAKEAAHQEQEKAKQLEQAN 299 
SEQ2180         ---KRNAETKARTAEEEAKQATADKEKAETEAKKAKEEAKTAKEAAHQEQEKAKQLEQAN 252 
SZO18970        ----------------------------------------------------------PK 2 
                                                                          .: 
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SEQ2190         QQANQRANLAEKSKKDLETQKEKLEQEIKEATEAKNKAEQKLKDLQDSASQGSELSKQLL 359 
SEQ2180         QQANQRANLAEKSKKDLETQKEKLEQEIKEATEAKNKAEQKLKDLQDSASQGSELSKQLL 312 
SZO18970        NRESKKATQAEQAKKALETQKEKLEKDIEQAKEAKNKAEQKLKDLQDSASQGSELSKQLL 62 
                :: .::*. **::** *********::*::*.**************************** 
 
SEQ2190         KEKEELTTKLQELQKQAEEKTTEIEKLKQELEANKQNSGQLGQQEQKLQEQLNKVQKELK 419 
SEQ2180         KEKEELTTKLQELQKQAEEKTTEIEKLKQELEANKQNSGQLGQQEQKLQEQLNKVQKELK 372 
SZO18970        KEKQELTTKLQDLQKQANEKTTEIEKLKQELEANKQSNGQLNQKEQELKNQLDKIQEELK 122 
                ***:*******:*****:******************..***.*:**:*::**:*:*:*** 
 
SEQ2190         QKEMELKQAQEQLKQEQKPHEGGGDSDASKARITELEKQVQTLTKEKADLSSTLESTKAQ 479 
SEQ2180         QKEMELKQAQEQLKQEQKPHEGGGDSDASKARITELEKQVQTLTKEKADLSSTLESTKAQ 432 
SZO18970        QKEMELEKAKEQLKQEQKPHEY---DDTSKTRITELEQQVQTLTKEKENLSSTLESTKAQ 179 
                ******::*:***********    .*:**:******:********* :*********** 
 
SEQ2190         LSETQARLSEAQKQLTAAQEKLTTLEAEKTALQHQVETISKQLSETRDLSEKEKAALQEQ 539 
SEQ2180         LSETQARLSEAQKQLTAAQEKLTTLEAEKTALQHQVETISKQLSETRDLSEKEKAALQEQ 492 
SZO18970        LTETQAKLSEAQKQLTAAQEKLTTLEAEKVALQQQVDTISKQLSEARDLSEKEKAALQEQ 239 
                *:****:**********************.***:**:********:************** 
 
SEQ2190         INKLKAEIEQKTKEIEALKQGMQSHQGQEKPKDPKTPETPK---DPKTPEKNDQPQAPEK 596 
SEQ2180         INKLKAEIEQKTKEIEALKQGMQSHQGQEKPKDPKTPETPK---DPKTPEKNDQPQAPEK 549 
SZO18970        INKLKAEIEQKTKEIEALKQGMQSHQGQEKPKEPKMPEAPMKPEEPKTPEKKDQPQTPEK 299 
                ********************************:** **:*    :******:****:*** 
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SEQ2190         RSVPWTALTPAKPIDTTKAPKSSAPSPQTGAATPKKQLPATGDTATPSFFTAAAMAVLAS 656 
SEQ2180         RSVPWTALTPAKPIDTTKAPKSSAPSPQTGAATPKKQLPATGDTATPSFFTAAAMAVLAS 609 
SZO18970        RSIPWTALTPAKPIDTTKAPKSSAPSSQTGAATPKKQLPATGDTATSSFFTTAAMAVLAS 359 
                **:***********************.*******************.****:******** 
 
SEQ2190         VGVLNLSPRRKKNQNNR 673 
SEQ2180         ACALTLSPRRKKNQNNR 626 
SZO18970        VGVLTLSPRRKKD---- 372 
                . .*.*******:     
 
Figure 3.3: Multiple alignment of SEQ2190, SEQ2180 and the orthologue SZO18970. 
Multiple alignments were performed using ClustalW2. * indicates identical amino acids,: indicates similar amino acids.  
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Table 3.1: Significant orthologues of the mature SEQ2190 protein. 
Blast search performed by tBLASTn. 
 
Accession Annotation Organism Identities Positives Gaps 
E 
number 
gb|ACI61926.1|  
Fc-gamma 
receptor 
Streptococcus 
pyogenes strain 
NZ131 
100/136 
(32%) 
147/316 
(47%) 
 54/316 
(17%) 
2.00E-
11 
emb|CAA56449.1|  M3 Protein 
Streptococcus 
pyogenes 
116/385 
(30%) 
186/385 
(48%) 
 63/385 
(16%) 
4.00E-
11 
NP_665531.1| 
antiphagocytic 
M protein, type 
3 
Streptococcus 
pyogenes 
MGAS315 
116/385 
(30%) 
186/385 
(48%) 
63/385 
(16%) 
5.00E-
11 
gb|CAA44062.1| 
M protein type 
1 
Streptococcus 
pyogenes 
92/325 
(28%) 
161/325 
(50%) 
68/325 
(14%) 
9.00E-
11 
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Figure 3.4: Predicted secondary structure of mature SEQ2190. 
Consensus secondary structure prediction achieved using Phyre. H, represents predicted α-helicies, c, represents coils and e, represents β-strands. 
The numerical value for each individual amino acid residue (bottom line) is representative of the confidence probability of the prediction from 0 
(low confidence) to 9 (high confidence).  
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Figure 3.5: Artemis screen capture of the seq2180 and seq2190 locus and their respective S. 
zooepidemicus orthologues szo18890 and szo18970 
Yellow bars represent orthology between the four inter-related orthologues of interest 
between S. equi and S. zooepidemicus. Red bars represent orthology between S. equi and S. 
zooepidemicus. The key S. equi paralogues are highlighted in bold.  
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3.3. PCR of seq2180 and seq2190  
 
Genomic DNA was extracted from cultures of S. equi 4047 and S. zooepidemicus H70 and 
used as template DNA for necessary amplifications (Figure 3.6). Due to an identical DNA 3’-
terminal region between seq2190 and its homologue seq2180 it was necessary to perform a 
nested PCR with complementary reverse sites downstream from the 3’-terminal target to 
obtain the correctly amplified products seq2190 and seq2180. Using primer pairs; 
Full2190_N_F,-Const_2190_R and Full_2180_N_F,-Const_2180_R two PCR fragments 
were amplified from the extracted genomic DNA of S. equi (See figure 3.7 and 3.8). Both 
primer sets amplified the correct nested construct yielding products of size consistent with the 
predicted length of 1900 bp and 1767 bp in length respectively. The products obtained were 
then further amplified to obtain only the mature target protein, removing the predicted N-
terminal signal peptide sequence.  
Using the primer pairs; Full2190_N_F,-Full2180/2190_E_R (a universal reverse 
primer for amplifications of both SEQ2190 and SEQ2180) and Full2180_N_F,-
Full2180/2190_E_R two PCR fragments were amplified. The products yielded were of size 
consistent with the predicted lengths of 1884 bp and 1750 bp respectively (Figures 3.9 and 
3.10). For investigation into the unique N-terminal sequence identified in SEQ2190, a further 
product was amplified consisting of only the variable seq2190 region (truncated seq2190, 
encoding SEQ2190 N). This product was amplified from the nested seq2190 amplimer using 
the primer set SEQFull2190_N_F,-Part_2190_E_R. The product obtained was shown to be of 
size consistent with its predicted length of 579 bp (Figure 3.11).  
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Notably this primer set also amplified additional larger PCR products; these were 
considered artefacts and not investigated further as no homologues of the target gene product 
were present in the seq2190-containing amplimer used as template.  
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Figure 3.6: Genomic DNA extraction of S. equi 4047 and S. zooepidemicus H70. 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
as follows: lane 1, 10 kbp size standard; lane 2, extracted S. equi genomic DNA; lane 3, 
extracted S. equi genomic DNA (biological replicate); lane 4, 10 kbp size standard; lane 5, 
extracted S. zooepidemicus genomic DNA; lane 6, extracted S. zooepidemicus genomic DNA 
(biological replicate).  
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Figure 3.7: PCR amplification of seq2190 and 3’ extension. 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
as follows: lane 1, 10 kbp size standard; lane 2, amplified product. 
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Figure 3.8: PCR amplification of seq2180 and 3’ extension. 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
loaded as follows: Lane 1, 10 kbp size standard; lane 2, amplified product.  
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Figure 3.9: PCR amplification of seq2190. 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
loaded as follows: Lane 1, 10 kbp size standard; lane 2, amplified product.  
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Figure 3.10: PCR amplification of seq2180. 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
loaded as follows: Lane 1, 10 kbp size standard; lane 2, amplified product.  
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Figure 3.11: PCR amplification of truncated seq2190 encoding SEQ2190 N. 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
loaded as follows: Lane 1, 10 kbp size standards; lane 2, amplified product.  
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3.4. Cloning of seq2180 and seq2190 (full length and truncated forms) 
 
The amplified DNA products were initially cloned into pCR
®
-Blunt vector, yielding plasmids 
pb2190, pb2180 and pb2190 N (Table 2.5). These plasmids were subsequently digested with 
appropriate restriction endonucleases to verify product integration. Cloning vectors (target 
gene in pCR-Blunt) were then digested with appropriate endonucleases, purified and cloned 
into similarly restriction digested and purified pET 28a vector. This generated plasmids 
p2190, p2180 and p2190 N (Table 2.5) that encoded the proteins of interest with a His6 tag at 
the N-terminus of the mature protein.  
Confirmation of the correct plasmid construction was undertaken by screening of 
plasmids extracted from candidate positive clones with appropriate restriction endonucleases. 
Following digestion, a successful clone was indicated by the visualisation of a product of the 
expected target gene size and the remaining restriction endonuclease cut pET 28a vector, 5.4 
kbp in size. The expected sizes for the products of the inserts in pb2180/p2180, 
pb2190/p2190 and pb2190/p2190 N are 1767 bp, 1884 bp and 579 bp as can be clearly seen 
in figures 3.12, 3.13 and 3.14. Each putative correct construct was sequenced for further 
confirmation.  
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Figure 3.12: Restriction endonuclease digestion of p2190 plasmid. 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
loaded as follows: Lane 1, 10 kbp size standard; lane 2, p2190 post treatment with NdeI and 
XhoI restriction endonucleases. Released seq2190 product (expected size 1884 bp) is 
indicated with an arrow. The upper band is the pET28a vector.  
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Figure 3.13: Restriction endonuclease digestion of p2180 plasmid. 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
loaded as follows: Lane 1, 10kbp size standard; lane 2, p2180 post treatment with NdeI and 
EcoRI restriction endonucleases. Released seq2180 product (expected size 1767 bp) is 
indicated with an arrow. The upper band is the pET28a vector. 
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Figure 3.14: Restriction endonuclease digestion of p2190 N plasmid. 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
loaded as follows: Lane 1, 10 kbp size standard; lane 2, p2190N post treatment with NdeI and 
EcoRI restriction endonucleases. Released truncated seq2190 product (expected size 579 bp) 
is indicated with an arrow. The upper band is the pET 28a vector.  
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3.5. Protein expression 
 
Plasmids p2190 p2180 and p2190 N, encoding SEQ2190, SEQ2180 and the SEQ2190 N 
respectively, were chemically transformed into a range of E. coli expression strains (Table 
2.1) and grown at 37°C to mid-exponential phase. Initially, the expression of the recombinant 
proteins from these strains was induced by the addition of 1 mM IPTG (final concentration) 
and the cultures were incubated overnight. Whole cell protein extractions were taken both at 
3 hours and 16 hours post induction. A temperature of 20°C was initially chosen as reduced 
temperature is a parameter known to limit the in vivo aggregation of recombinant proteins 
(Schein 1989). The whole cell protein extracts obtained were compared to a whole cell 
extract of E. coli BL21 (DE3) with no transformed expression plasmid present  
Whole cell protein extracts visualised by SDS-PAGE showed expression of the target 
SEQ2190 protein from plasmid p2190 best in two specific strains of E. coli, BL21 and B834 
(DE3) (Figure 3.15). However further analysis of expression of SEQ2190 in E. coli Tuner™ 
indicated a small visual increase in expressed protein and less variability regarding whole cell 
harvesting between 3 and 16 hours (Figure 3.16). The expressed protein visualised was 
consistent in size to the predicted protein size of His6-Tagged mature SEQ2190 (68.7 kDa).   
Furthermore, plasmids p2180 and p2190 were also found to have favourable levels of 
cloned protein expression in E.coli Tuner™, expressing proteins consistent in size to the 
predicted size of each His6- Tagged mature protein, 64.2 kDa and 24.4 kDa respectively 
(Figures 3.17 and 3.18). Expression of proteins were found to be favourable with 1.0 mM 
IPTG (final concentration) in cultures agitated at 100rpm at 37°C overnight (16 hours). 
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Figure 3.15: 15% SDS PAGE gel demonstrating SEQ2190 expression trials. 
SEQ2190 expression was induced by 1 mM IPTG and growth at 20ºC. The expected position 
of the SEQ2190 protein is marked with an asterisk. Lanes were loaded as follows: Lane 1, E. 
coli BL21 (DE3) p2190, 3 hour induction; lane 2,- E. coli BL21 (DE3) p2190, 16 hour 
induction; lane 3, molecular weight markers (66, 45, 36, 29, 24, 20 kDa); lane 4, E. coli B834 
(DE3) p2190, 3 hour induction; lane 5, E. coli B834 (DE3), 16 hour induction. 
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Figure 3.16: 15% SDS PAGE gel demonstrating SEQ2190 expression 
SEQ2190 expression was induced by 1 mM IPTG and growth at 20ºC. The expected position 
of the SEQ2190 protein is marked with an asterisk. Lanes were loaded as follows: Lane 1, 
molecular weight markers (66, 45, 36, 29, 24 kDa); lane 2, E. coli Tuner® (DE3) p2190, 3 
hour induction; lane 3, E. coli Tuner® (DE3) p2190, 16 hour induction. 
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Figure 3.17: 15% SDS PAGE gel demonstrating SEQ2180 expression. 
SEQ2180 expression was induced by 1 mM IPTG and growth at 20ºC. The expected position 
of the SEQ2180 protein is marked with an asterisk.  Lanes were loaded as follows: Lane 1, 
molecular weight markers (97, 66, 55, 36, kDa); lane 2,- E. coli Tuner® (DE3) p2180, 3 hour 
induction; lane 3,- E. coli Tuner® (DE3) p2180, 16 hour induction. 
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Figure 3.18: 15% SDS PAGE gel demonstrating SEQ2190 N expression. 
SEQ2190N expression was induced by 1 mM IPTG and growth at 20ºC. The expected 
position of the SEQ2190 N truncated protein is marked with an asterisk. . Lanes were loaded 
as follows: Lane 1, E. coli Tuner® (DE3) p2190N, 3 hour induction; lane 2,- E. coli Tuner® 
(DE3) p2190N, 16 hour induction; lane 3, molecular weight markers (66, 45, 36, 29, 24 kDa).  
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3.6. Protein purification 
 
All His6 –tagged proteins were expressed from cultures in 4 l of LB media and 
purified from cell free extracts by IMAC using a chelating Sepharose column and an 
automated gradient elution technique (section 2.13.4). Identification of proteins present in 
different fractions was indicated by U.V absorption. Fractions containing expressed 
SEQ2190, SEQ2180 and SEQ2190 N were checked for purity by SDS-PAGE (Figures 3.19, 
3.20 and 3.21 respectively) and concentrated. Proteins SEQ2180, SEQ2190 and SEQ2190 N 
were then further purified by FPLC, monitored by U.V absorption and checked for purity by 
SDS-PAGE, concentrated and quantified (Figures 3.22, 3.23 and 3.24 respectively). The 
quantities of purified SEQ2180, SEQ2190 and SEQ2190 N obtained were varied depending 
on the protein i.e. ~1.25 mg/L, ~1.75 mg/L and ~2.5 mg/L respectively.   
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Figure 3.19: 15% SDS PAGE of IMAC purified fractions of SEQ2190. 
Lanes were loaded as follows: Lane 1, molecular weight markers (66, 45, 36, 29, 24, 20 
kDa); lanes 2-7, individual IMAC fractions of purified SEQ2190 (fractions 48, 46, 44, 42, 40, 
38). 
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Figure 3.20: 15% SDS PAGE gel of IMAC purified fractions of SEQ2180. 
Lanes were loaded as follows: Lane 1, molecular weight markers (116, 97, 66, 55, 45, 36 
kDa); lanes 2-7, individual IMAC fractions of purified SEQ2180 (fractions 47, 49, 51, 53, 55, 
57,) 
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Figure 3.21: 15% SDS PAGE of IMAC purified fractions of SEQ2190 N. 
Lanes were loaded as follows: Lane 1, molecular weight markers (45, 36, 29, 24, 20 kDa); 
lanes 2-6, individual fractions of purified SEQ2190_N (fractions 45, 43, 41, 39, 37). 
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Figure 3.22: 15% SDS PAGE gel showing FPLC purified fractions of SEQ2190. 
Lanes were loaded as follows: Lane 1, molecular weight markers (66, 45, 36, 29, 24 kDa); 
lanes 2-6, individual fractions of purified SEQ2190_N (Fractions 15, 14, 13, 12, 11). 
 
 
 
 
 
    1          2             3             4             5              6                     
66kDa 
36kDa 
45kDa 
29kDa 
24kDa 
133 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23: 15% SDS PAGE gel showing FPLC purified fractions of SEQ2180. 
Lanes were loaded as follows: Lane 1, molecular weight markers (66, 45, 36, 29, 24, 20, 14 
kDa); lanes 2-5, individual fractions of purified SEQ2180 (Fractions 12, 13, 14, 15). 
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Figure 3.24: 15% SDS PAGE gel of FPLC purified fractions of SEQ2190 N 
Lanes were loaded as follows: Lane 1, molecular weight markers (66, 45, 36, 29, 24, 20 
kDa); lanes 2-6, individual fractions of purified SEQ2190 N (Fractions 25, 23, 21, 19, 17, 
15). 
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3.7. Preperation of crystals for X-ray crystallography 
 
A number of different crystallisation screens were used to attempt to crystallise SEQ2180, 
SEQ2190 and the truncated SEQ2190 N proteins. These included PEG/Ion, Hampton Screen 
(HS) I and II, PEG/Anion, PEG/Cation, Newcastle and Index screens (See appendix III for 
formulations).  
Crystals of the SEQ2190 proteins were recovered from the PEG/Ion screens 35 and 3 
(Figures 3.25 and 3.26) but unfortunately neither of these crystals was suitable for diffraction. 
Unfortunately no other crystals were observed for any other proteins despite extensive 
screening with the screen library available. 
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Figure 3.25: Crystal of SEQ2190 
Ratio of protein and buffer added was 1:1. The condition tested that yielded the crystal was 
0.2M ammonium sulphate, 20% w/v polyethylene glycol 3350, pH 6.0. 
 
 
Figure 3.26: Crystal of SEQ2190. 
Ratio of protein and buffer added was 1:1. The condition tested that yielded the crystal was 
0.2M ammonium fluoride, 20% w/v polyethylene glycol 3,350, pH 6.2. 
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3.8. Discussion and future work 
 
The data provided in this study has demonstrated the production of three useful plasmid 
constructs. Furthermore it has been demonstrated that useful quantities of purified SEQ2180, 
SEQ2190 and the truncated SEQ2190 N protein could be produced using these constructs for 
further research.  
Bioinformatic analysis has indicated that SEQ2190 represents a protein of three 
distinct domains with a significant N-terminal domain, unique to S. equi 4047 of particular 
note. This protein is accompanied by a structurally similar but N-terminal sequence variable 
paralogue encoded by seq2180. Moreover, an N-terminally deficient pseudogene homologue 
of seq2190 is also present in S. zooepidemicus (Figure 3.3). It can be speculated that an 
ancestral strain of S. equi and S. zooepidemicus may have possessed only one of these 
paralogues, which then duplicated prior to the sub-species divergence event. Furthermore it 
can be speculated that an earlier strain of S. zooepidemicus may have retained a functional 
copy of SEQ2190 which has since become lost. The previous work undertaken by 
collaborators at the Animal Health Trust indicated that SEQ2190 was conserved in all tested 
strains of S. equi and the loss of the N-terminal portion of the S. zooepidemicus homologue 
was consistent amongst strains. 
Whilst it was indicated that the S zooepidemicus seq2190 pseudogene homologue was 
also conserved it remains to be determined what level of variability, if any, is present 
upstream from the point of mutation that has isolated the coding region for the C-terminal 
section of the protein as pseudogene. Although also attempted in this study, the lack of loci 
synergism amongst paralogous S. zooepidemicus strains in this region has meant that typical 
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chain-termination methods of sequencing are not possible. It is however expected that a high-
throughput genome sequencing methods and the publication of further whole genome 
sequences of S. zooepidemicus strains will provide further insight into the seq2190 
pseudogene, the function of which was presumably lost as a result of a truncation event.   
It was also the aim of this study to deduce a 3-dimensional structure of SEQ2190 and 
SEQ2180 following successful diffraction of respective protein crystals. Although work was 
undertaken to achieve this and some crystals of SEQ2190 produced it is regrettable that in the 
time frame of this study that this aim was not completed. However a proposed structure can 
be predicted following the computational analysis undertaken in this study (Figure 3.27). This 
proposed structure is primarily a helical stalk structure and a β-strand portion representing of 
the previously discussed unique N-terminal region. The extensively alpha helical structure is 
likely to be necessary to project the N-terminal domain up to the cell surface and through the 
hyluronic acid capsule. It is this β-strand region that is exclusive to the mature SEQ2190 
proteins and hence the potentially significant putative host ligand interactive portion of each 
protein that may contribute to pathogenesis. 
One such benefit from the availability of 3-Dimensional structures of SEQ2180 and 
SEQ2190 would be clearer insight into potential ligands or catalytic activities. As 
demonstrated, other than in S. zooepidemicus, SEQ2190 has only orthologues of low 
significance in S. pyogenes and these are also highly helical proteins projecting from the cell 
wall (Timoney, et al. 1997). Indeed the homologous regions are only located within the 
common helical regions. It was expected that the solving of a 3-dimensional structure would 
have provided the tools to enable more stringent structure database searches for potential 
ligand candidates for SEQ2190 and SEQ2180. It should also be noted that the degree of 
ligand specificity has not been established for either SEQ2190 or SEQ2180 nor has the 
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potential of possible co-receptor ligand binding. However the absence of a functional partner 
to SZO18890 in S. zooepidemicus perhaps argues against this possibility.   
To provide insight into SEQ2190 as a potential virulence factor, it was also the initial 
aim of this study to produce ∆seq2190, ∆seq2180 and ∆seq2190 N strains of S. equi based on 
methodology described by Hamilton and colleagues (Hamilton, et al. 2006). However at the 
time of writing this has not yet been successful. It was expected that the production of these 
mutant strains would have enabled further study in a mouse model of strangles (Chanter, et 
al. 1995) and investigation of changes (if any) in the surface epithelial morphology of air 
interface organ cultures (Jackson, et al. 1996) exposed to these mutant S. equi strains.  
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Figure 3.27: Proposed predicted secondary structure model of the mature SEQ2190 protein with three distinct structural domains.  
(1) C-terminal region of predominantly protein coil. (2) Core region of long extended α-helicies (3) N-terminal region of β-strands, protein 
coil and α-helicies; W, cell wall; H, Hylauronic acid capsule; E, Exposed bacterial surface 
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4. Investigation into the secreted Phospholipase A2 enzyme, SlaA of S. equi.  
 
4.1. Introduction 
 
As described in section 1.8, PL represents an interesting class of multifunctional and diverse 
enzymes with particular attention given to sPLA2 enzymes. With regards to the streptococci, 
the ability of sPLA2 to result in the cleavage products, lysophospholipid and free fatty acid 
(crucially AA) represents an interesting prospect as a potential virulence factor. The work of 
Sitkiewicz et al (2006) in particular has already provided clear evidence for potency of sPLA2 
as a virulence factor with demonstrated effects of the S. pyogenes sPLA2, SlaA (here in 
refered to as SpSlaA) on eukaryotic cells.  
Since S. pyogenes shares many virulence factors with S. equi and S. zooepidemicus 
reasonable speculation can be given that the presence of SlaA in S. equi would possess 
similar potency as a virulence factor.  
The presence of SlaA however is not conserved amongst S. equi and S. zooepidemicus 
strains as shown by the work of Holden et al (2009) indicating that the presence of SlaA in 
some S. equi strains may have been acquired via mobile genetic elements similarly to its 
presence in the pathogenically more severe S. pyogenes M3 strains. SlaA has been detected in 
26 of 26 tested strains of S. equi (crucially including the M-protein plus strain, CF32) but 
only detected in 44 of 140 tested strains of S. zooepidemicus, indicating the 
acquisition/retention of slaA in S. equi has a far greater biological significance than its 
acquisition/retention in S. zooepidemicus. The absence of SlaA in a large proportion of S. 
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zooepidemicus strains also implies a potential molecular difference that may relate to the 
clear pathogenic contrast shown between S. equi and S. zooepidemicus (see section 1.2). 
Isolates from the early 20
th
 century (S. equi strain ATCC 9527) have been shown to 
encode SlaA (Ikebe et al., 2002), predating the isolation of SpSlaA expressing S. pyogenes 
strains (Beres, et al. 2002) also indicates that it is possible that SpSlaA was acquired in S. 
pyogenes via phage-mediated horizontal transfer from a SlaA-containing strain of S. equi 
(Holden, et al. 2009; Ikebe, et al. 2002).  
Currently it is not known if SlaA expressed by S. equi has the potential to trigger an 
inflammatory cascade via the cleaving of phospholipids, releasing AA. The degree of 
enzymatic activity expressed by SlaA and its paralogue SlaB in comparison with other 
similar sPLA2 activities also remains undetermined.  
According to current sPLA2 nomenclature (Burke and Dennis 2009) , SlaA and SlaB 
may represent a new family of sPLA2 enzymes with the molecular mass and the number of 
disulphide bonds present not consistent amongst any of the currently proposed groups. 
Aims of the present study 
The aims of the present study were: 
a) to clone and express SlaA identified in S. equi 4047 and SlaB identified in S. equi 
4047 and S. zooepidemicus H70 in E. coli.  
b) to obtain purified forms of SlaA and SlaB. 
c) to assess the enzymatic properties of SlaA and SlaB and provide a comparison to 
previously characterised similar sPLA2 enzymes.  
d) to investigate the ability of SlaA and SlaB to release AA from phospholipids.  
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4.2. Bioinformatic identification of SlaA and an SlaA homologue in S. equi. 
 
The amino acid sequence of the putative sPLA2, SlaA (SEQ0849) was obtained from UniProt 
in a FASTA format. The SEQ0849 sequence was analysed for identification of a signal 
peptide cleavage site by using the SignalP Hidden Markov Models and Neural Networks 
outputs, with a cleavage site predicted between position 27 and 28, with a probability of 1.0. 
A canonical lipoprotein ‘lipobox’ (LAAC13) is noted to be present in the signal peptide, but 
due to the atypical shortness of the preceding H- region, SlaA is not predicted to be a putative 
lipoprotein. A BLAST search of the translated S. equi genome database for homologues to 
SlaA revealed an amino acid sequence with 80% identity (130/191 amino acids), annotated as 
SlaB (SEQ2155). The amino acid sequence of SEQ2155 also differed from SEQ0849 in that 
the signal peptide cleavage site was instead predicted between position 26 and 27. Notably, 
the predicted non-functional lipobox in the SlaA signal peptide is not conserved in SlaB.  
A BLAST search was undertaken for both SEQ0849 and SEQ2155 of the S. equi sub 
sp. zooepidemicus H70 genome project (http://www.sanger.ac.uk/cgi-
bin/blast/submitblast/s_zooepidemicus). Notably, no orthologue to SlaA was found in S. 
zooepidemicus H70. However, an identifiable orthologue of SEQ2155 was identified in S. 
zooepidemicus H70 showing 90.0% identity (172/190 amino acids, SZO18670), (Figure 4.1).  
Database searches of homologues to the amino acid sequence of the mature SlaA 
(SEQ0849) protein using BLAST revealed a large number of proteins with significant 
similarities, and some proteins with low similarities but of biological significance (Table 4.1). 
Of particular interest, is the SpSpaA protein investigated by Nagiec et al. (2004) and 
identified as a phage encoded protein in the genomes of S. pyogenes strains MGAS315 
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(Beres et al 2002) and N1H1 (Ikebe et al. 2002). This orthologue was shown to have 99% 
identity (162/164 amino acids) to S. equi SlaA (Figure 4.2).  
Database searches of protein families also revealed that SlaA and SlaB were likely to 
be representatives of the sPLA2 family of phospholipase enzymes. BLAST analyses noted a 
significant match to the Pfam family, Phospholip_A2_1 (PF00068), Phospholipase A2 
(Figure 4.3) and also noted less significant matches to the Pfam family PLA2G12 (PF06951, 
Group XII secretory phospholipase A2 precursor) and Phospholip_A2_2 (PF05826, 
Phospholipase A2). As indicated in Figure 4.1, the putative Ca
2+
loop consensus sequence 
region and active site consensus region was identified based on putative regions defined in 
SpSlaA (Nagiec, et al. 2004). 
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Table 4.1: Representative orthologues of SEQ0849. 
 
Accession Annotation Organism Identities Positives Gaps E number 
gb|AY050245.2| 
Putative methionine sulfoxide 
reductase gene 
Streptococcus 
pyogenes strains 
NIH1 and 
MGAS315 
162/164 
(99%) 
164/164 
(100%) 
0/164 (0%) 1.00E-92 
gb|GQ923934.1| Phospholipase A2 (slaA gene) 
Streptococcus 
dysgalactiae subsp. 
equisimilis strain 
B107 
162/164 
(99%) 
164/164 
(100%) 
0/164 (0%) 3.00E-92 
gb|CP001709.1| Plasmid pAPRE01 
Anaerococcus 
prevotii DSM 
20548 
72/159 (45%) 101/159 (64%) 5/159 (3%) 5.00E-31 
gb|CP002618.1| Hypotentical protein 
Lactobacillus casei 
BD-II 
38/100 (38%) 52/100 (52%) 
14/100 
(14%) 
3.00E-07 
gb|CP001001.1| 
Conserved hypothetical 
protein 
Methylobacterium 
radiotolerans JCM 
2831 
25/50 (50%) 30/50 (60%) 5/50 (10%) 7.00E-05 
 
 
146 
 
SEQ2155         MKKRLAFILVAFGILGFSLGN---EVLAADTAPASATMATDSDVSFYNGELLKKYLVQSG 57 
SZO18670        MKKRLAFILVAFGILGFSLGN---EVLAADTAPASATMATDSDVSFHNGELLKKYLVQSG 57 
SEQ0849         MKKVINTILLAACFL-FFLGNFTTNVLAEGIN-DKIENGTESDISFQNGELLKNYLILEG 58 
                *** :  **:*  :* * ***   :*** .    .   .*:**:** ******:**: .* 
 
SEQ2155         DRLYFDYDKAIQDKVSDGVIDMGFLVETISEDYSQQTFTSRKYFKAGWQLYGNYCGPGHN 117 
SZO18670        DRLYFDYDKAIQDKVSDSVIDMGFLVETISEDYSQQTFTPRKYFKAGWQLYGNYCGPGHN 117 
SEQ0849         ERVYFDYDRATQDKVSDDVLEMGMLVEAISKDYSEKTFTPDKYFKASWPIHGNYCGPGHN 118 
                :*:*****:* ******.*::**:***:**:***::***. *****.* ::********* 
 
SEQ2155         GNHFTLPVIDVLDQGCQNHDSCYRWGAGIGANCECNRQLVNYIKVYRRWMPAHALGVADA 177 
SZO18670        GNHFTLPVIDVLDQGCQNHDSCYRWGAGIGANCECNRQLVNYIKVYRRWMPAHALGVADA 177 
SEQ0849         GNNFTLPVVDVLDQGCQNHDSCYKWGAGIGANCECNRQLVNYIKVYRRWMPANVLGVADA 178 
                **:*****:**************:****************************:.****** 
 
SEQ2155         IRVYFETVGAIGC 190 
SZO18670        IRVYFETVGAIGC 190 
SEQ0849         IRVYFETVGSIGC 191 
                *********:*** 
 
Figure 4.1: Multiple alignment of SEQ0849, SEQ2155 and the S. zooepidemicus  orthologue (SZO18670). 
Multiple alignments were performed using ClustalW2. * indicates identical amino acids,: indicates similar amino acids. The Ca
2+
 loop consensus 
sequence región is highlighted in blue, and the active site concensus sequence is highlighted in green. Conserved cysteine residues are 
underlined.   
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SlaA            MKKVINTILLAACFLFFLGNFTTNVLAEGINDKIENGTESDISFQNGELLKNYLILEGER 60 
SpSlaA          MKKVINTILLAACFLFFLGNFTTNVLAEGINDKMENGTESDISFQNGELLKNYLILEGER 60 
                *********************************:************************** 
 
SlaA            VYFDYDRATQDKVSDDVLEMGMLVEAISKDYSEKTFTPDKYFKASWPIHGNYCGPGHNGN 120 
SpSlaA          VYFDYDRATQDKVSDDVLEMGMLVEAISKDYSEKTFTPDKYFKASWPVHGNYCGPGHNGN 120 
                ***********************************************:************ 
 
SlaA            NFTLPVVDVLDQGCQNHDSCYKWGAGIGANCECNRQLVNYIKVYRRWMPANVLGVADAIR 180 
SpSlaA          NFTLPVVDVLDQGCQNHDSCYKWGAGIGANCECNRQLVNYIKVYRRWMPANVLGVADAIR 180 
                ************************************************************ 
 
SlaA            VYFETVGSIGC 191 
SpSlaA          VYFETVGSIGC 191 
                *********** 
 
Figure 4.2: Pairwise alignment of SlaA and the SpSlaA protein encoded by temperate phage of S. pyogenes strains. 
Alignment was performedusing ClustalW2. * indicates identical amino acids, : indicates similar amino acids. The two variant amino acid 
positions are underlined.  
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#HMM       EYAEYGCYCGAGGSGTP.....KDELDRCCKVHDECYEEAEK..KGCKPKLKTYSY  
#MATCH     ++  +G yCg g +G+      +D lD+ C+ hd+Cy+       +c+ + +  +y  
#PP        566789*********8433334799************9654434566655555544  
#SEQ       SWPIHGNYCGPGHNGNNftlpvVDVLDQGCQNHDSCYKWGAGigANCECNRQLVNY 
 
Figure 4.3 Identification of Pfam family. 
The conserved PLA2 domain was identified between position 78 and 133 of the mature SlaA (SEQ0849) protein with an Expect value of 
0.00021, indicating that the likelihood of a correct match is high. #HMM refers to the consensus of the hidden markov models (HMM), 
#MATCH refers to the match between the Pfam family and the amino acid sequence of SEQ0849, #PP refers to the posterior probability and 
#SEQ refers to the matched portion of SEQ0849.   
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4.3.  PCR of seq0849 and seq2155 
 
Using the designed primers pairs- SEQ0849f-SEQ0849r and SEQ2155f-SEQ2155r (Table 
2.4), two PCR fragments were amplified from the extracted genomic DNA of S. equi (Figure 
3.4). Both primer sets amplified only the mature protein and removed the predicted N-
terminal signal peptide sequence and the reverse primer of each primer set contained its 
complementary base sequence downstream from the target gene. Primer set SEQ0849f and 
SEQ0849 yielded a product of size consistent with its predicted length of 717bp (Figure 4.4) 
and primer set SEQ2155f and SEQ2155r yielded a product of size consistent with its 
predicted length of 779bp in length (Figure 4.5). Notably these primers also amplified 
additional larger PCR products which were not investigated further as BLAST searches 
strongly suggest that SEQ0849 and SEQ2155 are the only putative sPLA2 paralogues 
encoded in the S. equi 4047 genome (Figure 4.5).  
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Figure 4.4: PCR amplification of seq0849. 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
loaded as follows: Lane 1, 10 kbp size standard; lane 2, PCR product from amplification of 
seq0849 from S. equi 4047 genomic DNA, Lane 3; PCR product technical replicate. 
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Figure 4.5: PCR amplification of seq2115. 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
loaded as follows: Lane 1, 10 Kbp size standard; lane 2, PCR product from amplification of 
seq2155 from S. equi 4047 genomic DNA; lane 3, PCR product technical replicant.  
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4.4. Cloning of seq0849 and seq2155 
 
The amplified DNA products were initially cloned into pCR
®
 -Blunt vector, yielding 
plasmids pb0849 and pb2155. These plasmids were subsequently digested with appropriate 
restriction endonucleases to verify product integration. Cloned target gene and pCR-Blunt 
plasmid DNA was then digested with appropriate endonucleases, purified and cloned into 
similarly restriction digested and purified pET 28a vector. This generated plasmids p0849 
and p2155 that encoded the proteins of interest with a His6-tag at the N-terminus of the 
mature protein.  
Confirmation of the correct plasmid construction was undertaken by screening of 
plasmids extracted from candidate positive clones with appropriate restriction endonucleases. 
Following digestion, a successful clone was indicated by the visualisation of a product 
consisting of the expected target gene size and the remaining restriction endonuclease cut 
pET 28a vector, 5.4 kbp in size (Figures 4.6). 
 Further confirmation was undertaken by the gene sequencing of the plasmid from the 
T7 promoter region. The sequences obtained were checked for fidelity and aligned to their 
respective nucleotide sequences in the S. equi 4047 genome (See appendix IV). Dr Meng 
Zhang is thanked for technical assistance with some of the steps in this cloning procedure.  
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Figure 4.6: Restriction endonuclease digestion of p0849 and p2155 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
loaded as follows: Lane 1, 10 kbp size. Lane 2, p0849 post treatment with NdeI and XhoI 
restriction endonucleases. Lane 3, p2155 post treatment with NdeI and XhoI. Released 
seq0849 and released seq2155 product (expected sizes 715bp and 779bp respectively) are 
indicated with an arrow. 
 
2.0 kbp 
1.5 kbp 
1.0 kbp 
800 bp 
2.5 kbp 
3.0 kbp 
4.0 kbp 
5.0 kbp 
6.0 kbp 
8.0 kbp 
10.0 kbp 
1                   2                3            
154 
 
4.5. Protein expression of SEQ0849 and SEQ2155 
 
Plasmids p0849 and p2155, encoding SlaA and SlaB respectively, were chemically 
transformed into a range of E. coli expression strains (see Table 2.1) and grown at 37 °C to 
mid-exponential phase. Initially when plasmid, p0849 was transformed into a variety of E. 
coli expression strains, expression of the recombinant proteins was induced by the addition of 
1 mM IPTG (final concentration) and the cultures were incubated at a variety of 
temperatures. A temperature of 20°C was initially chosen as a reduced temperature is a 
known technique to limit the in vivo aggregation of recombinant proteins (Schein 1989).  
Whole cell protein extractions visualised by SDS-PAGE yielded poorly expressed 
target protein (Figure 4.7).  The cultivation temperature was therefore increased to 37°C as it 
has been shown that increased temperature of cultivation can result in an increased level of 
replication, transcription and translation (Shaw et al 1967). It was however shown that 
expression at 37°C produced a notably reduced level of expressed soluble protein compared 
to cultures incubated at 20°C (Figure 4.8).  
As well as the two common E. coli expression strains (BL21 and B834), two strains 
were chosen specifically for this expression, Tuner™ and C43 (DE3). The expression strain 
E.coli Tuner™ is useful since this strain enables the adjustment of protein expression by 
adjusting the concentration of IPTG. A reduced level of expression has been shown to 
enhance the solubility and activity of difficult target proteins (Novagen 2003). The 
expression strain C43 (DE3) can significantly increase soluble protein expression of some 
difficult recombinant proteins that are unable to express in the parent strain BL21 (DE3) 
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(Miroux, 1996). The strain C43 (DE3) has also been demonstrated to increase the stability of 
plasmids encoding toxic proteins (Dumon-Seignovert et al 2004).  
A further area of investigation was the use of glucose to control basal expression in 
the pET system. It has been demonstrated that the addition of 0.1% glucose to cultures in LB 
medium can increase the expression of a target protein (Novy and Morris 2001).  
In summary, SDS-PAGE analysis indicated that expression of SlaA was found to be 
most favourable when expressed in the E. coli expression strain Tuner™, induced with 0.5 
mM IPTG (final concentration) followed by the addition of 0.1% w/v glucose, agitated at 
100rpm at 20°C overnight (Figure 4.9).  
Expression of SlaB recombinant protein from plasmid p2155 was also found to be 
most favourable under conditions similar to that of the SlaA recombinant protein (Figure 
4.10). The molecular weight of the mature SlaA and SlaB proteins including the His6 N-
terminal tag was estimated to be 20.6 kDa using the Expasy ProtParam tool 
(http://expasy.org/tools/protparam.html). 
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Figure 4.7: 17% SDS PAGE of SlaA expression trials. 
Protein expression was induced by 1 mM IPTG and growth at 20ºC. The expected position of 
the SlaA protein is marked with an asterisk. Lanes were loaded as follows: Lane 1, molecular 
weight markers (66, 45, 36, 29, 24, 20kDa); lane 2, E.coli Tuner (DE3) p0849; lane 3, E. coli 
C43 (DE3) p0849; lane 4, E. coli B834 (DE3) p0849; lane 5, E. coli BL21 (DE3) p0849. 
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Figure 4.8: 17% SDS PAGE of SlaA expression trials. 
Protein expression was induced by 1 mM IPTG. The expected position of the SlaA protein is 
marked with an asterisk. Lanes were loaded as follows: Lane 1, molecular weight markers 
(66, 45, 36, 29, 24, 20 kDa); lane 2, E. coli BL21 (DE3) p0849 induced at 20 ˚C; lane 3, E. 
coli BL21 (DE3) p0849 induced at 20 ˚C overnight; lane 4, E. coli BL21 (DE3) p0849 
induced at 37˚C; lane 5, E. coli BL21 (DE3) p0849 induced at 37˚C overnight. 
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Figure 4.9: 17% SDS PAGE of SlaA expression. 
Lanes were loaded as follows: Lane 1, molecular weight markers (66, 45, 36, 29, 24, 20, 14 
kDa); lane 2, E .coli Tuner® p0849 induced at 20 ˚C overnight with the addition of 0.1% w/v 
D-Glucose. Induced SlaA protein is marked with an asterisk.  
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Figure 4.10: 17% SDS PAGE of SlaB expression trials. 
SlaB expression was induced by the addition of 0.1% w/v D-Glucose. Lanes were loaded as 
follows: Lane 1, molecular weight markers (66, 45, 36, 29, 24, 20 kDa); lane 2, Control 
(AKTA Purified SlaA); lane 3, E. coli BL21 (DE3) expressed at 20˚C overnight; lane 4, E. 
coli BL21 (DE3) expressed at 37˚C; lane 5; E.coli Tuner (DE3) expressed at 20˚C overnight; 
lane 6, E. coli Tuner (DE3) expressed at 37˚C overnight; lane 7, control (E. coli BL21 with 
p2155 plasmid not present).  
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4.6. Protein purification of SlaA and SlaB 
 
Both His6 –tagged proteins were expressed in 4 litres of LB media and purified from cell free 
extracts by (IMAC) using a chelating Sepharose column and an automated gradient elution 
technique (Section 2.13.4). Confirmation of proteins present in different fractions was 
indicated by U.V absorption; fractions were checked for purity by SDS-PAGE (Figures 4.11 
and 4.12) and concentrated. Proteins were then further purified by FPLC, monitored by U.V 
absorption and checked for purity by SDS-PAGE, concentrated and quantified (Figures 4.13 
and 4.14). Quantities of purified SlaA obtained were ~3.75 mg/L. It was noted that quantities 
of purified SlaB obtained from recombinant protein expression was significantly less than 
comparable expression quantities of SlaA (~0.125 mg/L). 
The purified SlaB product was also noted to have a lower stability compared with 
similarly obtained purified SlaA, showing visible degradation on SDS-PAGE analysis during 
a shorter time-frame. Additionally a reduced level of purification was observed showing 
residual E. coli protein present at a higher molecular weight than the target protein on SDS-
PAGE analysis (Figure 4.15). A serine specific protease inhibitor was added during 
recombinant expression of SlaB but was found to have little effect on the quantity or quality 
of recombinant protein obtained (data not shown) 
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Figure 4.11: 17% SDS PAGE of IMAC purified fractions of SlaA. 
Lanes were loaded as follows: Lane 1, molecular weight markers (66, 45, 36, 29, 24, 24, 20kDa); lanes 2-8, individual fractions of purified SlaA 
(Fractions 49, 51, 53, 55, 57, 59, 61).   
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Figure 4.12: 17% SDS PAGE of IMAC purified fractions of SlaB. 
Lanes were loaded as follows: Lane 1, molecular weight markers (66, 45, 36, 29, 24, 24, 20 kDa); lanes 2-7, individual fractions of purified SlaB 
(Fractions 55, 57, 59, 61, 63, 65). 
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Figure 4.13: 17% SDS PAGE of FPLC purified fractions of SlaA. 
Lanes were loaded as follows: Lane 1 purified SlaA (fraction 23); lane 2, molecular weight 
markers (45, 36, 29, 24, 20, 14 kDa); lanes 3-5, individual fractions containing purified SlaA 
(fractions 24, 25, 26).  
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Figure 4.14: 17% SDS PAGE of FPLC purified fractions of SlaB. 
Lanes were loaded as follows: Lanes 1-7, individual fractions containing purified SlaB (23, 24, 25, 26, 27, 28, 29 kDa); lane 8, molecular weight 
markers (45, 36, 24, 24, 20 kDa).  
 1                2                 3                4            5            6             7          8 
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Figure 4.15: 17% SDS PAGE of the purified SlaA and SlaB products obtained 
Lanes were loaded as follows: Lane 1, molecular weight markers (66, 45, 36, 29, 24, 24, 
20kDa); lane 2, purified SlaA; lane 3, purified SlaB. 2µg of purified protein was added to 
each sample lane.  
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4.7. Confirmation of His6-Tagged SlaA and SlaB by western blotting 
 
The presence of His6-Tagged SlaA and SlaB in the protein samples obtained was screened by 
Western immunoblotting, using a commercial polyclonal antiserum raised against the His6-
tag. The antiserum was shown to cross-react with a ~20kDa proteins in each preparation 
consistent to the predicted size of SlaA and SlaB. Cross-reaction was especially strong 
against SlaA, with a less intense reaction shown against SlaB. Notably a reaction was also 
detected above and below the expected band size of ~20kDa against SlaA. The reaction 
above is likely to represent protein aggregation products and the reaction below is likely to 
represent protein degradation products (Figure 4.16).  
 
4.8. Detection of antibodies to SlaA and SlaB in equine convalescent serum 
 
The presence of antibodies to SlaA and SlaB in equine convalescent serum was investigated 
by Western immunoblotting, using equine convalescent serum acquired from three ponies, 
pre and post infection with S. equi.  Strong antibody cross-reactivity with SlaA was shown in 
one of the serum pony samples acquired post-infection and a very weak reaction shown 
against SlaB. No cross reactivity was detected in serum acquired pre-infection against either 
SlaA or SlaB (Figure 4.17). Note that two different molecular weight markers were used in 
each separate panel. The left hand panel (lanes 1-3) used a pre-stained molecular weight 
marker whereby the right hand panel used a marker that was only visible using reversible 
staining with Ponceau reagent (marked in pencil prior to western blot development). 
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Figure 4.16: His6-tag Western blot analysis of SlaA and SlaB. 
Lanes were loaded as follows: Lane 1, molecular weight markers (20, 25, 37, 50, 
75,100kDa); lane 2, SlaA. The purified protein amount added was 2µg. 
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Figure 4.17: Western blot analysis of purified SlaA and SlaB against equine convalescent serum (pre and post infection). 
Lanes were loaded as follows: Lane 1and 6: molecular weight markers (20, 25, 37, 50, 75, 100 kDa); lane 2, SlaA; lane 3, SlaB; lane 4, SlaA; 
lane 5, SlaB. Amount of protein added to each well was 2µg. Left hand pannel (lanes 1-3), blot probed with post-infection serum (from Pony 
5080). Right hand panel (lanes 4-6), blot probed with matched pre-infection serum.  
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4.9. Enzymatic assay of SlaA and SlaB activity 
 
4.9.1. Sigma method 
 
For investigation of the activity of SlaA and SlaB against L-α-phosphatidylcholine, the initial 
assay method recommended by Sigma-Aldrich
®
 was undertaken (see section 2.14.2.1). A 
positive control sPLA2 enzyme (source – bee venom) was employed to test the robustness of 
the chosen assay. Initially a calibration curve was calculated using L-α-phosphatidylcholine 
as the standard. Subsequently positive control sPLA2 and purified SlaA protein was tested, 
due to a superior quantity available in comparison to SlaB. The total amount of both enzymes 
added to each reaction mixture was 5µg at 37˚C and absorbance was read at 570 nm. 
Although visual colorimetric changes were observed in the initial series of assays for both 
enzymes, the data obtained did not reflect true Michaelis-Menten kinetics. Furthermore poor 
enzyme stability was observed and a large degree of variation amongst replicates was 
observed. This assay method was therefore deemed inappropriate for enzyme activity 
quantification (data not shown). 
 
4.9.2. Price method 
 
A second assay method detailed by Price (2007) was investigated (see section 2.14.2.2), as a 
viable cost-effective alternative. As the assay detects phospholipase activity from the release 
of protons, initial evaluation of the assay was conducted using measured amounts of HCl in 
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place of the enzyme. The range of the assay when HCl was used as an evaluator reagent was 
shown to be linear but overall stability of the reaction mixture and reproducibility of the 
dataset was poor (Figure 4.18).  
Regarding sPLA2 enzymatic activity, initial assays were undertaken using SlaA to 
assess the optimum viable enzyme concentration suitable for further investigations with a 
standard final concentration of 5 mM phosphatidylcholine substrate. The initial assay 
assessment indicated that an amount of 2 µg was most appropriate although again general 
poor reproducibility of results was observed (Figure 4.19). Finally a further investigation of 
the effect of substrate concentration was undertaken with this assay method. Data indicated 
that true Michaelis-Menton kinetics for enzyme activity was not observed for this assay when 
undertaken with SlaA (Figure 4.20). The Assay was also performed with 0.2 µg of SlaB, 
although visually a colorimetric reaction was observed, the absorbance change recorded was 
not significant (data not shown).  
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Figure 4.18: Enzyme assay by the method of Price (2007). 
The reactions were performed in triplicate as detailed in section2.14.1. Each reaction was 
undertaken for approx 10 minutes with varying concentrations of HCL present and a standard 
concentration of 5mM of substrate. Error bars represent the standard deviation from the 
mean. 
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Figure 4.19: Enzyme assay by the method of Price (2007). 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction was 
undertaken for approx 10 minutes with varying amounts of SlaA enzyme and a standard 
concentration of 5 mM of substrate. Error bars represent the standard deviation from the 
mean. 
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Figure 4.20: sPLA2 enzyme assay by the method of Price (2007). 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction was 
undertaken for approx 10 minutes with 2.0 µg of active SlaA. Error bars represent the 
standard deviation from the mean. 
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4.9.3. Chromogenic substrate release assay 
 
A further assay was investigated that was based on the work of Reynolds (1992), using a 
commercial kit obtained from Cayman Chemical Company and detailed in section 2.14.2.3. 
Initially the assay was assessed for linearity and accuracy using 1 µg of a commercially 
available enzyme control and a substrate concentration of 1.66 mM (PLA2 obtained from Bee 
venom). The reaction was allowed to proceed at room temperature with the absorption 
measured at 414 nm for 10 minutes and demonstrated to be linear (Figure 4.21). The specific 
activity of Bee venom PLA2
 
against diheptanoyl thio-phosphatidylcholine (DHT-PC) was 
calculated to be 1.743 ± 0.19 µmol/min/mg.  
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Figure 4.21: Standard rate of sPLA2 activity over against time. 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction was 
undertaken for approx 10 minutes with 1.0 µg of active sPLA2 (source- bee). Error bars 
represent the standard deviation from the mean.  
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4.9.3.1. Michaelis-Menten parameters for SlaA 
 
For the investigation of the activity of SlaA against DHT-PC, the enzyme was assayed for an 
increase in absorbance at 414 nm. A total amount of 10 µg of enzyme (determined 
empirically) was added to each reaction to assay SlaA and a total amount of 1 µg of enzyme 
was added to each reaction to assay SlaB.   
For kinetic analysis, 4 substrate concentrations (determined empirically) were chosen 
and reactions performed in triplicate with changes in absorbance observed over a total of ten 
minutes (Figure 4.22). The calculated Km for SlaA was determined to be 14.40 ± 7.866 mM 
and demonstrated on a Lineweaver-Burk plot (Figure 4.23). Specific activity was determined 
to be 5.06x10
-2
 ± 3.01x10
-3 
µmol/min/mg.  
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Figure 4.22: Rate of SlaA activity against substrate concentration. 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction was 
undertaken for 10 minutes with 10.0 µg of active SlaA. Error bars represent the standard 
deviation from the mean.  
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Figure 4.23: Lineweaver-Burk plot for SlaA against DHT-PC. 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction was 
undertaken for 10 minutes with 10.0 µg of active SlaA.  
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4.9.3.2. Determination of temperature optimum 
 
An investigation was undertaken to assess the optimal temperature of enzyme activity for 
SlaA. A total of 10 µg of enzyme and 1 mM of DHT-PC substrate were used in each reaction 
and the reaction was undertaken for a period of 10 minutes.  
As shown in figure 4.24, SlaA demonstrated the highest rate of activity against DHT-
PC at 45˚C, (6.1x10-2 ± 2.3x10-3 µmol/min/mg). Significant standard deviation of the means 
was demonstrated at 50 ˚C (±5.6x10-3 µmol/min/mg) perhaps suggesting enzyme instability 
or degradation at the higher temperatures. 
 
4.9.3.3. Determination of divalent ion requirement 
 
When SlaA was tested with a range of divalent cations, it was observed that the enzyme had a 
specific requirement for Ca
2+
 ions. A final concentration for each divalent ion added was 
10mM, which was noted as the standard amount in reference sPLA2 assays.  
The data for the effect of divalent cations on activity is presented in figure 4.25. No 
activity was recorded when activity was investigated with either Cu
2+
 or Mn
2+
, slight activity 
was recorded when Co
2+
 replaced the standard Ca
2+
 although this varied considerably 
amongst replicates and not deemed significant. 
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The replacement of Ca
2+
 with Mg
2+
 revealed a quantifiable level of specific activity 
(6.8x10
-3 
µmol/min/mg). Comparisons of the control and replacement of Ca
2+
 with Mg
2+
 
demonstrated that the rate of enzymatic activity was reduced by approximately 88.2%. 
The effect of increased concentration of Ca
2+
 was also demonstrated and showed a 
significant measurable increase when the concentration of available divalent cation’s was 
increased 4-fold to a final concentration of 40 mM. An increase of 76.3% in activity was 
observed from an enzyme activity of 4.34x10
-2 
±2.4x10
-3 
µmol/min/mg to 0.181 ± 5.3x10
-3 
µmol/min/mg (Figure 4.26).  
A reduction of Ca
2+ 
concentration in the reaction (below the standard concentration of 
10mM)
 
was found to have minimal effect on enzyme activity.  The rate of activity was 
demonstrated to have little variation between the standard concentration of 10 mM and a 
reduced concentration of 2.5 mM. Unexpectedly a small amount of activity was detected in 
the absence of any Ca
2+
 (3.23x10
-3
 ± 4.9 x10
-4
 µmol/min/mg).  
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Figure 4.24: The effect of temperature on the rate of SlaA enzyme activity against DHT-PC 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction had a 
final substrate concentration of 0.5 mM and 10.0 µg of active SlaA. Error bars represent the 
standard deviation from the mean. 
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Figure 4.25: The effect of divalent ion replacement on the rate of SlaA enzyme activity. 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction had a 
final DHT-PC substrate concentration of 0.5 mM and 10.0 µg of active SlaA. The control 
contained 10 mM Ca
2+
 ions. Error bars represent the standard deviation from the mean.  
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Figure 4.26: The effect of calcium ion concentration on the rate of SlaA enzyme activity. 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction had a 
final DHT-PC substrate concentration of 0.5 mM and 10.0 µg of active SlaA. Error bars 
represent the standard deviation from the mean. 
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4.9.3.4. Determination of SlaA and SlaB activity against arachidonyl thio-PC 
 
Cayman Chemical Co. provides a kit for sPLA2 assay with arachidonyl thio-PC (AT-PC) as 
an alternative substrate. Enzymatic activity of control Bee sPLA2 was initially tested against 
AT-PC at a final substrate concentration of 1 mM and an enzyme quantity of 1µg. The 
enzymatic rate of activity of 1µg of Bee sPLA2 against AT-PC, compared to the standard 
DHT-PC substrate was demonstrated to be reduced by 87.4% (0.243 ± 7.4x10
-3
 and 1.887 ± 
9.2x10
-3 
µmol/min/mg respectively; figure 4.27). The enzymatic rate of activity of SlaA and 
SlaB was assayed against AT-PC with 10.0 µg of SlaA and 1 µg of SlaB at 37ºC. It was 
however demonstrated that neither SlaA nor SlaB possessed any significant activity against 
AT-PC. 
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Figure 4.27: sPLA2 specific enzyme activity of positive control phospholipases against 
different lipid substrates. 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction had a 
final substrate concentration of 1.0 mM and 10.0 µg of active bee sPLA2. Error bars represent 
the standard deviation from the mean. 
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4.10. Discussion and future work 
 
Bioinformatical analysis showed that S. equi encodes two sPLA2 enzymes, designated slaA 
and slaB. Furthermore it was shown that the closely related S. zooepidemicus encodes only an 
orthologue of slaB, with that of slaA absent. It would be reasonable to speculate that an 
ancestral organism of S. equi and S. zooepidemicus possessed both slaA and slaB prior to the 
sub-species divergence event. Logically, S. zooepidemicus then probably lost slaB during this 
process; this is consistent with S. zooepidemicus possessing a smaller genome with fewer 
predicted CDSs (Holden et al. 2009). The presence of SpSlaA is thus likely to have occurred 
via acquisition of SlaA from S. equi since a SpSlaA strain of S. pyogenes has yet to be 
identified that predates the emergence of SlaA in S. equi (Sitkiewicz et al. 2007). Although 
an alternative scenario could indeed be that a S. equi ancestral stain possessed only SlaB and 
SlaA was a result of a duplication event.  
As shown in this study, the ORF’s encoding SlaA and SlaB were successfully cloned 
into expression strains of E. coli. This was initially demonstrated with the successful 
amplification of slaA and slaB and successful release of each respective gene fragment 
following restriction enzyme digestion with appropriate restriction endonucleases. Short 
sequencing of the resulting construct also indicated that the sequence cloned represented the 
full mature protein and was shown to be intact.  
As demonstrated, expression was not achieved using standard expression strains of E. 
coli. It can be speculated that a potential reason for this may be due to the inherent potential 
of secreted phospholipase enzyme to damage the bacterial host cell envelope thus severely 
affecting the survivability of E. coli expressing these constructs.  
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The work of Sitkiewicz and colleagues (Sitkiewicz et al. 2007) indicated difficulty in 
expressing constructs of wild type SpSlaA. The author attributed this to the cytotoxic effect 
of SpSlaA but suggested such effects required intracellular localization. It was also noted that 
expression of SpSlaA in yeast resulted in a rapid decrease in cell viability.  
The analysis of the purified proteins obtained in this study also indicated that a 
substantial portion of purified SlaA protein aggregated, as indicated by Western –blot 
analysis using anti-His-Tag antisera. A disparity was also demonstrated between the detection 
of SlaA and SlaB; this however is likely due to differential amounts of protein added to each 
sample well.  
The obtained quantities of purified proteins were not as favourable as expected, 
especially in the case of purified SlaB protein and as such did not permit protein 
crystallisation studies. It is unclear why the quantity of purified SlaB protein obtained was 
substantially lower than SlaA. SlaB also showed reduced stability compared to SlaA (Figure. 
4.15). It should however be noted though that SlaA demonstrated a far lower protein 
instability index (23.83) than SlaB (36.45) when estimating protein stability for both mature 
proteins with the inclusion of a His6-tag. A instability index of >40 is defined as ‘unstable’ by 
the method of Guruprasad and colleagues (Guruprasad et al. 1990). 
Regarding the demonstrated activity of SlaA, a Km of 14.40±7.866 mM and a specific 
activity of 5.06x10
-2
±3.01x10
-3 
µmol/min/mg were recorded. An obvious choice for 
comparison is the closely related, SpSlaA, characterised by Nagiec and colleagues (Nagiec et 
al. 2004). However despite the investigation of SpSlaA activity against a variety of 
substrates, no standard catalytic values were published. To my knowledge at time of writing 
no other sPLA2 enzymes from a bacterial source have been cloned into an expression host 
system and tested for catalytic activity.  
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The substrate utalised in this study (DHT-PC) was also not the preferred substrate 
choice utilised in the non-colorimetric sPLA2 enzymatic assays which were the reference 
standard until recently.  
However comparisons can be made with the sPLA2 standard used in this study 
obtained from Apis mellifera. Compaisons have shown that SlaA processed a specific activity 
87.4% lower than the recorded specific activity of the standard sPLA2. Considering that the 
standard sPLA2 used has been shown to reversibly induce rabbit platelet aggregation at 
concentrations of 1-10 µg/ml (Ouyang and Huang 1984) it is highly likely that SlaA 
possesses a similar damaging effect in vivo at similarly relatively low concentrations. This 
potential in vivo exact level of expression of either slaA or slaB in S. equi and slaB in S. 
zooepidemicus however currently remains unknown. This could be revealed in vivo by the 
utilization of Reverse transcription PCR techniques. Moreover, the Western blot analysis of 
SlaA and SlaB against equine convalescent sera (Figure 4.17) is important as this 
demonstrates that SlaA is clearly presented to the equine host defences early in infections 
(due to a strong detection in strangles positive serum and no detection in strangles negative 
sera). Thus phospholipase activity of secreted SlaA may be a significant factor in damaging 
host cells during pathogenesis in vivo.  
As demonstrated, SlaA was shown to have an optium rate of activity with DHT-PC at 
45 °C with a reduction of activity demonstrated at 50 °C. The significant standard deviation 
of the means at 50 °C perhaps suggest enzyme instability or degradation at a higher than 
optimum temperature. The standard body temperature of the healthy horse is 38°C, however 
as noted in section 1.3, the pathogenesis of an S. equi infection is strongly associated with an 
onset of fever (pyrexia). During equine fever the temperature of the horse can become 
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elevated to >40°C. The demonstration that SlaA remains potent enzymically at temperatures 
>40 °C could be considered significant with respect to the enzyme activity in situ.  
SlaA displayed an enzymatic requirement for Ca
2+
 which is consistent with literature 
observations of other sPLA2 enzymes as notated in BRENDA, the comprehensive enzyme 
information system (http://www.brenda-enzymes.org/php/result_flat.php4?ecno=3.1.1.4). 
The specificity of interaction with Ca
2+
 was also as expected, given the identification of a 
calcium binding loop (Figure 4.1), the ability of Mg
2+
 to act as a replacement of Ca
2+
 
however was not. Some evidence of observations similar to the results demonstrated in this 
study regarding this have however been noted in the literature, most notably Mg
2+
 has been 
shown to replace Ca
2+
 with decreased activity in sPLA2 of Apis. mellifera (Cottrell 1981).  
As demonstrated, no activity was shown for SlaB against either DHT-PC or AT-PC. 
A likely reason for this relates to the obtained quality and quantity of purified protein 
available for enzymatic assay. In the inaccurate Sigma/Price colurmetic assays reactivity was 
visually observed (data not shown). Regarding the Caymen assay, a small detectable optical 
absorbance measurement was also observed. However the level of absorbance changes 
between a standard reaction (standard 1.66 mM substrate concentration) of SlaB against 
DHT-PC and a blank standard was neligable and lacked significance. It could therefore be 
concluded that the lack of enzymatic activity displayed by SlaB was likely to have been a 
result of the low amount of enzyme available to assay rather than a significant biological 
characteristic.  
It was highly unexpected that SlaA demonstrated no activity towards AT-PC since 
SpSlaA has previously been shown to release AA from phoshatidylcholine (Nagiec et al. 
2004). Currently the amino acid residues in SlaA that differ from SpSlaA are also not known 
to play a role in enzyme catalysis. However this has proved difficult to confirm due to the 
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absence of a crystal structure of SlaA or SpSlaA and difficulty in structural predictions based 
on molecular models due to low sequence identities between both enzymes and structures 
depositied in the Protein Data Bank (Nagiec et al. 2004).  
Several possible potential reasons can however be established for the observed lack of 
activity of SlaA against AT-PC. Firstly as demonstrated, activity was observed for a control 
sPLA2 against AT-PC with a specific activity significantly 87.4% reduced from a control 
reaction against DHT-PC. Since SlaA was demonstrated to have a significantly lower specific 
activity against DHT-PC compared to that of the control sPLA2 it is possible that the level of 
activity of SlaA against AT-PC may not have been at a sufficient level to be detected by the 
assay. A further explanation could relate to the biochemical nature of the assay as the 
colourmetric nature of the assay presumes that substrate cleavage is specific for the sn-2 
position when using DHT-PC. Thus a cleavage at the sn-1 position would not be detected by 
this biochemical assay, if indeed SlaA fitted more accurately with sPLA1 rather than sPLA2 
nomenclature.  
However this is highly unlikely based on the observations of Nagiec and colleagues 
with SpSlaA which was shown to cleave substrates at the sn-2 position. Furthermore it has 
been established that SpSlaA is not a PLB enzyme, as incubation of SpSlaA with 
dipalmitoyl-[1, 2-palmitoyl-1-
14
C] PC produced detectable palmitic acid and LPC (Nagiec et 
al. 2004) so hence SlaA clearly does not have the ability to cleave both sn-1 and sn-2 
positions.  
Regarding future work, in order to provide strong evidence regarding SlaA and SlaB 
as  bona fide virulence factors it is nessesary to produce a isogenic mutant strains of S. equi, 
one with an inactivated slaA gene and another with an inactivated slaB gene, and also a 
slaA/slab double mutant (with relevant complementation strains). This was attempted in this 
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study utilising the same methodology as described in section 3.8. Unfortunately at time of 
writing this has not yet been succssesful. It would however be expected that ΔSlaA would 
also possess a similar reduced ability to adhere to equine epithelial cells as noted in SpSlaA 
(Sitkiewicz et al. 2007), unless there is redundancy between SlaA and SlaB (which could be 
determined by comparison with a double mutant). Comparing ΔSlaB and ∆SlaASlaB mutants 
would provide the ability to assess the biological comparisons between S. equi and S. 
zooepidemicus and provide potential clues to the molecular basis of differing pathogenicity 
amongst the two organisms.  
As previously demonstrated in figure 4.2, SlaA closely resembles SpSlaA with two 
amino acid substitutions (At amino acid positions 34 and 108). However as Nagiec and 
colleagues demonstrated in SpSlaAgene mutagenesis experiments, even single substitutions 
were shown to result in either minor of significant reductions in enzyme activity or in some 
cases an increase in activity (Nagiec et al. 2004). As expected, substitutions in critical regions 
(Such as the catalytic site and Ca
2+ 
binding loop) resulted in a significant reduction of 
activity. However of particular interest is the substitution of the tyrosine at amino acid 
position 101 which resulted in a 50% loss in enzyme activity.  
Of the amino acid substitutions conducted by Nagiec and colleagues neither of the 
residues corresponding to those unique to SlaA was investigated (Figure 4.28). The tyrosine 
at position 101 is however situated in a portion of the protein predicted to possess a coil 
secondary structure (data not shown), in a region shared by a SlaA variant amino acid (an 
isoleucine at position 108). It is therefore appealing to suspect that if a substitution in an 
amino acid in SpSlaA not associated with any critical region of the protein primary structure 
can result in a drastically different rate of enzyme activity then a variant amino acid in SlaA 
in a similar position may also have a distinguishing effect on the properties of the enzyme. In 
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the absence of a crystal structure of SlaA the production of SlaA gene mutants possessing 
substitutions at amino acid position 34 and 108 by site-directed mutagenesis would allow this 
investigation.  
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EGINDKIENGTESDISFQNGELLKNYLILEGERVYFDYDRATQDKVS 
 
DDVLEMGMLVEAISKDYSEKTFTPDKYFKASWPIHGNYCGPGHNGNN 
 
FTLPVVDVLDQGCQNHDSCYKWGAGIGANCECNRQLVNYIKVYRRWM 
 
PANVLGVADAIRVYFETVGSIGC  
 
 
Figure 4.28 Amino acid sequence of SlaA highlighting the effect of amino acid substitution 
as demonstrated by Nagiec and colleagues (Nagiec et al. 2004). 
 
Amino acids unique to SlaA and absent in SpSlaA are underlined. Amino acids in red have a 
significant reduction in enzyme activity when substituted (below 25% of total activity). 
Amino acids in blue have moderate to little reduction in enzyme activity when substituted 
(between 25-100% of total activity). Amino acids in green have a small increase in enzyme 
activity when substituted (between 0-50% increases of total activity). Amino acid in yellow 
have a significant increase in enzyme activity when substituted (over 50% increase of total 
activity).  
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5. Investigation into the Acid phosphatase, LppC of S. equi and S. zooepidemicus 
 
5.1. Introduction 
 
As previously described in Section 1.9, acid phosphatases are representative of a group of 
enzymes that may participate in the virulence of pathogenic bacterial species with 
phosphatase activity indicated to be highly variable between even closely related species. 
Western blotting using rabbit polyclonal antibody to the Class C NSAP, LppC has previously 
indicated the presence of acid phosphatases in S. equi strains 1026, 1742, 4047, 9682  and S. 
zooepidemicus strains 7023, 3682, 461 and K3 using whole cell extracts (Hamilton et al. 
2000). The non-biologically significant substrate pNPP was also employed to demonstrate 
acid phosphatase activity in S. equi 9682 using whole cell extracts. One acid phosphatase 
activity was detected which possessed an activity optimum at pH 5.0 and another optimum at 
6.0-6.5, with only the former also exhibiting resistance to EDTA inhibition (similar to LppC 
of S. equisimilis).  
Zymographic analysis of S. equi strains 9682 and 4047 also detected a low level of 
acid phosphatase activity; the low level of zymographic activity has been attributed to the use 
of whole cell extracts during analysis.  
PCR was originally used to identify an internal sequence (340 bp) of the S. equi and S. 
zooepidemicus lppC genes (Hamilton et al 2000). With the availability of the S. equi and S. 
zooepidemicus genomes, it has now been possible to identify seq0346, the gene responsible 
for encoding LppC in S. equi (herein referred to as SeLppC). Furthermore with the 
availability of the S. zooepidemicus genome it has also been possible to bioinformatically 
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identify an orthologue of SeLppC in S. zooepidemicus H70, notated as szo16870 (herein 
referred to as SzLppC). However, the S. zooepidemicus H70 genome sequence indicates a 
possible frame shift in the SzLppC-5’ coding region that would introduce a stop codon in the 
SzLppC lipoprotein signal peptide sequence. Thus szo16870 was annotated as pseudogene in 
S. zooepidemicus H70 (Holden et al 2009) and so LppC may represent an additional 
difference between S. equi and S. zooepidemicus  
Currently, the catalytic rate of activity of SeLppC and SzLppC remains to be 
determined. The substrate specificity and other physicochemical parameters of SeLppC and 
SzLppC also remain to be determined, with other with NSAP’s described as retaining activity 
across a wide variety of substrates as described in section 1.9.1.  
 
Aims of the present study 
The aims of the present study were: 
a) To assess the presence of putative class C NSAP in the genome sequenced strains of 
S. equi and S. zooepidemicus using Western blotting of whole cell extracts.  
b) To short sequence SzLppC to investigate the possible frame shift in the SzLppC 
coding region.  
c) To clone, SeLppC and SzLppC identified in S. equi 4047 and S. zooepidemicus H70 
respectively for expression and purification from E. coli.  
d) To detect recombinant forms of SeLppC and SzLppC with zymography 
e) To assess the enzymatic properties of SeLppC and SzLppC and provide a comparison 
to previously characterised similar class C NSAP enzymes.  
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5.2. Bioinformatic analysis of SeLppC and SzLppC 
 
The nucelotide and amino acid sequences of the putative SeLppC (SEQ0346) and SzLppC 
(SZO16870) were obtained from Uniprot in a FASTA format. Multiple alignment of the two 
full nucleotide sequences indicated similarity of 99% (698/704), highlighting the possible 
frame shift in the SzLppC-5’ coding region between nucleotide between nucleotides 15 and 
16 of SzLppC (Figure 5.1). Full translation of the nucleotide sequence of SzLppC does 
indicate that SzLppC is a putative pseudogene with a stop codon introduced at nucleotide 
position 3 (Figure 5.2). It should be noted that SzLppC is not listed as a pseudogene in the S. 
zooepidemicus MGAS 10565 genome.  
The sequence encoding SeLppC was analysed for identification of a lipoprotein signal 
peptide cleavage site by using Pred-Lipo Hidden Markov Models outputs, with a cleavage 
site predicted between 21 and 22 with a probability of 0.994. A tBLASTn search of the 
translated S. equi genome database for homologues to SeLppC indicated no significant 
homologues other than itself. Multiple alignment of the mature amino acid sequences of 
SeLppC and SzLppC reveal that both proteins are nearly identical with the exception of an 
amino acid substitution at position 2 of the mature protein (Figure 5.3). Database searches for 
orthologues to the amino acid sequence of the mature SeLppC protein using BLAST search 
revealed a large number of proteins with significant similarities (Table 5.1).  
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SeLppC          ATGACATCTAAAAAAATTCTTAACCTTGTGTCTTTAGGGTTATCGTTGGTTTTAATCTCT 60 
SzLppC          ATGACATCTAAAAAA-TTCTTAACCTTGTGTCTTTAGGGTTATCGTTGGTTTTAATCTCT 59 
                *************** ******************************************** 
 
SeLppC          GGCTGTACGACAAATGGAGAGAAAAAAGCAGCTCCTAGTCAAGACAAGGATAAGCAAGAA 120 
SzLppC          GGCTGTGCGACAAATGGAGAGAAAAAAGCAGCTCCTAGTCAAGACAAGGATAAGCAAGAA 119 
                ****** ***************************************************** 
 
SeLppC          AAGGTTGTCCGTCTAACCAATGATCAGCTAAGGGCTAGGGAAAATACCATGGCCACACTC 180 
SzLppC          AAGGTTGTCCGTCTAACCAATGATCAGCTAAGGGCTAGGGAAAATACTATGGCCACACTC 179 
                *********************************************** ************ 
 
SeLppC          TGGTATCAGCAGTCTGAAGAGGCTAAGGCTCTCTACTTACAGGGGTACCAAGTGGCTAAG 240 
SzLppC          TGGTATCAGCAGTCTGAAGAGGCTAAGGCTCTCTACCTACAGGGGTACCAAGTGGCTAAG 239 
                ************************************ *********************** 
 
SeLppC          CAGCGCTTAGATACATTATTGAGTCAAGCAACTGATAAACCATACTCTATTGTTTTGGAC 300 
SzLppC          CAGCGCTTAGATACATTATTGAGTCAAGCAACTGATAAACCATACTCTATTGTTTTGGAC 299 
                ************************************************************ 
 
SeLppC          ATTGATGAGACAGTGCTCGATAATAGTCCTTACCAGGCTAAAAATATTAAAGAGGGCACA 360 
SzLppC          ATTGATGAGACAGTGCTCGATAATAGTCCTTACCAAGCTAAAAATATTAAAGAGGGCACA 359 
                *********************************** ************************ 
 
SeLppC          GGCTTTACGCCGGATTCTTGGGATAAATGGGTCCAAAAGAAATCAGCCAAGGCAGTAGCA 420 
SzLppC          GGCTTTACGCCGGATTCTTGGGATAAATGGGTCCAAAAGAAATCAGCCAAGGCAGTAGCA 419 
                ************************************************************ 
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SeLppC          GGTGCTAAGGACTTCTTGCAGTATGCAAATGACAAGGGCGTTCAGATTTACTATGTTTCT 480 
SzLppC          GGTGCTAAGGACTTCTTGCAGTATGCAAATGACAAGGGCGTTCAGATTTACTATGTTTCT 479 
                ************************************************************ 
 
SeLppC          GACAGAACGACTAAGCAAGTAGAGCCGACTATGGAAAATCTTGAAAAAGAAGGTATTCCA 540 
SzLppC          GACAGAACGACTAAGCAAGTAGAGCCGACTATGGAAAATCTTGAAAAAGAAGGTATTCCA 539 
                ************************************************************ 
 
SeLppC          GTGCAAGGCAAGGATCATTTCTTGTTCTTAGAGGAGGGTGTAAAATCAAAAGAGGGCCGT 600 
SzLppC          GTGCAAGGCAAGGATCATTTCTTGTTCTTAGAGGAGGGTGTAAAATCAAAAGAGGGCCGT 599 
                ************************************************************ 
 
SeLppC          CGTCAAAAGGTGCAAGAAACAACAAATCTAGTGTTGTTATTTGGTGACAATTTGCTTGAT 660 
SzLppC          CGTCAAAAAGTGCAAGAAACAACAAATCTAGTGTTGTTATTTGGTGATAATTTGCTTGAT 659 
                ******** ************************************** ************ 
 
SeLppC          TTTGCAGAGTTTTCTAAGACCTCTCATGAAGATAGAAGAAAGCTT 705 
SzLppC          TTTGCAGAGTTTTCTAAGACCTCTCATGAAGATAGAAGAAAGCTT 704 
                ********************************************* 
 
Figure 5.1: Pairwise alignment of SeLppC and SzLppc. 
Alignment was performed using ClustalW2. * indicates identical nucleotides. The variant nucleotide positions are underlined. The sequences 
start at the signal peptide region. Stop position introduced by the frameshift (missing A from the poly A tract) is underlined. 
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Met T S K K F T L C L Stop  
K I L N L V S L G L S L V L I S G C A T N G E K K A A 
P S Q D K D K Q E K V V R L T N D Q L R A R E N T Met 
A T L W Y Q Q S E E A K A L Y L Q G Y Q V A K Q R L D 
T L L S Q A T D K P Y S I V L D I D E T V L D N S P Y 
Q A K N I K E G T G F T P D S W D K W V Q K K S A K A 
V A G A K D F L Q Y A N D K G V Q I Y Y V S D R T T K 
Q V E P T Met E N L E K E G I P V Q G K D H F L F L E 
E G V K S K E G R R Q K V Q E T T N L V L L F G D N L 
L D F A E F S K T S H E D R R K L 
 
Figure 5.2: Translated amino acid sequence of SzLppC, either side of the stop codon 
introduced by the putative frameshift 
Translation was undertaken using Expasy translate tool. Stop position introduced by the 
frameshift (missing A from the poly A tract) is underlined.  
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SeLppC          CTTNGEKKAAPSQDKDKQEKVVRLTNDQLRARENTMATLWYQQSEEAKALYLQGYQVAKQ 60 
SzLppC          CATNGEKKAAPSQDKDKQEKVVRLTNDQLRARENTMATLWYQQSEEAKALYLQGYQVAKQ 60 
                *:********************************************************** 
 
SeLppC          RLDTLLSQATDKPYSIVLDIDETVLDNSPYQAKNIKEGTGFTPDSWDKWVQKKSAKAVAG 120 
SzLppC          RLDTLLSQATDKPYSIVLDIDETVLDNSPYQAKNIKEGTGFTPDSWDKWVQKKSAKAVAG 120 
                ************************************************************ 
 
SeLppC          AKDFLQYANDKGVQIYYVSDRTTKQVEPTMENLEKEGIPVQGKDHFLFLEEGVKSKEGRR 180 
SzLppC          AKDFLQYANDKGVQIYYVSDRTTKQVEPTMENLEKEGIPVQGKDHFLFLEEGVKSKEGRR 180 
                ************************************************************ 
 
SeLppC          QKVQETTNLVLLFGDNLLDFAEFSKTSHEDRRKLLDQLHAEFGSKFIIFPNPMYGSWESS 240 
SzLppC          QKVQETTNLVLLFGDNLLDFAEFSKTSHEDRRKLLDQLHAEFGSKFIIFPNPMYGSWESS 240 
                ************************************************************ 
 
SeLppC          VYNGQKLDSEGQIKARDKALEAY 263 
SzLppC          VYNGQKLDSEGQIKARDKALEAY 263 
                *********************** 
 
Figure 5.3: Pairwise alignment mature of SeLppC and SzLppc. 
Alignment was performed using ClustalW2. * indicates identical amino acids,: indicates similar amino acids. The variant amino acid position is 
underlined. The sequences start from the lipidated cysteine of the mature lipoprotein.  
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Table 5.1: Significant orthologues of mature SeLppC. Blast search performed by tBLASTn 
Accession Annotation Organism Identities Positives Gaps E number 
gb|ABV10563.1| 
5'-nucelotidase, 
lipoprotein, e(P4) family 
Streptococcus 
gordonii str. Challis 
substr. CH1 
174/242 
(72%) 
210/242 
(87%) 
0/242 (0%) 9.00E-133 
gb|ALL98443.1| Acid phosphatase 
Streptococcus 
pyogenes 
MGAS8232 
169/239 
(71%) 
203/239 
(85%) 
0/239 (0%) 1.00E-126 
gb|EFR44871.1| 
5'-nucelotidase, 
lipoprotein, e(P4) family 
Streptococcus 
pseudoporcinus 
SPIN 20026 
185/268 
(69%) 
217/268 
(81%) 
11/268 
(4%) 
2.00E-133 
YP_002997631.1| 
5'-nucelotidase, 
lipoprotein, e(P4) family 
Streptococcus 
dysgalactiae subsp. 
equisimilis 
GGS_124 
182/263 
(69%) 
213/263 
(81%) 
1/263 (0%) 3.00E-132 
gb|EDT27341.1| 
5’-nucleotidase, 
lipoprotein e(P4) family 
Clostridium 
perfringens 
99/211 (43%) 
137/211 
(65%) 
3/211 (1%) 3.00E-58 
gb|EEW75817.1| 
Lipoprotein e(P4) family 
5’-nucleotidase 
Haemophilus 
influenzae RdAW 
79/229 (34%) 
124/229 
(54%) 
8/229 (3%) 4.00E-35 
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5.3. PCR across SzLppC Signal Peptide region 
 
In order to short sequence the region of interest the designed primer pair, H70APSEQFOR 
and H70APSEQREV (Table 2.4) was used to amplify one PCR fragment from the genomic 
DNA of S. zooepidemicus. The primer set was designed to amplify a short section of DNA, 
spanning the nucleotide region suspected of representing the possible frame shift in the 
SzLppC signal peptide coding sequence. Amplification of the primer set yielded a product 
consistent with the expected length of 163bp (Figure 5.4)  
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Figure 5.4: PCR amplification of SzLppC signal peptide region. 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
loaded as follows: Lane 1, 10 kbp size standard; Lane 2, PCR product from amplification of 
SzLppC signal peptide coding region. 
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5.4. DNA sequencing of SzLppC 
 
The product amplified from the designed primer pair, H70APSEQFOR and H70APSEQREV 
(Figure 5.4) was subjected to Sanger Sequencing. In total 4 replicate samples were sequenced 
and the obtained sequences were aligned to confirm sequence integrity. The background trace 
was also used to confirm the obtained sequence (see appendix IV). The obtained partial 
sequence for SzLppC was then compared to that of the annotated sequence obtained from the 
S. zooepidemicus H70 genome project (Figure 5.5).  
ClustalW alignment of the obtained sequence gave 99% positive identity (103/104 
conserved nucleotides) between the sequenced region of SzLppC and corresponding sequence 
n the S. zooepidemicus H70 genome. The gap indicated in the S. zooepidemicus H70 genome 
database between the thymine at position 1887168 and the adenine at position 1887169 was 
shown to be incorrect with the obtained sequence of szo16870 shown to have a correctly 
positioned thymine at position 1887169 of the genome. Note that SzLppC is encoded on the 
reverse strand and so the sequence presented in Figure 5.1 is the reverse complement of that 
in Figure 5.5.  
These data indicate that the deposited sequence for S. zooepidemicus H70 contains a 
sequencing error and that the true szo16870 sequence is not a pseudogene. This is further 
supported by the observation that the corrected S. zooepidemicus H70 sequence is now 
identical to the corresponding region of the S zooepidemicus MGCS10565 genome sequence.  
 
 
205 
 
 
 
 
 
 
Query:       2 AAACCAACGATAACCCTAAAGACACAAGGTTAAGAATTTTTTTAGATGTCATAAAATCCT 61 
               |||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||| 
Sbjct: 1887127 AAACCAACGATAACCCTAAAGACACAAGGTTAAGAATTTTTT-AGATGTCATAAAATCCT 1887185 
 
Query:      62 CCTAATATTCCATACATTATTAAGTACGGTTATTTATCCACCTC 105 
               |||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1887186 CCTAATATTCCATACATTATTAAGTACGGTTATTTATCCACCTC 1887229 
 
Figure 5.5: Multiple alignment of sequenced portion of SzLppC (this study, 4 replicates) and the depositied nucleotide sequence of SzLppC, 
obtained from the S. zooepidemicus H70 genome. 
Multiple alignment was performed using ClustalW2. ‘Query’ represents obtained SzLppC sequence and ‘sbjct’ represents nucleotide sequence of 
SzLppC, obtained depositied S. zooepidemicus H70 genome sequence.   
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5.5. Identification of LppC enzymes in S. equi and S. zooepidemicus 
 
The presence of acid phosphatase lipoprotein in a range of whole cell protein extracts of S. 
equi and S. zooepidemicus strains (Figure 5.6) was screened by Western immunoblotting, 
using a polyclonal antiserum raised against LppC of S. equisimilis (Malke 1998). The 
antiserum was shown to cross-react strongly at a molecular weight consistent with the 
expected size of SeLppC (32 kDa) with three strains of S. equi, i.e 4047 and 1026 (as shown 
by Hamilton et al 2000) and 9672. Cross reaction was also evident with four S. 
zooepidemicus strains; (7626, H70, 3635 and K3) but detection level was significantly 
reduced. Of these strains, only K3 has previously been investigated for LppC (Hamilton et al. 
2000). Notably antibody-cross reactivity was not detected in S. zooepidemicus 3682 and was 
detected strongly in strain S. zooepidemicus H70 but at a reduced molecular weight of under 
30 kDa (Figure 5.7). Three replicate growths of the S. zooepidemicus strains were undertaken 
and this observation was confirmed throughout the replicates (data not shown).  
This data is consistent with the resequencing data indicating that S zooepidemicus H70 
specifically (and S. zooepidemicus strains generally) are capable of expressing LppC i.e. that 
the annotation of szo16870 as a pseudogene in the S. zooepidemicus H70 genome is a 
sequencing artefact.  
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Figure 5.6: 15% SDS PAGE of range of S. equi and S. zooepidemicus strains. 
Lane were loaded as follows: Lane 1, molecular weight markers (250, 150, 100, 75, 50, 37, 25, 20 kDa); lane 2, S. equi 9672; lane 3, S. equi 
4047; lane 4, S. equi 1026; lane 5, - S. zooepidemicus 7622; lane 6, - S. zooepidemicus H70; lane 7, S. zooepidemicus 3635; lane 8, S. 
zooepidemicus K3; Lane 9, S. zooepidemicus 3682. 
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Figure 5.7: LppC Western blot analysis of a range of S. equi and S. zooepidemicus strains. 
Lanes were loaded as follows: Lane 1, molecular weight markers (250, 150, 100, 75, 50, 37, 25, 20 kDa); lane 2, S. equi 9672; Lane 3, S. equi 
4047; lane 4, S. equi 1026; Lane 5, S. zooepidemicus 7622; lane 6, S. zooepidemicus H70; lane 7, S. zooepidemicus 3635; lane 8, S. 
zooepidemicus K3; lane 9, S. zooepidemicus 3682.  
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5.6. PCR of mature SeLppC and SzLppC 
 
Using the designed primers pair, SEQLPPCf- SEQLPPCr (Table 2.4), two PCR fragments 
were amplified from the genomic DNA of S. equi and S. zooepidemicus (Figure 3.4 and 
Figure 3.5 respectively). Both primer sets amplified only a portion of each representative 
genome encompassing the necessary gene product that encoded the mature SeLppC/SzLppC 
protein and a small non-coding region downstream of the target genes. Amplification of the 
primer set yielded two products consistent with their predicted length of 817 bp (Figure 5.8). 
Notably these primers also amplified additional larger PCR products which were not 
investigated further as BLAST searches strongly suggest that seq0346 and szo16870 are the 
only putative LppC homologues encoded in the S. equi 4047 genome and S. zooepidemicus 
H70 genome respectively.  
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Figure 5.8: PCR amplification of seq0346 and szo16870. 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
loaded as follows: Lane 1, 10 kbp size standard; Lane 2, PCR product from amplification of 
seq0346 from S. equi 4047 genomic DNA; Lane 3, PCR product from amplification of 
szo16870.  
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5.7. Molecular cloning of SeLppC and SzLppC 
 
The amplified DNA products obtained from the designed primer pair, SEQLPPCf- 
SEQLPPCr (Figure 5.8) were initially cloned into pCR
®
-Blunt vector, yielding plasmids 
pbSeLppC and pbSzLppC. These plasmids were subsequently digested with appropriate 
restriction endonucleases to verify product integration. Cloned target genes and pCR
®
-blunt 
plasmid DNA was then digested with appropriate endonucleases, purified and cloned into 
similarly restriction digested and purified pET 28a vector. This generated plasmids pSeLppC 
and pSzLppC that encoded the proteins of interest with a His6-tag at the N-terminus of the 
mature protein. Confirmation of the correct plasmid construction was undertaken by 
screening of plasmids extracted from candidate positive clones with appropriate restriction 
endonucleases. Following digestion, a successful clone was indicated by the visualisation of a 
product consisting of the target gene size and the remaining restriction endonuclease cut pET 
28a vector, 5.4 kbp in size (Figure 5.9). Further confirmation was undertaken by the gene 
sequencing of the plasmid T7 promoter region. The sequences obtained were checked for 
fidelity and aligned to their respective nucleotide sequences in the S. equi 4047 and S. 
zooepidemicus H70 genome (See appendix IV). Technical assistance from Mian Bilal Munir 
with this cloning work is acknowledged.  
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Figure 5.9: Restriction endonuclease digestion of pSeLppC and pSzLppC 
Samples were run on a 1% agarose gel containing ethidium bromide (0.5 µg/ml). Lanes were 
loaded as follows: Lane 1, 10 kbp size standards; lane 2, pSeLppC post treatment with EcoRI 
and XhoI restriction endonucleases; lane 3, pSzLppC post treatment with EcoRI and XhoI. 
Released SeLppC and released SzLppC product (expected sizes of 817 bp) are indicated with 
an arrow. 
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5.8. Protein expression of SeLppC and SzLppC 
 
Plasmids pSeLppC and pSzLppC encoding SeLppC and SzLppC respectively were 
chemically transformed into a range of E. coli expression strains (Table 2.1) and grown at 37 
°C to mid-exponential phase. Initially, expression of the recombinant proteins was induced 
by the addition of 1 mM IPTG (final concentration) and the cultures were incubated at 20ºC 
with two replicates also incubated at 30ºC and 37ºC (Figure 5.10).  
All standard E. coli strains tested yielded poorly expressed target proteins. The 
presence of the pLysE plasmid is thought to potentially improve expression of soluble and 
active recombinants, by providing additional stability to target genes via the inhibition of T7 
RNA polymerase (Studier 1991) . Chemical transformation of pSeLppC and pSzLppC into E. 
coli BL21 (DE3) pLysE cells was shown to significantly improve the expression of 
recombinant protein sufficient for further studies. It was also shown that variation in 
incubation temperature between 20°C and 37°C produced no notable variation (Figure 5.11).  
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Figure 5.10: 15% SDS PAGE gel demonstrating SeLppC and SzLppC expression trials. 
Protein expression was induced by 1 mM IPTG and growth at 20ºC. The expected position of both proteins is marked with an asterisk. Lanes 
were loaded as follows: Lane 1, E .coli BL21 (DE3) pSeLppC; lane 2,- E. coli BL21 (DE3) pSzLppC; lane 3,- E. coli C41 (DE3) pSeLppC; lane 
4, E. coli C41 (DE3) pSzLppC; lane 5, E. coli B834 (DE3) pSeLppC; lane 6, E. coli B834 (DE3) pSzLppC; lane 7, E. coli Tuner (DE3) 
pSeLppC; lane 8, E. coli Tuner (DE3) pSzLppC; lane 9, molecular weight markers (20, 25, 37, 50, 75 kDa).  
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Figure 5.11: 15% SDS PAGE demonstrating SeLppC and SzLppC expression. 
Protein expression was induced by 1 mM IPTG with E. coli (DE3) carrying the pLysE plasmid. The expected position of both SeLppC and 
SzLppC is marked with an asterisk. Lanes were loaded as follows: Lane 1, molecular weight markers (150, 100, 75, 50, 37, 25, 20 kDa); lane 2, 
unexpressed pSeLppC plasmid; lane 3, pSzLppc at 20ºC; lane 4, pSzLppC at 37ºC; lane 5, pSeLppC at 20ºC; lane 6, pSeLppC at 37ºC 
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5.9. Protein purification of SeLppC and SzLppC  
 
Both His6 –tagged proteins were expressed during E. coli growth in 4 litres of LB media and 
purified from cell free extracts by IMAC using a chelating Sepharose column and an 
automated gradient elution technique (Section 2.13.4). Confirmation of proteins present in 
different fraction was indicated by U.V absorption; fractions were checked for purity by 
SDS-PAGE and concentrated. Proteins were then further purified by FPLC, monitored by 
U.V absorption and checked for purity by SDS-PAGE, concentrated and quantified. 
Quantities of purified SeLppC and SzLppC obtained were ~0.625 mg/L.  
A summary of all proteins produced for use in further studies is shown in Figure 5.12, 
which also shows the purity of a control commercial acid phosphatase from potato.  
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Figure 5.12: 15% SDS PAGE demonstrating proteins used in further work in this study. 
Lanes were loaded as follows: lane 1, SeLppC (FPLC purified protein); lane 2, SeLppC (IMAC purified protein); lane 3, SeLppC (Cell free 
extract); lane 4, Acid phosphatase (Source: Potato); lane 5, SzLppC (FPLC purified protein); lane 6, SzLppC (IMAC purified protein); lane 7, 
SzLppC (Cell free extract); lane 8, molecular weight markers (250, 150, 100, 75, 50, 37, 25, 20 kDa).  
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5.10. Confirmation of His6-tagged SeLppC and SzLppC 
 
The presence of His6-Tagged SeLppC and SzLppC in the protein samples obtained was 
screened by Western immunoblotting, using a polyclonal antiserum raised against the His6-
tag. The antiserum was shown to cross-react with proteins consistent with the size expected 
for SeLppC and SzLppC (32 kDa) in both the FPLC purified SeLppC and SzLppC products 
(Figure 5.13). A whole cell extract of S. equi was used as a negative control and showed no 
cross-reaction with the anti-His antibody. The molecular marker utilised was unstained and 
was only visible using reversible staining with Ponceau S reagent (marked in pencil prior to 
western blot development).  
 
5.11. Detection of SeLppC and SzLppC using anti-LppC antiserum 
 
The obtained purified protein products of SeLppC and SzLppC were screened by Western 
immunoblotting, using the polyclonal antiserum raised against LppC of S. equisimilis along 
with two control whole cell samples of each organism. The antiserum was shown to cross-
react strongly with SeLppC purified protein product, additionally whole cell extracts of S. 
equi (strains 4047 and 9672) also cross-reacted similarly to that demonstrated in Figure 5.7. 
Only very weak cross-reactivity was shown with whole cell extracts of S. zooepidemicus 
(H70 and 3682), However the SzLppC purified protein product demonstrated a strong cross-
reactivity similar to that demonstrated by SeLppC (Figure 5.14).  
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5.12. Western immunoblotting of purified SeLppC and SzLppC using equine convalescent  
serum 
 
The presence of antibodies to SeLppC and SzLppC in equine convalescent serum was 
investigated by Western immunoblotting, using equine convalescent serum acquired from 
three ponies, pre and post infection with S. equi. Very faint antibody cross-reactivity with 
SeLppC and SzLppC was detected in all sera acquired post-infection, althought only poor 
quality blot images could be obtained (Figure 5.15). No cross-reactivity was detected in pre-
infection serum acquired from the ponies (not shown). Note that two different molecular 
markers were used in each separate panel. Both panels utilised molecular markers that were 
unstained and were only visible using reversible staining with Ponceau S reagent (marked in 
pencil prior to Western blot development).   
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Figure 5.13: His6-tag Western blot analyses of SeLppC and SzLppC. 
Lanes were loaded as follows: Lane 1, molecular weight markers (25, 37, 50, 75 kDa); lane 2, 
SeLppC; lane 3, Whole cell extract of S. equi (negative control); lane 4, SzLppC. The 
purified protein amount added was 0.1 µg. 
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Figure 5.14: Anti-LppC Western blot analysis of purified SeLppC and SzLppC products. 
The lanes were loaded as follows: Lane 1, SeLppC; lane 2, S. equi 4047; lane 3, S.equi 9672; lane 4, molecular weight markers (20, 25, 37, 50, 
75 kDa); lane 5, SzLppC; lane 6, S. zooepidemicus H70; lane 7, S. zooepidemicus 3682; lane 8, molecular weight markers (20, 25, 37, 50, 75 
kDa). Amount of protein added to each well was 5µg 
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Figure 5.15: Western blot analysis of purified SeLppC and SzLppC against equine convalescent serum (pre and post infection). 
The expected position of both SeLppC and SzLppC is marked with an asterisk by the left hand panel. Lanes were loaded as follows: Lane 1, 
molecular weight markers (37, 50, 75, 100 kDa); lane 2, SeLppC; lane 3, SzLppC; lane 4, whole cell extract of S. equi 4047; lane 5, molecular 
weight markers (20, 25, 37, 50, 75, 100, 150 kDa); lane 6, SeLppC; lane 7, SzLppC. Amount of protein added to each well was 1µg. Left hand 
pannel (lanes 1-4), blot probed with post-infection serum. Right hand panel (lanes 5-7), blot probed with matched pre-infection serum. 
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5.13. Zymographic detection of acid phosphatase activity 
 
Purified SeLppC and SzLppC were assayed for acid phosphatase activity by zymography (see 
section 2.14.6). A total amount of 5 µg of purified protein was added to each well within the 
initial SDS-PAGE-gel. An identical SDS-PAGE replicate was also undertaken alongside 
zymographic analysis and stained using Coomassie blue to provide a molecular weight and 
protein reference point. Both purified protein samples appeared as strong bands on the 
zymograph, at a size consistent with the expected protein size of SeLppC and SzLppC (~32 
kDa) as indicated on the Coomassie blue stained SDS-PAGE-gel replicate (Figure 5.16). 
These data are important in confirming the functional acid phosphatase activity of the 
recombinant proteins using 4-nitrophenyl phosphate (pNPP) as substrate.  
 
 
 
 
 
 
 
 
224 
 
 
 
 
 
 
 
 
 
Figure 5.16: 15% SDS PAGE Zymograph of SeLppC and SzLppC and SDS PAGE (Standard Coomassie stained replicate). 
Lanes were loaded as follows: Lane 1, SeLppC; lane 2, SzLppC. (These lanes are from a gel developed by zymography); lane 3, molecular 
weight markers (14.3, 20, 27, 66.4 kDa); lane 4, SeLppC; lane 5, SzLppC. Lanes 3-5 are from a gel developed by Coomassie blue staining. 
Amount of protein added to each lane was 5µg.  
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5.14. Enzymatic assays of SeLppC and SzLppC activity 
 
5.14.1. Michelis-Menton parameters 
 
Initially the activity of SeLppC and SeLppC pNPP was investigated. A total amount of 0.5µg 
of enzyme (determined empirically) was added to each reaction to assay SeLppC and 
SzLppC and the reaction was allowed to proceed for 10 minutes.  
For kinetic analysis, 5 substrate concentrations (determined empirically) were chosen 
and reactions performed in triplicate. Linearity of each assay was confirmed prior to 
calculations. Prior to SeLppC and SzLppC assays a trial assay was conducted with potato 
acid phosphatase and the Km calculated to be 5.77±0.69 mM (Figure 5.17 and Figure 5.18). 
To determine if the data reflected true Michaelis-Menten kinetics for SeLppC and 
SzLppC against the substrate pNPP, a Lineweaver-Burk plot was constructed for SeLppC and 
SzLppC (Figures 4.19 and 4.20 respectively). To further investigate substrate specificity, 
SeLppC and SzLppC were also assayed against the substrate Uridine 5’ monophosphate 
(Figures 5.21 and 5.22 respectively) and Adenosine 5’ monophosphate (Figures 5.23 and 5.24 
respectively) using 3 substrate concentrations also determined empirically. Note that the acid 
phosphatase assay for these nucleotide monophosphate substrates cannot be measured 
colorimetrically and so phosphate released was determined using a phosphate standard curve 
(Figure 5.25).  
A summary table is presented indicating the comparative Km calculated for each substrate 
between SeLppC and SzLppC (Table 5.2).  
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Figure 5.17: Standard absorbance of control potato acid phosphatase against NPP. 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction was 
undertaken for approx. 10 minutes with 5U of potato acid phosphatase.  
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Figure 5.18: Lineweaver-Burk plot of control potato acid phosphatase against pNPP. 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction was 
undertaken for approx. 10 minutes with 5U of potato acid phosphatase. 
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Figure 5.19: Linewever-Burk plot for SeLppC against pNPP 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction was 
undertaken for approx. 10 minutes with 0.5µg of SeLppC.  
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Figure 5.20: Lineweaver Burk plot for SzLppC against pNPP 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction was 
undertaken for approx 10 minutes with 0.5µg of SzLppC.  
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Figure 5.21: Lineweaver Burk plot for SeLppC against 5’UMP 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction was 
undertaken for approx. 10 minutes with 0.5µg of SeLppC.  
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Figure 5.22: Lineweaver-Burk plot for SzLppC against 5’UMP 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction was 
undertaken for approx. 10 minutes with 0.5µg of SzLppC. 
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Figure 5.23: Lineweaver Burk plot of SeLppC against 5’AMP 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction was 
undertaken for approx. 10 minutes with 0.5µg of SeLppC. 
 
 
 
233 
 
 
 
 
 
 
Figure 5.24: Lineweaver Burk plot of SzLppC against 5’AMP 
The reactions were performed in triplicate as detailed in section 2.14.1. Each reaction was 
undertaken for 10 minutes with 0.5µg of active SzLppC.  
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Figure 5.25: Standard curve of inorganic phosphate assay 
The reactions were performed in triplicate as detailed in section 2.14.1. Error bars represent 
the standard deviation from the mean.  
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Table 5.2: Km (mM) activities of SeLppC and SzLppC 
 
Substrate SeLppC SzLppC 
pNPP 13.27±3.91 4.681±0.48 
5’AMP 0.63±0.17 0.8152±0.18 
5’UMP 1.46±0.44 2.407±1.65 
 
*AP control (source potato) had a Km of 5.772±0.6895 mM against pNPP. 
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5.14.2. Determination of temperature optimum of SeLppC and SzLppC 
 
An investigation was undertaken to assess the optimal temperature of enzyme activity for 
SeLppC and SzLppC. A total of 0.5µg of enzyme and 1mM of pNPP substrate was used in 
each reaction and the reaction was undertaken for a period of 10 minutes. Data is presented as 
relative activity against the standard activity of each enzyme at 37°C (Figure 5.26). SeLppC 
and SzLppC showed a somewhat linear increase in activity with increasing temperature. The 
rates of activity of both enzymes were shown to steadily increase towards the highest 
temperature tested (50ºC), at which temperature the enzymes were shown to have a relative 
activity of around 120%. Standard deviations of the means remained minimal throughout 
absorbance readings.  
 
5.14.3. Determination of divalent ion requirement 
 
SeLppC and SzLppC were tested with a range of divalent ions using 0.5µg of enzyme, 
1.0mM of pNPP under standard conditions. Data is presented as relative activity against the 
standard activity of each enzyme with 10 mM of Cu
2+ 
added. Cu
2+
 is referred to as the 
reference divalent ion used in previous activity assays for SeLppC and SzLppC (Hamilton et 
al. 2000). Although the replacement of Cu
2+
 by other common divalent cations was 
demonstrated to result in reduced enzyme activity it was observed that the enzymes did 
notappear to possess a specific requirement for Cu
2+ 
ions (Figures 5.27 and 5.28). Standard 
deviations of the means remained minimal throughout absorbance readings and both SeLppC 
and SzLppC produced consistent activity profiles.  
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5.14.4. Determination of optimum pH  
 
The pH activity range of SeLppC and SzLppC was investigated against 5’UMP, a total of 
0.5µg of each enzyme and 0.1mM of 5’UMP in each reaction. It was not possible to assess 
the pH optimum of SeLppC and SzLppC against pNPP across the full pH range as the 
addition of basic ions has been previously showed to interfere with the standard colorimetric 
acid phosphatase assay. Hamilton at al. (2000) demonstrated pH optima of 5.2 for EDTA 
resistant acid phosphatase in whole cell extracts of S. equi. An optimum pH of 5.2 is common 
for similar NSAP enzymes and as such data is presented as percentage relative activity to the 
recorded activity at pH 5.2.  
As demonstrated, for both SeLppC and SzLppC, enzyme activity was maintained at a 
broad range between pH 4 and pH 6.5, with the rate of activity fairly consistent between the 
two enzymes. The highest activity was recorded at pH 4.0 with a small increase of ~10% 
activity detected for both enzymes. At pH 7.0 both enzymes have a significantly reduced rate 
of activity (~20% relative activity) indicating that both enzymes are bona fide acid 
phosphatases (Figure 5.29). Standard deviations of the means remained minimal throughout 
absorbance readings. 
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Figure 5.26: The effect of temperature on the rate of SeLppC and SzLppC enzyme activity. 
The reactions were performed in triplicate as detailed in section 2.14.1. 100% activity was 
defined as the rate of activity of SeLppC/SzLppC at a pNPP concentration of 1.0 mM, 
utilizing 0.5µg of active SeLppC/SzLppC at pH 5.2 at a temperature of 37°C. Error bars 
represent the standard deviation from the mean. The blue bars represent SeLppC relative 
activity and the grey bars represent SzLppC relative activity 
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Figure 5.27: The effect of divalent cations on the rate of SeLppC enzyme activity. 
The reactions were performed in triplicate as detailed in section 2.14.1. 100% activity was 
defined as the rate of activity of SeLppC at a pNPP concentration of 1.0 mM, a Cu
2+ 
final 
concentration of 10mM and utilizing 0.5µg of active SeLppC. N/A indicates no divalent 
cation added. Error bars represent the standard deviation from the mean. 
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Figure 5.28: The effect of divalent cations on the rate of SzLppC enzyme activity. 
The reactions were performed in triplicate as detailed in section 2.14.1. 100% activity was 
defined as the rate of activity of SzLppC at a pNPP concentration of 1.0 mM, a Cu
2+ 
final 
concentration of 10mM and utilizing 0.5µg of active SeLppC. N/A indicates no divalent 
cation added. Error bars represent the standard deviation from the mean. 
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Figure 5.29: The effect of changes in pH on the rate of SeLppC and SzLppC enzyme activity. 
The reactions were performed in triplicate as detailed in section 2.14.1. The reference 100% 
activity was defined as the rate of activity of SeLppC/SzLppC at a 5’UMP concentration of 
0.1 mM, utilizing 0.5µg of active SeLppC/SzLppC at pH 5.2. The blue bars represent 
SeLppC relative activity and the grey bars represent SzLppC relative activity.  
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5.15. Discussion and future work. 
 
Bioinformatic analysis of SeLppC indicated that as expected a close homologue is also 
encoded in the genome of S. zooepidemicus H70, SzLppC. Comparing the sequences of 
SeLppC and SzLppC obtained from the genomes of S. equi 4047 and S. zooepidemicus SzH70 
indicated a deletion of one base between the nucleotide position 1887168 and 1887169 of the 
S. zooepidemicus H70 genome. However sequence analysis conducted in this study indicated 
that the sequence depositied from the S. zooepidemicus H70 genome project was incorrect i.e. 
indicating that this strain does have the capacity to synthesise a full length LppC (as with the 
S. zooepidemicus MGCS10565 genome).  
Western blot analysis of SeLppC and SzLppC using LppC specific antisera indicated 
that antibody detection was significantly poorer in S. zooepidemicus compared to S. equi 
whole cell extracts. The correction of the single base pair deletion in the signal peptide 
coding region of szo18670 demonstrates that this is not because szo18670 is a pseudogene. 
As shown in this study, the sequences encoding SeLppC and SzLppC were 
successfully cloned into pLysE (DE3) BL21 E. coli for protein expression. The use of pLysE 
has been previously shown to produce high levels of the closely related NSAP, e(p4) (Reilly 
1999). Both SeLppC and SzLppC were demonstrated to be present in the presumptive 
pSeLppC and pSzLppC constructs by restriction enzyme digestion and short confirmatory 
sequencing. Reasonable quantities of purified SeLppC and SzLppC proteins were also 
successfully obtained with post-FPLC, with SDS-PAGE analysis indicating a high level of 
purification. The presence of a histidine N-terminal tag was also verified by Western blotting. 
Zymography also confirmed that both SeLppC and SzLppC were acid phosphatases.  
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Furthermore Western blot analysis of the recombinant SzLppC indicated that 
discrepant molecular weight (Figure 5.7) between SzLppC from strain H70 and SeLppC (e.g. 
from strain 4047) was limited to whole cell extracts of SzLppC, suggesting perhaps some 
specific proteolytic processing. Failure to detect SzLppC in whole cell extracts of other 
strains could perhaps be explained by a discrepancy between levels of expression of SzLppC 
and SeLppC in vitro.  
Further Western blot analysis of SeLppC and SzLppC using equine sera obtained post 
S. equi infection indicated a very weak detection for both SeLppC and SzLppC. This may 
indeed be consistent with SeLppC and SzLppC expression in vivo and suggests that both 
enzymes are only weakly immunogenic.  
As previously described, Class C NSAP have fairly broad substrate specificity and as 
expected the arylphosphate p-NPP represented a readily hydrolysed substrate for SeLppC and 
SzLppC with recorded Km values of 13.27±3.91 and 4.68±0.482mM respectively. Of greater 
significance was the hydrolysis of the 5’ nucleoside monophosphates, AMP and UMP by 
SeLppC and SzLppC. Both enzymes were shown to possess a greater affinity to 5’UMP than 
5’AMP. 
It has not been determined whether or not either SeLppC or SzLppC have affinity 
towards 3’ nucleoside monophosphates. The closely related Class C NSAP, e (P4) of H. 
influenzae (79/229 amino acid sequence identity to SeLppC) has previously been shown to 
have little affinity to 3’ nucleoside monophosphates with a suggestion that e(p4) of H. 
influenzae discriminates between the 3’ and 5’ phosphomonoester binding within the active 
site (Reilly and Calcutt 2004). Enzyme kinetic comparisons of SeLppC/SzLppC with other 
similar enzymes such as e(P4) of H. influenzae and LppC of S. equisimilis are difficult 
244 
 
because neither of these enzymes were subjected to detailed kinetic analysis. Comparisons 
can however be made with the enzymes OlpA (Passariello 2003), rCppa (Reilly 2009) and 
rHppa (Reilly & Calcutt, 2004) (Table 5.3). SeLppC and SzLppC were demonstrated to have 
a far higher Km to pNPP then OlpA. Interestingly SeLppC and SzLppC appear to have 
substantially higher Km to 5’UMP than any of the other similar enzymes previously 
analysed. Throughout kinetic enzyme studies of SeLppC and SzLppC, SzLppC was 
demonstrated to have higher Km values for all substrates compared to SeLppC, although both 
enzymes possessed comparative kinetic trends. Since the sequencing data (Figure 5.5) has 
demonstrated that the mature SeLppC and SzLppC are nearly identical in terms of amino acid 
sequence it is unlikely that enzyme kinetic analysis variations are a result of genuine 
biochemical differences. A likely explanation of this discrepancy is that the obtained purified 
proteins have differing levels of purification.  
 
The activity of several class C enzymes has been shown to possess a requirement for 
divalent cations. As demonstrated in this study, neither SeLppC nor SzLppC possessed an 
absolute requirement for divalent cations; both enzymes retained a strong catalytic activity in 
apparent absence of any divalent ion. These findings are consistent with studies of the e (P4) 
acid phosphatase, in which some activity was retained after dialysis against buffer containing 
EDTA followed by dialysis against buffer to remove the chelator (Reilly 1999).  
 
It was also demonstrated that SeLppC and SzLppC possess a selective affinity for 
divalent cations with only the presence of Cu
2+
 demonstrated to increase catalytic activity 
amongst a group of the most commonly known divalent cations affecting the reported 
activities of acid phosphatases. These findings place SeLppC and SzLppC in a similar group 
as e (P4) (Reilly et al. 1999; Reilly et al. 2001), HppA (Reilly et al. 2006) and LppC (Malke 
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1998) with a demonstrated affinity towards Cu
2+ 
as opposed to OlpA (Ou et al. 2006) and 
SapS (Du Plessis et al. 2002) which possess a demonstrated preference towards Mg
2+
.  
 
As expected, both SeLppC and SzLppC had a demonstrated optimal pH activity at pH 
5 or less, an optimum shared with several members of its class. However a strong level of 
activity was retained across a fairly broad range between pH 4.0 and pH 6.5. This is 
contrasting to the demonstrated pH optima of LppC of S. equisimilis which featured a sharp 
peak at pH ~5 with significantly reduced activity demonstrated between pH 3-4.5 and pH 5.5-
6.5 (Malke 1998). It has yet to be determined if this difference in pH range has biological 
significance in vivo. The effect of pH could not be determined accurately for SeLppC and 
SzLppC against pNPP.  
 
The results of the investigation of temperature against the activities of SeLppC and 
SzLppC indicated a high level of enzyme activity was maintained at temperatures of at least 
50°C. Although unexpected, this may be consistent with the data reported here for SlaA (see 
chapter 4), in that an enzyme’s ability to remain potent enzymically at higher temperatures is 
advantageous during the strangles disease state in which an infected pyrexic horse can exhibit 
elevated temperatures above (>40°C). 
 
A well-documented characteristic of all class C NSAP enzymes is a DDDD motif 
assumed to be of catalytic significance. This has been experimentally verified in both CppA 
of C. perfringens (Reilly et al. 2009) and e (P4) of H. influenzae but it remains to be 
determined whether or not this is also the case for SeLppC or SzLppC, although this would 
be expected to be so. By undertaking site directed mutagenesis of one or more of the aspartic 
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acid residue of this motif, it would be expected that mutant SeLppC and SzLppC would also 
exhibit reduced zymogram detection and a significantly reduced enzyme activity.  
A further area of interest regards the level of conservation of SeLppC and SzLppC 
amongst different S. equi and S. zooepidemicus strains. Since the activities of NSAP have 
been known to vary amongst closely related strains it would be interesting to reveal whether 
or not different strains possess different enzyme profiles. The strong reaction of a range of 
whole cell extracts of S. equi to LppC specific antisera indicates that it is probable that 
SeLppC is consistently well expressed amongst S. equi strains whereas lower/anomalous 
cross reactions were obtained with S. zooepidemicus strains. However, a more extensive 
strain collection must be investigated under highly standardised growth and protein 
preparation conditions. Moreover it may be possible that short sequencing of respective 
coding sequences amongst a variety of strains of the two subspecies may reveal differences. 
Alternatively, the availability of further whole genome sequences of each species would 
allow for this.  
It remains to be determined whether or not SeLppC and SzLppC play a critical role in 
the survival of either or both bacteria in vivo or in vitro. Mutagenesis studies need to be 
carried out to address this. The demonstrated hydrolysis of 5’ nucleoside monophosphates 
indicates that SeLppC and SzLppC are likely to constitute a nucleotide biosynthetic salvage 
pathway. This conclusion is consistent with the role proposed to LppC of S. equisimilis and 
CppA of C. perfringens (Reilly et al. 2009).  
The production of an isogenic mutant strain of SeLppC in S. equi would provide the 
tools to elucidate the role of SeLppC in virulence. It would also be interesting whether or not 
a ∆SeLppC strain was defective in intramacrophage survival/replication, similar to that 
demonstrated by ∆acpA of Francisella spp (Mohapatra 2007). Furthermore an obvious 
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further experiment involving a ∆SeLppC strain would be the investigation of possible reduced 
virulence in either the mouse or equine models of infection.  
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Table 5.3: Recorded Km’s of SeLppC and SzLppC for three substrates and other closely 
related NSPC’s 
Data obtained in this study is highlighted in bold. 
 
Enzyme Substrate Km (mM) Reference 
SeLppC 
4-nitrophenyl 
phosphate 13.27±3.910 N/a 
SzLppC 
4-nitrophenyl 
phosphate 4.681±0.4820 N/a 
OlpA 4-nitrophenyl phosphate 0.180 ± 0.06 
(Passariello, et 
al. 2003) 
SeLppC 5' AMP 0.23±0.04 N/a 
SzLppC 5’AMP 0.8152±0.1789 N/a 
rCppA 5’AMP 0.269±0.05 
(Reilly, et al. 
2009) 
rHppA 5’AMP 1.06± 0.18 
(Reilly and 
Calcutt 2004) 
OlpA 5’AMP 0.016±0.001 
(Passariello, et 
al. 2003) 
SeLppC 5’UMP 1.459±0.4386 N/a 
SzLppC 5’UMP 2.407±1.651 N/a 
rCppA 5’UMP 0.221±0.03 
(Reilly, et al. 
2009) 
rHppA 5‘UMP 0.91±0.03 
(Reilly and 
Calcutt 2004) 
sOlpA 5‘ UMP 0.013±0.08 
(Passariello, et 
al. 2003) 
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6. Conclusion 
 
As discussed, the likelihood of an improved vaccine against equine strangles relies on the 
identification and characterisation of novel immunogens followed by the development of 
combinatory subunit vaccines based on those immungens deemed to provide sufficient 
protection in equine challenge studies (Timoney et al. 2007, Florindo et al. 2009, Waller and 
Jolly 2007b). Recent advancements towards a recombinant vaccine have clearly been 
hastened by the availability of the genomes of S. equi and S. zooepidemicus thus allowing the 
identification of many novel surface exposed and secreted proteins 
Herein this thesis we have presented the investigation of three novel pairs of proteins; 
the covalently attached, surface exposed proteins SEQ2190 and SEQ2180, the secreted 
phospholipase A2 enzymes SlaA and SlaB and the lipoprotein encoded Acid phosphatase 
enzymes SeLppC and SzLppC. All of the afore-mentioned proteins were initially identified 
following genome comparisons of the S. equi and S. zooepidemicus of genomes and 
demonstrated to possess uniqueness in relation to S. equi.  
SEQ2190 was demonstrated to be unique in S. equi (with a seq2190 paralogue 
pseudogene in S. zooepidemicus) and had previously been shown to be immunogenic. This 
cell surface associated protein was also demonstrated in this study to possess a close 
homologue (SEQ2180) with a similar paralogue in S. zooepidemicus (SZO18890). 
Bioinformatic structural analysis of SEQ2190 conducted in this study has also revealed a 
putative structure dominated by an alpha helical stalk protruding through the hyaluronic acid 
capsule, with highly probable putative host ligand interaction.  
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Although the exact function(s) of SEQ2190 and SEQ2180 in relation to virulence 
remains unknown and three dimensional structures of either protein were not successfully 
solved in this study during the time-frame given, constructs with the ability to express both 
proteins with N-terminal Histidine tags were successfully created as demonstrated. An N-
terminal portion of SEQ2190 was also shown to be wholly unique to S. equi and a construct 
was also created in this study expressing only this unique, truncated protein.  
The secreted phospholipase A2, SlaA and SlaB was also investigated in this thesis. 
SlaA was demonstrated to be unique to S. equi and bear close similarity to the investigated 
virulence factor SpSlaA of S. pyogenes. Although some studies had previously been 
undertaken (Nagiec et al 2004) this study has further characterised SlaA utilising constructs 
expressing N-terminal Histidine tagged SlaA.  
Using the created constructs it has been possible to obtain purified SlaA and gain 
further insight into the enzyme kinetics of this enzyme. The data obtained from this study has 
now shown that SlaA is active against DHT-PC but not AT-PC, has a optimum temperature 
of 45°C and a specific requirement for Ca
2+
. The Km and specific activity values for SlaA 
have also now been recorded. Western blot analysis has also indicated that antibodies are 
indeed raised against SlaA in the early onset of a strangles infection.  
Finally, the acid phosphatases SeLppC and SzLppC were investigated. Although 
SeLppC and SzLppC had been previously investigated and characterised (Hamilton et al. 
2000), characterisation was carried out using only whole cell extracts of S. equi and S. 
zooepidemicus strains (non-genome strains) and undertaken prior to the availability of the S. 
equi and S. zooepidemicus genomes. Additionally it was thought that the genome strain 
possessed a ‘frame-shift’ mutation, rendering SeLppC a pseudogene.  
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Following this study it can now be concluded that SeLppC in S. equi H70 is not a 
pseudogene. Furthermore it has been shown that SeLppC and it’s close paralogue SzLppC are 
active against the substrate pNPP and the biologically relevant substrates 5’-AMP and 
5’UMP, possessing activity at temperatures up to at least 50°C, possessing the strongest 
activity at pH <5 and possessing no apparent specific requirement to Cu
2+
. 
Finally, it is hoped that the data generated during this study will be informative 
towards the understanding of the molecular basis of virulence of S. equi and that the 
constructs created will be further used to investigate these potential virulence factors further 
in view of the creation of mutant strains of S. equi suitable for equine challenge studies in the 
future.  
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Appendix I – Media, solutions and enzyme buffers 
Media 
 
Luria-Bertani (Liquid media, per 100 ml) 
Tryptone         1.0g  
NaCl2          1.0g 
Yeast extract         0.5g 
pH 7.0 
 
Luria-Bertani (Solid media, per 100 ml)  
Tryptone         1.0g  
NaCl2          1.0g 
Yeast extract         0.5g 
Agar (bacteriological agar N
o
1)      2.0g 
pH 7.0 
 
Todd-Hewitt (Liquid media, per 100 ml) 
Todd-Hewitt          3.64g 
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pH 7.0    
 
Todd-Hewitt (Solid Media, per 100 ml) 
Todd-Hewitt         3.64g 
Agar (bacteriological agar N
o
1)      2.0g 
pH 7.0 
 
Solutions 
Coomassie blue protein stain 
Brilliant Blue R250        1.0g 
Methanol         450ml 
ddH2O          450ml 
Glacial acetic acid        100ml 
 
Elution Buffer (per litre) 
Na2HPO4 (20mM)        2.84g 
NaCl2 (500 mM)        29.22g 
Imidizole (10 mM)        34.0g 
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pH  7.0-7.5 
 
Equilibration buffer (1 litre) 
Sodium acetate (100mM, pH 5.0)      8.203g 
 
PBS- TWEEN (per litre) 
KH2PO4 (1.4mM)        0.19g 
Na2HPO4 (8.0mM)        1.136g 
NaCl (140mM)        8.2g 
KCl (2.7mM, pH 7.3)        0.202g 
Tween 80         0.5ml 
 
Phosphate colour reagent (50 ml) 
Sulphuric acid (3M)        10ml 
Ammonium molybate (2.5%)       10ml 
18.2MΩ H2O         30ml 
Ascorbic acid         1.0g 
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Renaturation buffer (1 litre) 
Tris HCl (100mM, pH 7.0)       12.114g 
MgSO4 (2mM)        0.24072g 
ZnCl2 (0.05mM)        6.82mg 
Triton X-100 (2%, v/v)       20ml 
 
SDS-PAGE Buffer B (per 200ml) 
Tris HCl (2M, pH 8.8)       150ml 
SDS (10%)         8ml 
18.2MΩ         42ml 
 
SDS PAGE Destain (per litre) 
Methanol         100ml 
Glacial Acetic Acid        100ml 
dH20          800ml 
 
SDS Loading Buffer (per 10 ml) 
Tris HCl (1M, pH 6.8)       0.6ml 
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Glycerol (50%)        5.0ml 
SDS (10%)         2.0ml 
β Mercaptoethanol        0.6ml 
Bromophenol Blue (1%)       0.1g 
dH20          0.9ml 
 
SDS-PAGE running buffer (1 litre) 
Tris-HCl (pH 8.0)        30.3g 
Glycine         144g 
SDS          10g 
pH 8.2 
 
Start Buffer (per litre) 
Na2HPO4 (20mM)        2.84g 
NaCl2 (500 mM)        29.22g 
Imadizole (10 mM)        0.68g 
pH  7.0-7.5 
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STETS Buffer (per litre) 
Sucrose         80.0g 
Tris-HCl         6.06g 
EDTA (0.5M)         100.0ml 
Triton X-100         50.0ml 
pH   8.0  
 
sPLA2 Assay buffer (per litre) 
CaCl2 (10mM)         1.1098g 
KCl (100mM)         7.45513g 
Tris HCl (25mM, pH 7.5)       3.02185g 
Triton X-100 (0.3mM)       176 µl 
pH 7.5 
 
TAE Running buffer (50 x stock)(per litre) 
Tris Base         242.0g 
Glacial acetic acid (17.51M)       57.1ml 
EDTA (0.5M, pH 8.0        100.0ml 
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TE buffer (per litre) 
Tris-Base (0.5M, pH 7.5)       20ml 
EDTA (0.5M, pH 8.0)       20ml 
pH 7.5 
 
Transfer Buffer (per litre) 
Glycine         2.93g 
Tris-HCl         5.82g 
Methanol         200ml 
ddH2O          800ml 
 
Western blot transfer buffer (per litre) 
Tris base         5.82g 
Glycine         2.93g 
Methanol         200ml 
 
Xylene cyanol (6x) loading buffer (per 10ml) 
Xylene cyanol         0.025g 
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Glycerol         3.000g 
 
Enzyme buffers 
Enzyme Buffer Composition 
KOD (DNA 
polymerase) 
Patented 
NdeI 
Buffer 4 (20 mM Tris-acetate, 10 mM Magnesium acetate, 50 
mM Potassium acetate, 1 mM DTT, pH 7.9) 
T4 DNA ligase 
50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 10 mM DTT, 1mM 
ATP, 25 mg ml
-1
 acetylated BSA 
XhoI 
Buffer 4 (20 mM Tris-acetate, 10 mM Magnesium acetate, 50 
mM Potassium acetate, 1 mM DTT, pH 7.9) 
EcoRI 
50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM 
Dithioehreitol, pH 7.9, 25°C 
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Appendix II – Commercial kits and equipment 
Commercial kits 
Qiagen:    QIAprep
® 
Spin Miniprep Kit 
    QIAquick
® 
Gel Extraction Kit 
    Qiagen
®
 Plasmid Maxi Kit 
 
Qiagen
®
 kit buffer Buffer functions / components 
P1 
Resuspension. 
50 mM Tris-HCl pH 8, 10 mM EDTA, 100 µg/ml RNase A 
P2 
Lysis. 
200 mM NaOH, 1% SDS (w/v) 
 
P3 
Neutralization. 
3 M Potassium Acetate pH 5 
N3 
Neutralization. 
25 – 50 % Guanidinium chloride, 10-25% acetic acid. 
EB 
Elution. 
Full components not available 
PE 
Wash. 
(Full components not available) 
QG Agarose gel dissolver. 
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50-100% Guanidinium chloride, (full compnents not available) 
PB 
Wash. 
25-50% Guanidinium chloride, 25-50% isopropanol. (Full 
components not available) 
QBT 
Equilibration. 
750 mM NaCl, 50 mM MOPS pH 7, 15% isopropanol (v/v), 0.15 % 
Triton X-100 (v/v) 
QC 
Wash. 
1 M NaCl, 50 mM Tris-HCl, pH 8.5, 15 % isopropanol (v/v) 
QF 
Elution. 
1.25 M NaCl, 50 mM Tris-HCl, pH 8.5, 15 % isopropanol (v/v) 
 
Caymen Chemical Company: sPLA2 assay kit 
Caymen chemical 
company kit  
Buffer functions / components 
sPLA2 Buffer Buffer 
25 mM Tris-HCl, pH7.5, containing 10 mM CaCl2, 100 mM 
KCl, 0.3 mM Triton X-100  
DTNB Chromogen 
10 mM DTNB, 0.4 M Tris-HCl 
Substrate DT-PC (1.66 mM) 
25 mM Tris-HCl, pH7.5, containing 10 mM CaCl2, 100 mM 
KCl, 0.3 mM Triton X-100 
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Control Bee venom (100 µg/ml) 
25 mM Tris-HCl, pH7.5, containing 10 mM CaCl2, 100 mM 
KCl, 0.3 mM Triton X-100 
 
 
Equipment 
Autoclaving 
Sterilisation was achieved using a benchtop Prestige
® 
Medical 2100 Classic autoclave. 
Incubators 
For the growth of bacteria either a Gallenkamp orbital or static incubator was used. 
pH meter 
When solutions and media were required at a set pH all adjustments were performed using a 
Jenway Ion Meter 3340 with calibration buffers at pH 4.0, 7.0 and 9.22. 
Centrifugation 
Centrifugation of volumes was performedusing a small Sigma 1-15 bench top 
microcentrifuge.  
SDS-PAGE gel kits 
Electropgoresis of proteins was performed using a Bio-Rad Mini-Protean 3 Cell kit with 
power supplied via an E-C 570-90 E-C Apparatus Corporation power pack  
Gel Documentation 
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Visualisation of agarose and SDS-PAGE gels was achieved using a Bio-Rad Gel Doc 2000 
system and Quantity One™ software. Hard copies of the gel picture were printed via a 
Mitsubishi Video Copy processor (Model P91), with Mutsubishi thermal paper.  
Sonication 
Cell lysis was performed using a MSE Soniprep 150 ultra-sonication machine 
Purification 
For purification of protein an AKTA Prime plus FPLC system was used and was controlled 
by PrimeView Software.  
Spectrophotometer 
For all spectrophotometric measurements a UV Visible Heλios α Spectronic Unicam 
spectrophotometer was used.  
Microtitre plate reader 
Measurements were made using a FL500 FAK microtitre plate reader.  
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Appendix III Crystal tray screens 
PEG/Ion Screen  
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Hamption (HT) – Screen I 
 
A1] Tube : 1  
0.02M 
Calcium 
chloride 
dihydrate 
0.1M Sodium 
acetate 
trihydrate 
pH4.6 
30%v/v 2-
methyl-2,4-
pentanediol  
 
[A2] 
Tube : 2  
 
0.4M 
Potassium 
sodium 
tartrate 
tetrahydrate  
 
[A3] 
Tube : 3  
 
0.4M 
Ammoniu
m 
dihydrogen 
phosphate  
 
[A4] Tube : 4  
 
0.1M Tris 
hydrochlorid
e pH8.5 
2M 
Ammonium 
sulfate  
 
[A5] Tube : 5  
0.2M tri-
Sodium 
citrate 
dihydrate 
0.1M Sodium 
HEPES 
pH7.5 
30%v/v 2-
methyl-2,4-
pentanediol  
 
[A6] Tube : 6  
0.2M 
magnesium 
chloride 
hexahydrate 
0.1M Tris 
hydrochlorid
e pH8.5 
30%w/v 
polyethylene 
glycol 4000  
 
[B1] Tube : 7  
 
0.1M sodium 
cacodylate 
pH6.5 
1.4M sodium 
acetate 
trihydrate  
 
[B2] 
Tube : 8  
0.2M tri-
sodium 
citrate 
dihydrate 
0.1M 
sodium 
cacodylate 
pH6.5 
30%v/v iso-
propanol  
 
[B3] 
Tube : 9  
0.2M 
ammonium 
acetate  
0.1M tri-
sodium 
citrate 
dihydrate 
pH5.6 
30%w/v 
polyethylen
e glycol 
4000  
 
[B4] 
Tube : 10  
0.2M 
ammonium 
acetate  
0.1M Sodium 
acetate 
trihydrate 
pH4.6 
30%w/v 
polyethylene 
glycol 4000  
 
[B5] 
Tube : 11  
 
0.1M tri-
sodium 
citrate 
dihydrate 
pH5.6 
1M 
Ammonium 
dihydrogen 
phosphate  
 
[B6] 
Tube : 12  
0.2M 
magnesium 
chloride 
hexahydrate 
0.1M Sodium 
HEPES 
pH7.5 
30%v/v iso-
propanol  
 
[C1] 
Tube : 13  
0.2M tri-
Sodium 
citrate 
dihydrate 
0.1M Tris 
hydrochlorid
e pH8.5 
30%v/v 
polyethylene 
glycol 400  
 
[C2] 
Tube : 14  
0.2M 
Calcium 
chloride 
dihydrate 
0.1M 
Sodium 
HEPES 
pH7.5 
28%v/v 
polyethylene 
glycol 400  
 
[C3] 
Tube : 15  
0.2M 
ammonium 
sulfate  
0.1M 
sodium 
cacodylate 
pH6.5 
30%w/v 
polyethylen
e glycol 
8000  
 
[C4] 
Tube : 16  
 
0.1M Sodium 
HEPES 
pH7.5 
1.5M lithium 
sulfate 
monohydrate  
 
[C5] 
Tube : 17  
0.2M lithium 
sulfate 
monohydrate 
0.1M Tris 
hydrochlorid
e pH8.5 
30%w/v 
polyethylene 
glycol 4000  
 
[C6] 
Tube : 18  
0.2M 
magnesium 
acetate 
tetrahydrate 
0.1M sodium 
cacodylate 
pH6.5 
20%w/v 
polyethylene 
glycol 8000  
 
[D1] 
Tube : 19  
[D2] 
Tube : 20  
[D3] 
Tube : 21  
[D4] 
Tube : 22  
[D5] 
Tube : 23  
[D6] 
Tube : 24  
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0.2M 
ammonium 
acetate  
0.1M Tris 
hydrochlorid
e pH8.5 
30%v/v iso-
propanol  
 
0.2M 
ammonium 
sulfate  
0.1M 
Sodium 
acetate 
trihydrate 
pH4.6 
25%w/v 
polyethylene 
glycol 4000  
 
0.2M 
magnesium 
acetate 
tetrahydrat
e 
0.1M 
sodium 
cacodylate 
pH6.5 
30%v/v 2-
methyl-2,4-
pentanediol  
 
0.2M sodium 
acetate 
trihydrate 
0.1M Tris 
hydrochlorid
e pH8.5 
30%w/v 
polyethylene 
glycol 4000  
 
0.2M 
magnesium 
chloride 
hexahydrate 
0.1M Sodium 
HEPES 
pH7.5 
30%v/v 
polyethylene 
glycol 400  
 
0.2M 
Calcium 
chloride 
dihydrate 
0.1M Sodium 
acetate 
trihydrate 
pH4.6 
20%v/v iso-
propanol  
 
[E1] 
Tube : 25  
 
0.1M 
imidazole 
pH6.5 
1M sodium 
acetate 
trihydrate  
 
[E2] 
Tube : 26  
0.2M 
ammonium 
acetate  
0.1M tri-
sodium 
citrate 
dihydrate 
pH5.6 
30%v/v 2-
methyl-2,4-
pentanediol  
 
[E3] 
Tube : 27  
0.2M tri-
Sodium 
citrate 
dihydrate 
0.1M 
Sodium 
HEPES 
pH7.5 
20%v/v iso-
propanol  
 
[E4] 
Tube : 28  
0.2M sodium 
acetate 
trihydrate 
0.1M sodium 
cacodylate 
pH6.5 
30%w/v 
polyethylene 
glycol 8000  
 
[E5] 
Tube : 29  
 
0.1M Sodium 
HEPES 
pH7.5 
0.8M 
Potassium 
sodium 
tartrate 
tetrahydrate  
 
[E6] 
Tube : 30  
0.2M 
ammonium 
sulfate  
30%w/v 
polyethylene 
glycol 8000  
 
[F1] 
Tube : 31  
0.2M 
ammonium 
sulfate  
30%w/v 
polyethylene 
glycol 4000  
 
[F2] 
Tube : 32  
 
2M 
Ammonium 
sulfate  
 
[F3] 
Tube : 33  
 
4M sodium 
formate  
 
[F4] 
Tube : 34  
 
0.1M sodium 
acetate 
trihydrate 
pH4.6 
2M sodium 
formate  
 
[F5] 
Tube : 35  
 
0.1M Sodium 
HEPES 
pH7.5 
0.8M sodium 
dihydrogen 
phosphate  
0.8M 
potassium 
dihydrogen 
phosphate  
 
[F6] 
Tube : 36  
 
0.1M Tris 
hydrochlorid
e pH8.5 
8%w/v 
polyethylene 
glycol 8000  
 
[G1] 
Tube : 37  
 
0.1M Sodium 
acetate 
trihydrate 
pH4.6 
8%w/v 
[G2] 
Tube : 38  
 
0.1M 
Sodium 
HEPES 
pH7.5 
1.4M tri-
[G3] 
Tube : 39  
 
0.1M 
Sodium 
HEPES 
pH7.5 
2%v/v 
[G4] 
Tube : 40  
 
0.1M tri-
sodium 
citrate 
dihydrate 
pH5.6 
[G5] 
Tube : 41  
 
0.1M Sodium 
HEPES 
pH7.5 
10%v/v iso-
propanol  
[G6] 
Tube : 42  
0.05M 
potassium 
dihydrogen 
phosphate  
20%w/v 
polyethylene 
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polyethylene 
glycol 4000  
 
sodium 
citrate 
dihydrate  
 
polyethylen
e glycol 400  
2M 
ammonium 
sulfate  
 
20%v/v iso-
propanol  
20%w/v 
polyethylene 
glycol 4000  
 
20%w/v 
polyethylene 
glycol 4000  
 
glycol 8000  
 
[H1] 
Tube : 43  
 
30%w/v 
polyethylene 
glycol 1500  
 
[H2] 
Tube : 44  
 
0.2M 
magnesium 
formate  
 
[H3] 
Tube : 45  
0.2M zinc 
acetate 
dihydrate 
0.1M 
sodium 
cacodylate 
pH6.5 
18%w/v 
polyethylen
e glycol 
8000  
 
[H4] 
Tube : 46  
0.2M 
calcium 
acetate 
hydrate 
0.1M sodium 
cacodylate 
pH6.5 
18%w/v 
polyethylene 
glycol 8000  
 
[H5] 
Tube : 47  
 
0.1M Sodium 
acetate 
trihydrate 
pH4.6 
2M 
Ammonium 
sulfate  
 
[H6] 
Tube : 48  
 
0.1M Tris 
hydrochlorid
e pH8.5 
2M 
Ammonium 
dihydrogen 
phosphate  
 
[I1] Tube : 49  
1M lithium 
sulfate 
monohydrate 
2%w/v 
polyethylene 
glycol 8000  
 
[I2] 
Tube : 50  
0.5M 
lithium 
sulfate 
monohydrat
e 
15%w/v 
polyethylene 
glycol 8000  
 
    
 
Hamption (HT) – Screen I 
[A1] 
Tube : 1  
2.0M 
sodium 
chloride  
10% PEG 
6000  
 
[A2] Tube : 2  
0.5M sodium chloride  
0.01M 
hexadecyltrimethylamm
onium bromide  
0.01M magnesium 
chloride hexahydrate  
 
[A3] 
Tube : 3  
 
25%v/v 
ethylene 
glycol  
 
[A4] 
Tube : 4  
 
35%v/v 
dioxane  
 
[A5] 
Tube : 5  
2.0M 
ammoniu
m sulfate  
5%v/v iso-
propanol  
 
[A6] 
Tube : 6  
 
pH7.0 
1M 
imidazole  
 
[B1] 
Tube : 7  
 
10%w/v 
polyethyle
[B2] Tube : 8  
1.5M sodium chloride  
10%v/v ethanol  
 
[B3] 
Tube : 9  
 
0.1M 
sodium 
[B4] 
Tube : 10  
0.2M 
sodium 
chloride  
[B5] 
Tube : 11  
0.01M 
cobaltous 
chloride 
[B6] 
Tube : 12  
0.1M 
cadmium 
chloride 
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ne glycol 
1000  
10%w/v 
polyethyle
ne glycol 
8000  
 
acetate 
trihydrate 
pH4.6 
2M 
sodium 
chloride  
 
0.1M 
sodium 
acetate 
trihydrate 
pH4.6 
30%v/v 
MPD  
 
hexahydra
te 
0.1M 
sodium 
acetate 
trihydrate 
pH4.6 
1M 1,6 
hexanediol  
 
dihydrate 
0.1M 
sodium 
acetate 
trihydrate 
pH4.6 
30%v/v 
polyethyle
ne glycol 
400  
 
[C1] 
Tube : 13  
0.2M 
ammoniu
m sulfate  
0.1M 
sodium 
acetate 
trihydrate 
pH4.6 
30%w/v 
polyethyle
ne glycol 
monomet
hyl ether 
2000  
 
[C2] Tube : 14  
0.2M potassium sodium 
tartrate tetrahydrate 
0.1M tri-sodium citrate 
dihydrate pH5.6 
2M ammonium sulfate  
 
[C3] 
Tube : 15  
0.5M 
ammoniu
m sulfate  
0.1M tri-
sodium 
citrate 
dihydrate 
pH5.6 
1M 
lithium 
sulfate 
monohydr
ate  
 
[C4] 
Tube : 16  
0.5M 
sodium 
chloride  
0.1M tri-
sodium 
citrate 
dihydrate 
pH5.6 
2%v/v 
ethylene 
imine 
polymer  
 
[C5] 
Tube : 17  
 
0.1M tri-
sodium 
citrate 
dihydrate 
pH5.6 
35%v/v 
tert-
butanol  
 
[C6] 
Tube : 18  
0.01M 
ferric 
chloride 
hexahydr
ate 
0.1M tri-
sodium 
citrate 
dihydrate 
pH5.6 
10%v/v 
jeffamine 
M-600  
 
[D1] 
Tube : 19  
 
0.1M tri-
sodium 
citrate 
dihydrate 
pH5.6 
2.5M 1,6 
hexanedio
l  
 
[D2] Tube : 20  
 
0.1M MES pH6.5 
1.6M magnesium sulfate 
heptahydrate  
 
[D3] 
Tube : 21  
0.1M 
sodium 
dihydroge
n 
phosphate  
0.1M MES 
pH6.5 
2M 
sodium 
chloride  
0.1 M  
potassium 
dihydroge
n 
phosphate  
 
[D4] 
Tube : 22  
 
0.1M 
MES 
pH6.5 
12%w/v 
polyethyle
ne glycol 
20,000  
 
[D5] 
Tube : 23  
1.6M 
ammoniu
m sulfate  
0.1M MES 
pH6.5 
10%v/v 
dioxane  
 
[D6] 
Tube : 24  
0.05M 
cesium 
chloride  
0.1M 
MES 
pH6.5 
30%v/v 
jeffamine 
M-600  
 
[E1] 
Tube : 25  
0.01M 
[E2] Tube : 26  
0.2M ammonium sulfate  
0.1M MES pH6.5 
[E3] 
Tube : 27  
0.01M zinc 
[E4] 
Tube : 28  
 
[E5] 
Tube : 29  
0.5M 
[E6] 
Tube : 30  
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cobaltous 
chloride 
hexahydr
ate 
0.1M 
MES 
pH6.5 
1.8M 
ammoniu
m sulfate  
 
30%w/v polyethylene 
glycol monomethyl ether 
5000  
 
sulfate 
heptahydr
ate 
0.1M MES 
pH6.5 
25%v/v 
polyethyle
ne glycol 
monometh
yl ether 
550  
 
pH6.5 
1.6M tri-
sodium 
citrate 
dihydrate  
 
ammoniu
m sulfate  
0.1M 
HEPES 
pH7.5 
30%v/v 
MPD  
 
0.1M 
HEPES 
pH7.5 
10%w/v 
polyethyle
ne glycol 
6000  
5%v/v 
MPD  
 
[F1] 
Tube : 31  
 
0.1M 
HEPES 
pH7.5 
20%v/v 
jeffamine 
M-600  
 
[F2] Tube : 32  
0.1M sodium chloride  
0.1M HEPES pH7.5 
1.6M ammonium sulfate  
 
[F3] 
Tube : 33  
 
0.1M 
HEPES 
pH7.5 
2M 
ammoniu
m formate  
 
[F4] 
Tube : 34  
0.05M 
cadmium 
sulfate 
hydrate 
0.1M 
HEPES 
pH7.5 
1M 
sodium 
acetate 
trihydrate  
 
[F5] 
Tube : 35  
 
0.1M 
HEPES 
pH7.5 
70%v/v 
MPD  
 
[F6] 
Tube : 36  
 
0.1M 
HEPES 
pH7.5 
4.3M 
sodium 
chloride  
 
[G1] 
Tube : 37  
 
0.1M 
HEPES 
pH7.5 
10%w/v 
polyethyle
ne glycol 
8000  
 
[G2] Tube : 38  
 
0.1M HEPES pH7.5 
20%w/v polyethylene 
glycol 10,000  
8%v/v ethylene glycol  
 
[G3] 
Tube : 39  
0.2M 
magnesiu
m chloride 
hexahydra
te 
0.1M tris 
pH8.5 
3.4M 1,6 
hexanediol  
 
[G4] 
Tube : 40  
 
0.1M tris 
pH8.5 
25%v/v 
tert-
butanol  
 
[G5] 
Tube : 41  
0.01M 
nickel (II) 
chloride 
hexahydra
te 
0.1M tris 
pH8.5 
1M 
lithium 
sulfate 
monohydr
ate  
 
[G6] 
Tube : 42  
1.5M 
ammoniu
m sulfate  
0.1M tris 
pH8.5 
12%v/v 
glycerol 
anhydrou
s  
 
[H1] 
Tube : 43  
0.2M 
ammoniu
m 
dihydroge
n 
phosphate  
[H2] Tube : 44  
 
0.1M tris pH8.5 
20%v/v ethanol  
 
[H3] 
Tube : 45  
0.01M 
nickel (II) 
chloride 
hexahydra
te 
0.1M tris 
[H4] 
Tube : 46  
0.1M 
sodium 
chloride  
0.1M 
bicine 
pH9.0 
[H5] 
Tube : 47  
 
0.1M 
bicine 
pH9.0 
2M 
magnesiu
[H6] 
Tube : 48  
 
0.1M 
bicine 
pH9.0 
2%v/v 
dioxane  
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0.1M tris 
pH8.5 
50%v/v 
MPD  
 
pH8.5 
20%w/v 
polyethyle
ne glycol 
monometh
yl ether 
2000  
 
20%v/v 
polyethyle
ne glycol 
monomet
hyl ether 
550  
 
m chloride 
hexahydra
te  
 
10%w/v 
polyethyle
ne glycol 
20,000  
 
 
* Newcastle screen formulations not available at time of writing.  
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Appendix IV: DNA sequencing outputs 
SEQ2190 
Query:     114 ATATGGATATGAAAAGCGATGCCAAAAAGGTATTAGCAACATTGCAAAAAGGTAATCATA 173 
               ||  |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2203279 ATGGGGATATGAAAAGCGATGCCAAAAAGGTATTAGCAACATTGCAAAAAGGTAATCATA 2203338 
 
Query:     174 AACAAGAGTTAAAAAAAGTTCTTAGAACTATTGGTGATGATAGTTTGCTATTATTATGGT 233 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2203339 AACAAGAGTTAAAAAAAGTTCTTAGAACTATTGGTGATGATAGTTTGCTATTATTATGGT 2203398 
 
Query:     234 TACTTGTATCGGGTGATTCCAATTTAGATGAAAGTAATAAAAGTTTTGATTATTTATCAA 293 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2203399 TACTTGTATCGGGTGATTCCAATTTAGATGAAAGTAATAAAAGTTTTGATTATTTATCAA 2203458 
 
Query:     294 TTTGGAATACTGGATCTAGAGTTGGTAAAGTGATATCTCCTACTGAATACTTTAAACAAG 353 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2203459 TTTGGAATACTGGATCTAGAGTTGGTAAAGTGATATCTCCTACTGAATACTTTAAACAAG 2203518 
 
Query:     354 AATCAAAAAACACTGAAAATAGGCAAGCTGTTTATAGTGAATTTAAACAACGCGTAGAAG 413 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2203519 AATCAAAAAACACTGAAAATAGGCAAGCTGTTTATAGTGAATTTAAACAACGCGTAGAAG 2203578 
 
Query:     414 AACGATCTAAAAAAGCCAAGGAAGCCACTGAAGCACTAAACCAAAAAGCTCAATTGGAGG 473 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2203579 AACGATCTAAAAAAGCCAAGGAAGCCACTGAAGCACTAAACCAAAAAGCTCAATTGGAGG 2203638 
 
Query:     474 CTACAGTTAAAAATATAAACGAAGAACTTGAAAAAACTAGAGAAGGTTTTAAAGTTGTGA 533 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2203639 CTACAGTTAAAAATATAAACGAAGAACTTGAAAAAACTAGAGAAGGTTTTAAAGTTGTGA 2203698 
 
Query:     534 GTGAAAACTCAAACAAATTAGAAAAACAATTAATGGCTGAGAAAATAAAAACACGTACAG 593 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2203699 GTGAAAACTCAAACAAATTAGAAAAACAATTAATGGCTGAGAAAATAAAAACACGTACAG 2203758 
 
Query:     594 CTGAAGAAACTGCCAAACAAGCTAAAACCGATAAAGAAAGAGCAGAGGCTGAAGCTAAAA 653 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2203759 CTGAAGAAACTGCCAAACAAGCTAAAACCGATAAAGAAAGAGCAGAGGCTGAAGCTAAAA 2203818 
 
Query:     654 AAGCGAAAGAGGAAGCTAAGACTGCGGAAGGAAAAGTTAAACAAGCAGAAACTGAGAAAA 713 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2203819 AAGCGAAAGAGGAAGCTAAGACTGCGGAAGGAAAAGTTAAACAAGCAGAAACTGAGAAAA 2203878 
 
Query:     714 GGAATGCGGAAGCTAAGGCTAGAACCGCTGAAGAAGAAGCTAAACAAGCTACGGCTGATA 773 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2203879 GGAATGCGGAAGCTAAGGCTAGAACCGCTGAAGAAGAAGCTAAACAAGCTACGGCTGATA 2203938 
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Query:     774 AAGAAAAGGCAGAGACTGAAGCTAAAAAAGCGAAAGAAGAAGCTAAGACCGCTAAAGAAG 833 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2203939 AAGAAAAGGCAGAGACTGAAGCTAAAAAAGCGAAAGAAGAAGCTAAGACCGCTAAAGAAG 2203998 
 
Query:     834 CTGCTCATCAAGAACAAGAAAAAGCTAAACAATTAGAACAAGCTAATCAACAGGCTAACC 893 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2203999 CTGCTCATCAAGAACAAGAAAAAGCTAAACAATTAGAACAAGCTAATCAACAGGCTAACC 2204058 
 
Query:     894 AAAGAGCTAATCTGGNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCTTG 953 
               |||||||||||||||                                         |||| 
Sbjct: 2204059 AAAGAGCTAATCTGGCAGAAAAATCTAAAAAAGATTTAGAAACTCAAAAAGAAAAACTTG 2204118 
 
Query:     954 AACAAGAGATTTAAGA 969 
               ||||||||||| |||| 
Sbjct: 2204119 AACAAGAGATTAAAGA 2204134 
 
SEQ2180 
Query:     118 GATATGAGTGCGGACGTNNNNNNNNTTGAGCAAGTTTTACAATCAGATAGTGGTAAGTTA 177 
               |||||||||||||||||        ||||||||||||||||||||||||||||||||||| 
Sbjct: 2192072 GATATGAGTGCGGACGTAAAAAAAATTGAGCAAGTTTTACAATCAGATAGTGGTAAGTTA 2192131 
 
Query:     178 AAAACAGTATTAGGACAAATTAGTGATCCCAATACATTGTTTGCTTTATTTGCTATTATA 237 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2192132 AAAACAGTATTAGGACAAATTAGTGATCCCAATACATTGTTTGCTTTATTTGCTATTATA 2192191 
 
Query:     238 TCAGCCGATGTAAATATAGATCCAGAAAGTTTTAGTTTTATATTAAATGGCCCAATCACA 297 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2192192 TCAGCCGATGTAAATATAGATCCAGAAAGTTTTAGTTTTATATTAAATGGCCCAATCACA 2192251 
 
Query:     298 CCATTATTATCATATTTCAACAATCCAAACAAAAATGATAATAGAAAGGCAGTTGTTAAT 357 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2192252 CCATTATTATCATATTTCAACAATCCAAACAAAAATGATAATAGAAAGGCAGTTGTTAAT 2192311 
 
Query:     358 GAAATNNNNNNNNGAGTCTCAGCTTTGGAGCAAGCTCAAAAATTAGAAACTAAAGCTAAA 417 
               |||||        ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2192312 GAAATAAAAAAAAGAGTCTCAGCTTTGGAGCAAGCTCAAAAATTAGAAACTAAAGCTAAA 2192371 
 
Query:     418 ATAGAGAAACAGATTGCAGAAAGTGAATTAGAAAAAACTAGGAATGCTTTCAAAGTAACA 477 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2192372 ATAGAGAAACAGATTGCAGAAAGTGAATTAGAAAAAACTAGGAATGCTTTCAAAGTAACA 2192431 
 
Query:     478 ATTGAAAATTTACATAAACTAGAGGGATTATTAGACACTGAAAAACAAAAAACTCGAAAA 537 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2192432 ATTGAAAATTTACATAAACTAGAGGGATTATTAGACACTGAAAAACAAAAAACTCGAAAA 2192491 
 
Query:     538 GTTGAGGAAGATTACCAACAAGCTAAAACCGATAAAGAAAAAGCAGAGGCTGATAAAAGG 597 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct: 2192492 GTTGAGGAAGATTACCAACAAGCTAAAACCGATAAAGAAAAAGCAGAGGCTGATAAAAGG 2192551 
 
Query:     598 AATGCGGAAACTAAGGCTAGAACCGCTGAAGAAGAAGCTAAACAAGCTACGGCTGATAAA 657 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2192552 AATGCGGAAACTAAGGCTAGAACCGCTGAAGAAGAAGCTAAACAAGCTACGGCTGATAAA 2192611 
 
Query:     658 GAAAAGGCAGAGACTGAAGCTAAAAAAGCGAAAGAAGAAGCTAAGACCGCTAAAGAAGCT 717 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2192612 GAAAAGGCAGAGACTGAAGCTAAAAAAGCGAAAGAAGAAGCTAAGACCGCTAAAGAAGCT 2192671 
 
Query:     718 GCTCATCAAGAACAAGAAAAAGCTAAACAATTAGAACAAGCTAATCAACAGGCTAACCAA 777 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2192672 GCTCATCAAGAACAAGAAAAAGCTAAACAATTAGAACAAGCTAATCAACAGGCTAACCAA 2192731 
 
Query:     778 AGAGCTAATCTGGNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCTTGAA 837 
               |||||||||||||                                         |||||| 
Sbjct: 2192732 AGAGCTAATCTGGCAGAAAAATCTAAAAAAGATTTAGAAACTCAAAAAGAAAAACTTGAA 2192791 
 
Query:     838 CAAGAGATTAAAGAAGCTACAGAAGCTAAAAACAAAGCCGAGCAAAAATTAAAAGACCTA 897 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2192792 CAAGAGATTAAAGAAGCTACAGAAGCTAAAAACAAAGCCGAGCAAAAATTAAAAGACCTA 2192851 
 
Query:     898 CAAGATTCAGCTAGTCAAGGCAGTGAATTGTCTAAACAGCTGTTAAAAGAATAAGAATGA 957 
               ||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| || 
Sbjct: 2192852 CAAGATTCAGCTAGTCAAGGCAGTGAATTGTCTAAACAGCTGTTAAAAGAAAAAGAA-GA 2192910 
 
Query:     958 CTTATCAACATATACTTCAAGAGCT 982 
                ||| ||||| | |||||||||||| 
Sbjct: 2192911 ATTAACAACAAA-ACTTCAAGAGCT 2192934 
 
SlaA (seq0849) 
Query:    125 GAAGGGATAAATGATAAAATAGAAAATGGCACTGAAAGCGATATTAGCTTCCAAAATGGT 184 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824165 GAAGGGATAAATGATAAAATAGAAAATGGCACTGAAAGCGATATTAGCTTCCAAAATGGT 824224 
 
Query:    185 GAACTCCTAAAAAATTATCTTATCCTAGAAGGTGAACGAGTATACTTTGATTATGATAGA 244 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824225 GAACTCCTAAAAAATTATCTTATCCTAGAAGGTGAACGAGTATACTTTGATTATGATAGA 824284 
 
Query:    245 GCAACTCAAGATAAAGTATCAGATGATGTTCTAGAGATGGGAATGTTAGTTGAAGCTATA 304 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824285 GCAACTCAAGATAAAGTATCAGATGATGTTCTAGAGATGGGAATGTTAGTTGAAGCTATA 824344 
 
Query:    305 AGTAAGGATTATTCTGAGAAGACATTCACCCCAGATAAATATTTTAAAGCTAGTTGGCCT 364 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824345 AGTAAGGATTATTCTGAGAAGACATTCACCCCAGATAAATATTTTAAAGCTAGTTGGCCT 824404 
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Query:    365 ATCCATGGTAACTATTGTGGACCAAGTCATAATGGGAATAACTTTACTTTGCCAGTAGTA 423 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824405 ATCCATGGTAACTATTGTGGACCAAGTCATAATGGGAATAACTTTACTTTGCCAGTAGTA 824464 
 
Query:    424 TATGTTTTGGATCAAGGTTGCCAAAACCACGATAGTTGCTATAAGTGGGGTGCCAGTATT 483 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824465 TATGTTTTGGATCAAGGTTGCCAAAACCACGATAGTTGCTATAAGTGGGGTGCCAGTATT 824524 
 
Query:    484 GGTGCTAATTGTGAATGTAACCGTCAGCTCGTTAATTACATAAAAGTTTATAGACGATGG 543 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824525 GGTGCTAATTGTGAATGTAACCGTCAGCTCGTTAATTACATAAAAGTTTATAGACGATGG 824584 
 
Query:    544 ATGCCAGCGAATGTCCTTGGCGTAGCCGATGCTATTAGAGTATATTTTGAGACAGTAGGT 603 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824585 ATGCCAGCGAATGTCCTTGGCGTAGCCGATGCTATTAGAGTATATTTTGAGACAGTAGGT 824644 
 
Query:    604 TCTATAGGATGTTAAATTTCNNNNNNNNCGTTAGTGATTATTCGAAGTACTATATTTTGA 663 
              ||||||||||||||||||||        |||||||||||||||||||||||||||||||| 
Sbjct: 824645 TCTATAGGATGTTAAATTTCAAAAAAAACGTTAGTGATTATTCGAAGTACTATATTTTGA 824704 
 
Query:    664 GTATAGTGTTATTATGGATAGGAATGTTCTTTGTTCCTTGGGATAAGACTCTATTCGGTG 723 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824705 GTATAGTGTTATTATGGATAGGAATGTTCTTTGTTCCTTGGGATAAGACTCTATTCGGTG 824764 
 
Query:    724 TTTCGATTTATCTGTTTGTTATGCAAAAGTTATTTATAGTTGTTTGGTTTGACGGCTATC 783 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824765 TTTCGATTTATCTGTTTGTTATGCAAAAGTTATTTATAGT-GTTTGGTTTGACGGCTATC 824823 
 
Query:    784 TTCTTGCCCTTGGTGTCCAACCTGATAAATCTATTTATTCGCGGAATATTATTTGTTCTC 843 
              ||| || |||| ||||| ||    ||||||||||||||| | |||||||||||| || || 
Sbjct: 824824 TTCATGGCCTTTGTGTCTAAAAAAATAAATCTATTTATTTGGGGAATATTATTTATTTTC 824883 
 
Query:    844 G 844 
              | 
Sbjct: 824884 G 824884 
 
 
SlaB (seq2155) 
Query:    117 GAAGGGATAAATGATAAAATAGAAAATGGCACTGAAAGCGATATTAGCTTCCAAAATGGT 176 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824165 GAAGGGATAAATGATAAAATAGAAAATGGCACTGAAAGCGATATTAGCTTCCAAAATGGT 824224 
 
Query:    177 GAACTCCTAAAAAATTATCTTATCCTAGAAGGTGAACGAGTATACTTTGATTATGATAGA 236 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824225 GAACTCCTAAAAAATTATCTTATCCTAGAAGGTGAACGAGTATACTTTGATTATGATAGA 824284 
 
Query:    237 GCAACTCAAGATAAAGTATCAGATGATGTTCTAGAGATGGGAATGTTAGTTGAAGCTATA 296 
316 
 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824285 GCAACTCAAGATAAAGTATCAGATGATGTTCTAGAGATGGGAATGTTAGTTGAAGCTATA 824344 
 
Query:    297 AGTAAGGATTATTCTGAGAAGACATTCACCCCAGATAAATATTTTAAAGCTAGTTGGCCT 356 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824345 AGTAAGGATTATTCTGAGAAGACATTCACCCCAGATAAATATTTTAAAGCTAGTTGGCCT 824404 
 
Query:    357 ATCCATGGTAACTATTGTGGACCAGGTCATAATGGGAATAACTTTACGTTGCCAGTAGTA 416 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824405 ATCCATGGTAACTATTGTGGACCAGGTCATAATGGGAATAACTTTACGTTGCCAGTAGTA 824464 
 
Query:    417 GATGTTTTGGATCAAGGTTGCCAAAACCACGATAGTTGCTATAAGTGGGGTGCCGGTATT 476 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824465 GATGTTTTGGATCAAGGTTGCCAAAACCACGATAGTTGCTATAAGTGGGGTGCCGGTATT 824524 
 
Query:    477 GGTGCTAATTGTGAATGTAACCGTCAGCTCGTTAATTACATAAAAGTTTATAGACGATGG 536 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824525 GGTGCTAATTGTGAATGTAACCGTCAGCTCGTTAATTACATAAAAGTTTATAGACGATGG 824584 
 
Query:    537 ATGCCAGCGAATGTCCTTGGCGTAGCCGATGCTATTAGAGTATATTTTGAGACAGTAGGT 596 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824585 ATGCCAGCGAATGTCCTTGGCGTAGCCGATGCTATTAGAGTATATTTTGAGACAGTAGGT 824644 
 
Query:    597 TCTATAGGATGTTAAATTTCNNNNNNNNCGTTAGTGATTATTCGAAGTACTATATTTTGA 656 
              ||||||||||||||||||||        |||||||||||||||||||||||||||||||| 
Sbjct: 824645 TCTATAGGATGTTAAATTTCAAAAAAAACGTTAGTGATTATTCGAAGTACTATATTTTGA 824704 
 
Query:    657 GTATAGTGTTATTATGGATAGGAATGTTCTTTGTTCCTTGGGATAAGACTCTATTCGGTG 716 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824705 GTATAGTGTTATTATGGATAGGAATGTTCTTTGTTCCTTGGGATAAGACTCTATTCGGTG 824764 
 
Query:    717 TTTCGATTTATCTGTTTGTTATGCAAAAGTTATTTATAGTGTTTGGTTTGACGGCTATCT 776 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 824765 TTTCGATTTATCTGTTTGTTATGCAAAAGTTATTTATAGTGTTTGGTTTGACGGCTATCT 824824 
 
 
Query:    777 TCATGGCCTTTGTGTCTAAAAAAATAAATCTATTTATTTGGGGAATATTATTTATTCTCG 836 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| 
Sbjct: 824825 TCATGGCCTTTGTGTCTAAAAAAATAAATCTATTTATTTGGGGAATATTATTTATTTTCG 824884 
 
SeLppC (seq0346) 
Query:    834 ACGCCAAATGGAGAGAAAAAAGCAGCTCCTAGTCAAGACAAGGATAAGCAAGAAAAGGTT 775 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 328189 ACGACAAATGGAGAGAAAAAAGCAGCTCCTAGTCAAGACAAGGATAAGCAAGAAAAGGTT 328248 
 
Query:    774 GTCCGTCTAACCAATGATCAGCTAAGGGCTAGGGAAAATACCATGGCCACACTCTGGTAT 715 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct: 328249 GTCCGTCTAACCAATGATCAGCTAAGGGCTAGGGAAAATACCATGGCCACACTCTGGTAT 328308 
 
Query:    714 CAGCAGTCTGAAGAGGCTAAGGCTCTCTACTTACAGGGGTACCAAGTGGCTAAGCAGCGC 655 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 328309 CAGCAGTCTGAAGAGGCTAAGGCTCTCTACTTACAGGGGTACCAAGTGGCTAAGCAGCGC 328368 
 
Query:    654 TTAGATACATTATTGAGTCAAGCAACTGATAAACCATACTCTATTGTTTTGGACATTGAT 595 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 328369 TTAGATACATTATTGAGTCAAGCAACTGATAAACCATACTCTATTGTTTTGGACATTGAT 328428 
 
Query:    594 GAGACAGTGCTCGATAATAGTCCTTACCAGGCTAAAAATATTAAAGAGGGCACAGGCTTT 535 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 328429 GAGACAGTGCTCGATAATAGTCCTTACCAGGCTAAAAATATTAAAGAGGGCACAGGCTTT 328488 
 
Query:    534 ACGCCGGATTCTTGGGATAAATGGGTCCAAAAGAAATCAGCCAAGGCAGTAGCAGGTGCT 475 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 328489 ACGCCGGATTCTTGGGATAAATGGGTCCAAAAGAAATCAGCCAAGGCAGTAGCAGGTGCT 328548 
 
Query:    474 AAGGACTTCTTGCAGTATGCAAATGACAAGGGCGTTCAGATTTACTATGTTTCTGACAGA 415 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 328549 AAGGACTTCTTGCAGTATGCAAATGACAAGGGCGTTCAGATTTACTATGTTTCTGACAGA 328608 
 
Query:    414 ACGACTAAGCAAGTAGAGCCGACTATGGAAAATCTTGAAAAAGAAGGTATTCCAGTGCAA 355 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 328609 ACGACTAAGCAAGTAGAGCCGACTATGGAAAATCTTGAAAAAGAAGGTATTCCAGTGCAA 328668 
 
Query:    354 GGCAAGGATCATTTCTTGTTCTTAGAGGAGGGTGTAAAATCAAAAGAGGGCCGTCGTCAA 295 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 328669 GGCAAGGATCATTTCTTGTTCTTAGAGGAGGGTGTAAAATCAAAAGAGGGCCGTCGTCAA 328728 
 
Query:    294 AAGGTGCAAGAAACAACAAATCTAGTGTTGTTATTTGGTGACAATTTGCTTGATTTTGCA 235 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 328729 AAGGTGCAAGAAACAACAAATCTAGTGTTGTTATTTGGTGACAATTTGCTTGATTTTGCA 328788 
 
Query:    234 GAGTTTTCTAAGACCTCTCATGAAGATAGAAGAAAGCTTTTGGATCAGCTGCATGCAGAG 175 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 328789 GAGTTTTCTAAGACCTCTCATGAAGATAGAAGAAAGCTTTTGGATCAGCTGCATGCAGAG 328848 
 
Query:    174 TTTGGCAGCAAGTTTATCATCTTCCCTAATCCAATGTATGGATCATGGGAAAGCAGTGTC 115 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 328849 TTTGGCAGCAAGTTTATCATCTTCCCTAATCCAATGTATGGATCATGGGAAAGCAGTGTC 328908 
 
Query:    114 TATAATGGTCAAAAATTAGACAGTGAAGGCCAAATCAAAGCACGTGACAAGGCTNNAGGG 55 
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||  || | 
Sbjct: 328909 TATAATGGTCAAAAATTAGACAGTGAAGGCCAAATCAAAGCACGTGACAAGGCTTTAGAG 328968 
 
Query:     54 GCTTATTAA 46 
              ||||||||| 
Sbjct: 328969 GCTTATTAA 328977 
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SzLppC (szo16870) 
Query:     944 TTAATAAGCCTCTAAAGCTTTGTCACGTGCTTTGATTTGGCCTTCACTGTCTAATTTTTG 885 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1886324 TTAATAAGCCTCTAAAGCTTTGTCACGTGCTTTGATTTGGCCTTCACTGTCTAATTTTTG 1886383 
 
Query:     884 ACCATTATAGACACTGCTTTCCCATGATCCATACATTGGATTAGGGAAGATGATAAACTT 825 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1886384 ACCATTATAGACACTGCTTTCCCATGATCCATACATTGGATTAGGGAAGATGATAAACTT 1886443 
 
Query:     824 GCTGCCAAATTCTGCATGCAGCTGATCCAAAAGCTTTCTTCTATCTTCATGAGAGGTCTT 765 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1886444 GCTGCCAAATTCTGCATGCAGCTGATCCAAAAGCTTTCTTCTATCTTCATGAGAGGTCTT 1886503 
 
Query:     764 AGAAAACTCTGCAAAATCAAGCAAATTATCACCAAATAACAACACTAGATTTGTTGTTTC 705 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1886504 AGAAAACTCTGCAAAATCAAGCAAATTATCACCAAATAACAACACTAGATTTGTTGTTTC 1886563 
 
Query:     704 TTGCACTTTTTGACGACGGCCCTCTTTTGATTTTACACCCTCCTCTAAGAACAAGAAATG 645 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1886564 TTGCACTTTTTGACGACGGCCCTCTTTTGATTTTACACCCTCCTCTAAGAACAAGAAATG 1886623 
 
Query:     644 ATCCTTGCCTTGCACTGGAATACCTTCTTTTTCAAGATTTTCCATAGTCGGCTCTACTTG 585 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1886624 ATCCTTGCCTTGCACTGGAATACCTTCTTTTTCAAGATTTTCCATAGTCGGCTCTACTTG 1886683 
 
Query:     584 CTTAGTCGTTCTGTCAGAAACATAGTAAATCTGAACGCCCTTGTCATTTGCATACTGCAA 525 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1886684 CTTAGTCGTTCTGTCAGAAACATAGTAAATCTGAACGCCCTTGTCATTTGCATACTGCAA 1886743 
 
Query:     524 GAAGTCCTTAGCACCTGCTACTGCCTTGGCTGATTTCTTTTGGACCCATTTATCCCAAGA 465 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1886744 GAAGTCCTTAGCACCTGCTACTGCCTTGGCTGATTTCTTTTGGACCCATTTATCCCAAGA 1886803 
 
Query:     464 ATCCGGCGTAAAGCCTGTGCCCTCTTTAATATTTTTAGCTTGGTAAGGACTATTATCGAG 405 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1886804 ATCCGGCGTAAAGCCTGTGCCCTCTTTAATATTTTTAGCTTGGTAAGGACTATTATCGAG 1886863 
 
Query:     404 CACTGTCTCATCAATGTCCAAAACAATAGAGTATGGTTTATCAGTTGCTTGACTCAATAA 345 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1886864 CACTGTCTCATCAATGTCCAAAACAATAGAGTATGGTTTATCAGTTGCTTGACTCAATAA 1886923 
 
Query:     344 TGTATCTAAGCGCTGCTTAGCCACTTGGTACCCCTGTAGGTAGAGAGCCTTAGCCTCTTC 285 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1886924 TGTATCTAAGCGCTGCTTAGCCACTTGGTACCCCTGTAGGTAGAGAGCCTTAGCCTCTTC 1886983 
 
Query:     284 AGACTGCTGATACCAGAGTGTGGCCATAGTATTTTCCCTAGCCCTTAGCTGATCATTGGT 225 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1886984 AGACTGCTGATACCAGAGTGTGGCCATAGTATTTTCCCTAGCCCTTAGCTGATCATTGGT 1887043 
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Query:     224 TAGACGGACAACCTTTTCTTGCTTATCCTTGTCTTGACTAGGAGCTGCTTTTTTCTCTCC 165 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1887044 TAGACGGACAACCTTTTCTTGCTTATCCTTGTCTTGACTAGGAGCTGCTTTTTTCTCTCC 1887103 
 
Query:     164 ATTTGTCGC 156 
               ||||||||| 
Sbjct: 1887104 ATTTGTCGC 1887112 
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–Appendix V:  Cloning vector maps, molecular weight markers and standards 
 
pET-28a expression vector 
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pCR
®
 -Blunt cloning vector. 
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DNA electrophoresis standards 
HyperLadder I (Bioline) 
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Protein standards 
Precision Plus Protein™ Standards (Bio-Rad) 
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SigmaMarkers (Both high and low ranges used throughout this work) 
 
 
 
 
 
